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Abstract 
Introduction: Equine sarcoids (ES) are fibroblastic cutaneous tumours, affecting 
members of the Equidae family (horses, donkeys, zebras), hybrids (mules) and 
other ungulates (tapirs and giraffes) (Marti et al., 1993; Reid et al., 1994; 
Knottenbelt et al., 1995; Nel et al., 2006; Valentine, 2006; Kidney & Berrocal, 
2008; van Dyk et al., 2009; van Dyk et al., 2011; Schaffer et al., 2013). This 
debilitating disease has a prevalence of 5.6% in the British equestrian population 
and it is a major welfare concern in less developed countries (Ayele et al., 2007; 
NEHS, 2015). Age (younger horses), genetic predisposition (presence of equine 
leucocyte antigens class I A3 and class II B1; regions of the equine genome in 
chromosomes 20, 22, 23, 25 with microsatellite markers, single nucleotide 
polymorphisms or deletions) and breed (Quarter horse and Thoroughbred) have 
been identified as risk factors (Lazary et al., 1985; Brostrom et al., 1988; 
Mohammed et al., 1992; Marti et al., 1993; Wobeser et al., 2010; Jandova et 
al., 2012; Bugno-Poniewierska et al., 2016; Staiger et al., 2016). Diagnosis and 
treatment are challenging due to the variable clinical presentation (six clinical 
types), inconsistent histopathological findings and gaps in the understanding of 
the aetiology (Martens et al., 2000; Knottenbelt, 2005b; Taylor & Haldorson, 
2013). Bovine papillomavirus type 1 and 2 (BPV-1/-2) are intrinsically linked to 
the development of ES. Episomal viral genomes (from 2 to over 100 copies per 
cell) as well as expression of the viral oncoprotein E5, E6 and E7 have been 
found in clinical lesions in several studies (Amtmann et al., 1980; Angelos et al., 
1991; Nasir & Reid, 1999; Carr et al., 2001b; Chambers et al., 2003b; Ambros, 
2004; Bogaert et al., 2007; Yuan et al., 2007b; Borzachiello et al., 2008; Nasir & 
Campo, 2008; Haralambus et al., 2010; Brandt et al., 2011b; Nasir & Brandt, 
2013; Wilson et al., 2013). Activation of the platelet-derived growth factor  
receptor (PDGF-R) signaling pathway and the intracellular retention of major 
histocompatibility complex (MHC) class I, both driven by the BPV-1/-2 E5 
oncoprotein, are the most studied cellular events in tumoural transformation in 
equine sarcoids (Petti et al., 1991; Ashrafi et al., 2002; Borzacchiello et al., 
2006; Borzachiello et al., 2008; Marchetti et al., 2009; Altamura et al., 2013). 
Other recognised effects of BPV-1/-2 oncoproteins in ES are activation of p38 
mitogen-activated protein kinases (p38-MAPK) (Yuan et al., 2011c), intracellular 
mislocation of tumour suppressor p53 (Yuan et al., 2008a), activation of p600, a 
member of the retinoblastoma family (Corteggio et al., 2011), downregulation of 
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toll-like receptor 4 (TLR4) (Yuan et al., 2010a) and increased expression of 
forkhead box protein 3 (FOXP3). However, to date, the mechanisms by which the 
virus activates or inhibits these pathways are still poorly understood. It has been 
shown that in human papillomavirus (HPV) induced cancer, multiple oncogenic 
pathways are regulated by microRNAs (miRNAs), which are small non-coding 
RNAs and essential regulators at a cellular level (Gómez-Gómez et al., 2013; 
Honegger et al., 2015). The aberrant expression of miRNAs found in high-risk 
HPVs-infected cells (HR-HPV) and cervical cancer samples has contributed to the 
understanding of the mechanisms by which the virus initiates and perpetuates 
malignant transformation. Dysregulation of miRNAs (miR-106b, miR-145, miR-
15/16 cluster, miR-196a, miR-21, miR-23b and miR-92 amongst other miRNAs) 
has been attributed to the presence of the HPV oncoproteins E6 and E7 (Lajer et 
al., 2012; Ben et al., 2015; Honegger et al., 2015). Currently in the official 
database of miRNAs, miRBase 20.0 (www.mirbase.org) there are 711 annotated 
equine miRNA precursors, encoding 690 mature miRNAs, of which more than half 
are predicted sequences (359) (Zhou et al., 2009) and the rest have been 
verified in one equine testicular sample with the use of high throughput 
sequencing (HTS) (331 sequences) (Platt et al., 2014). Nonetheless, other studies 
attempted to describe miRNAs in the horse using HTS in equine semen, bone, 
cartilage, colon, liver and muscle (Das et al., 2013; Desjardin et al., 2014; Kim 
et al., 2014) although these are not included in the miRBase 20.0.  
Aims: The goals of the present study were to produce a detailed catalogue of 
mature sequences expressed in equine normal fibroblast cells (equine primary 
fibroblasts) and study the differential expression of miRNAs in equine sarcoids 
using an in vitro model previously developed at the University of Glasgow (Yuan 
et al., 2008a). 
Materials and methods: RNA was extracted from three cell lines from an equine 
in vitro sarcoid model: normal equine fibroblasts (EqPalFs); cells transformed 
with the BPV-1 genome, EqPalF-BPV-1 cells referred to as S6-2 cells; and equine 
tumoural fibroblasts, named EqSO4bs (Yuan et al., 2008b). miRNAs contained in 
the RNA fraction were assessed using miRNA microarray (EqPalF vs S6-2 cells), 
high throughput sequencing (HTS) (EqPalF, EqSO4b and S6-2 cells) and real-time 
reverse transcription polymerase chain reaction (qRT-PCR). An adjusted p-value 
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of less than 0.05 was taken to be statistically significant when studying the 
differential expression of miRNAs in the three cell lines.  
Results: Out of the 2164 probes in the microarray, once quality probes were 
removed (90 probes), 402 probes had signal above the background level, 
representing 402 mature miRNA sequences present in equine fibroblasts. 
Additionally, the results confirmed that 124 of the equine predicted miRNAs 
currently in the official miRBase are indeed encoded within the equine genome 
and expressed in equine fibroblasts. In total 206 miRNAs were found to be 
significantly dysregulated in BPV-transformed equine primary fibroblasts (S6-2 
cells) when compared to control primary fibroblasts (EqPalF) using miRNA 
microarray (adjusted p<0.05). Dysregulated miRNAs of interest in BPV-1 
transformed cells captured in the microarray results were let-7b, miR-106a, miR-
23b, miR-143 and miR-181a. 
With the use of HTS, 593 putative miRNA candidates in EqPalF cells were 
described providing experimental verification of the existence of 258 equine 
miRNAs and the presence of an additional 335 novel miRNAs in the horse (162 
were homologous to miRNAs identified in other species and 173 have not been 
reported before in the horse or other species).  Descriptive parameters 
(sequence length, nucleotide composition, number of miRNAs in each 
chromosome, miRNA abundance, ratio 3p/5p) were found similar to previous 
studies except a higher number of miRNAs found in equine chromosome 24 
(ECA24). Amongst the expressed miRNAs in equine primary fibroblasts, the 
miRNAs provisionally named as eca-miR-21, eca-miR-22, eca-miR-26a, eca-miR-
27b, eca-miR-28-3p, eca-miR-92a, eca-miR-127, eca-miR-143, eca-miR-181a and 
eca-miR-191a were the 10 most abundantly in equine primary fibroblasts. 
Moreover, with the use of HTS and bioinformatic tools miRNAs additional 22 
equine predicted miRNAs and additional 112 novel miRNAs were identified in the 
BPV-1 positive cells that were not expressed in the equine primary fibroblasts. 
When studying the differences between cell lines, 201 miRNAs were linked to 
BPV-1 presence, 128 to tumoural transformation and 106 had the potential of 
biomarkers for the presence of BPV-1 and/or tumoural development. 
Interestingly the degree of correlation of miRNA read counts between BPV-1 
positive cells (EqSO4b and S6-2) was very high (Pearson’s coefficient of 0.91). 
Novel miRNAs will be submitted to miRBase (http://mirbase.org/) to confirm 
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their identity and they will represent an important contribution to the scientific 
community as a resource for further studies on equine miRNAs. Amongst the 
dysregulated miRNAs, miR-181a and miR-181b were found to be downregulated 
by both HTS and microarray in BPV-1 positive cells and miR-181a showed the 
same pattern by qRT-PCR. Importantly, low levels of miR-181a were flagged up 
by the biomarker algorithm as a suitable biomarker for BPV-1 presence and were 
also encoded in areas of the equine genome previously reported to be linked to 
ES (Jandova et al., 2012; Bugno-Poniewierska et al., 2016). Interestingly, the 
human homologues are linked to HR-HPV carcinogenesis (Lee et al., 2015). Other 
miRNAs of interest were miR-196a/b that were found upregulated only in 
tumoural cells and were reported to be associated with increased levels of MMPs 
through activation of NME4-JNK-TIMP1-MMPs pathway in oral cancer, and in 
colon cancer (Lu et al., 2014; Mo et al., 2015). Other dysregulated miRNAs that 
were also predicted biomarkers for BPV-1 presence were miR-92a (member of 
the miR-17~92 cluster), miRNAs from the 15/16 cluster and miR-21. Dysregulated 
miRNAs in BPV-1 positive cells were found to be in networks related to cellular 
growth, cancer, and HPV related networks. 
Conclusions: With the use of several molecular biology and bioinformatic tools, 
280 previously predicted equine miRNAs and 285 novel miRNAs were 
demonstrated in equine fibroblasts. Presence of BPV-1 is linked to 201 
dysregulated miRNAs and 128 miRNAs were intrinsically linked to tumoural 
transformation in ES. These results will be an addition to the scientific 
community when deposited in miRBase and have contributed to a better 
understanding of miRNAs in the horse and BPV-1 oncogenesis in ES.  
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1.1.  Introduction to equine sarcoids 
1.1.1. Definition of equine sarcoids 
Equine sarcoids (ES) are locally aggressive fibroblastic cutaneous tumours 
affecting members of the Equidae family (horses, donkeys, zebras and mules) 
(Marti et al., 1993; Reid et al., 1994; Knottenbelt et al., 1995; Nel et al., 2006; 
Valentine, 2006; van Dyk et al., 2009; Schaffer et al., 2013). Sarcoids also have 
been described in non-equids such as tapirs and giraffes (Kidney & Berrocal, 
2008; van Dyk et al., 2011; Schaffer et al., 2013). Equine sarcoids were firstly 
reported in 1936 as fibro-epithelial tumours affecting horses in South Africa and 
the pattern of spread suggested an infectious origin (Jackson, 1936). They are 
classified by the World Health Organisation as tumours of fibrous tissue within 
the group of mesenchymal-soft tissue tumours (Weiss, 1974). 
The term ‘sarcoid’, which in Greek means ‘a disease that resembles crude 
flesh’, was transferred to veterinary medicine from human sarcoidosis (Boeck’s 
disease). However, distinction should be made to human ‘sarcoidosis’, a rare 
condition of unknown aetiology affecting the immune system with formation of 
visceral granulomas derived from the reticuloendothelial system, causing 
respiratory and other clinical signs that differ from equine sarcoids (Hunninghake 
et al., 1999).  
1.1.2. Epidemiology of equine sarcoids 
1.1.2.1. Prevalence 
Equine sarcoids are the most common cutaneous tumours in horses (Schaffer et 
al., 2013). Prevalence rates range between 0.4-15.8% of all clinical referral 
cases (Lory et al., 1993; Valentine, 2006) and from 11.7% to 67% of all equine 
neoplasms (Marti et al., 1993; Valentine, 2006; Schaffer et al., 2013; Taylor & 
Haldorson, 2013). In the United Kingdom and USA, equine sarcoids are amongst 
the most common equine cutaneous diseases (Schaffer et al., 2013; NEHS, 2014). 
The most recent epidemiological study in the United Kingdom, based on the 
questionnaire responses from 4951 owners in reference to 14952 horses, shows a 
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prevalence of equine sarcoids of 5.6% in the British equine population (NEHS, 
2015). The five most common skin diseases reported by horse owners during this 
study are presented in Figure 1.1. 
In wild zebras, prevalence of ES is higher (53%) although this may be a reflection 
of an elevated degree of inbreeding in this species (Zimmerman, 2004; Nel et 
al., 2006; Marais et al., 2007). 
Figure 1.1. Prevalence of the five most common equine skin diseases 
reported in the British equine population. Data from 14952 horses, (NEHS, 2015) 
Equine sarcoids are seldom life threatening but they have an effect on equine 
health and welfare as well as the material value of a horse (Gerber, 1989; Marti 
et al., 1993). The presence of sarcoid tumours decreases the commercial value 
of an equid during pre-purchase examination and it can lead to a horse being 
excluded from an insurance policy. Bacterial infection, difficulties in defecation, 
urination and locomotion and mastication have been reported to be secondary 
consequences of sarcoids in working horses (Ayele et al., 2007). 
1.1.2.2. Risk factors in equine sarcoids 
Gender and age 
Although the earliest studies found that younger males were at higher risk, there 
is no consistent evidence to support gender predilection in equine sarcoids 
(Mohammed et al., 1992; Reid et al., 1994; Torrontegui & Reid, 1994; Wobeser 
et al., 2010). Sarcoids have been reported to develop in skin discontinuities and 
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areas of the body subjected to trauma (Voss, 1969; Torrontegui & Reid, 1994) 
and flies have been attributed a role in the dissemination of the disease (Finlay 
et al., 2009). These findings, combined with the fact that male neutering with 
healing by second intention is a common practice (Kilcoyne et al., 2013), may 
facilitate the entrance in the peri-inguinal area in recently castrated young 
horses of the bovine papillomavirus type 1/-2, virus associated with the 
development of equine sarcoids (for more details on aetiology please refer to 
section  1.1.4.1, current Chapter). This may have led to the belief that this 
group are at higher risk. A recent study enlisting 302 equids has shown no 
statistical evidence that geldings are at higher risk of developing ES compared to 
stallions or mares (Wobeser et al., 2010). 
Studies found that prevalence of sarcoids is indeed higher in younger animals 
and decreases with age after a peak at 15 years old (Mohammed et al., 1992; 
Marti et al., 1993; Reid & Mohammed, 1997; Valentine, 2006). Equine sarcoids 
can develop in equids as young as 6 months old (Ayele et al., 2007; Wobeser et 
al., 2010). The mean age, despite variability across studies, is around 3.5-4 
years old (Miller & Campbell, 1982; Marti et al., 1993; Torrontegui & Reid, 1994; 
Brostrom, 1995; Scott et al., 2001). The latest epidemiological study carried out 
in Canada over 12 years in 686 horses shown that those biopsied due to the 
presence of a sarcoid were significantly younger than those biopsied due to 
other skin conditions (Wobeser et al., 2010). To explain this age distribution, it 
has been hypothesised that older horses may develop immunity to ES and that 
genetically predisposed animals suffer from neoplasias at an earlier age 
(Torrontegui & Reid, 1994). 
Genetic predisposition 
The major histocompatibility complex (MHC) has been reported as a risk factor 
in equine sarcoids. The MHC contains genes that encode for lymphocyte-
presenting glycoproteins and other molecules that participate in the immune 
adaptive and innate responses. MHC encoded molecules are conventionally 
classified as class I, II and III. In Equus caballus, the genes that encode for the 
equine MHC, named equine leucocyte antigens (ELA) are located on chromosome 
20 (Ansari et al., 1988).  
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ELA haplotypes A3 (class I, previously named as W3) and B1 (class II, previously 
named as W13) have been linked to susceptibility to sarcoids in tests performed 
on 134 horses from different breeds (mainly Swiss Warmblood, Irish hunter, 
French Warmblood and Freiberger) (Lazary et al., 1985). This has been 
confirmed for Swedish half-bred horses (Brostrom et al., 1988; Brostrom, 1995) 
and Thoroughbred horses (Meredith et al., 1986), where the autosomal ELA-
linked genes for class I A3 and class II B1 were strongly associated with sarcoid 
development. ELA class II B1 (W13) has not been detected in Standardbreds, one 
of the breeds with the lowest incidence of ES (Meredith et al., 1986). The link 
between the presence of certain ELA antigens and the risk of developing equine 
sarcoids is still not clear, as not all horses with haplotype B1 suffer from sarcoids 
(Goodrich et al., 1998). 
Quantitative trait locus (QTL) mapping has identified regions within 
chromosomes 20, 23 and 25 linked with increased susceptibility to equine 
sarcoids in a population of 26 Swiss Warmblood horses (Jandova et al., 2012). 
Interestingly, the microsatellite markers linked to increased risk for ES on equine 
chromosome 20 were mapped outside of the ELA region. More recently, allelic 
association tests, using genome wide microchip single nucleotide polymorphisms 
(SNPs), in a study conducted on 59 horses with clinically diagnosed sarcoids, 
revealed that the phenotype associated with presence of ES may be linked to 
polymorphisms found on chromosome 20 (20q28-20q33, within the region of ELA 
genes) and chromosome 22 (22q24-22q26). Highly significant SNPs mapped to 
these two genomic regions encoded the gene DQ alpha 1 (DQA1) an MHC class II 
gene (chromosome 20), matrix metalloproteinase 24 (MMP-24) (chromosome 22), 
eukaryotic translation initiation factor 6 (EIF6) (chromosome 22), endoplasmic 
reticulum degradation-enhancing a-mannosidase I-like receptor (EDEM2) 
(chromosome 22) and endothelial protein C receptor (PROCR) (chromosome 22) 
(Staiger et al., 2016). 
Comparative genomic hybridisation was used recently to assess regions of 
deletion or amplification linked to ES. In tumoural cells from naturally occurring 
sarcoids (NOS) there is a significant deletion in equine chromosome 23 (23q18-
23q19) and duplications of several telomere and rDNA regions (Bugno-
Poniewierska et al., 2016). 
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It is unclear whether ELA types and loci identified as being linked to sarcoid 
development are virus permissive or whether they lead to an impaired immune 
response that facilitates the development of sarcoids (please refer to section 
1.1.4.1 for more details, current Chapter). It is likely that susceptibility to ES is 
driven by multiple genes (Christen et al., 2014). 
Breed 
It is well established that Standardbred horses are less likely to suffer from 
sarcoids compared to other breeds (Meredith et al., 1986; Angelos et al., 1988; 
Mohammed et al., 1992), although a recent study placed Warmblood horses at a 
lower risk when compared to Standardbred horses (Wobeser et al., 2010). The 
disparity between Wobeser et al. (2010) and previous studies could be due to 
early studies not accounting for Warmblood horses as a separate group. Quarter 
horses on the other hand are consistently quoted within the top three breeds 
with higher risk and incidence of ES (Angelos et al., 1991; Mohammed et al., 
1992; Wobeser et al., 2010). Arabs, Appaloosas and Thoroughbreds have been 
reported to be within the top five breeds with higher risk of developing sarcoids, 
and the placement depends on the study and the breeds included in the study 
(Angelos et al., 1991; Mohammed et al., 1992; Wobeser et al., 2010). Donkeys 
on the other hand have a much higher risk of suffering ES compared to horses 
(Wobeser et al., 2010).  
Anatomical region 
Equine sarcoids can affect any part of the body. Typically, they develop in the 
head (periorbital and ear), neckline, axilla, distal limbs, ventral abdomen 
(paragenital region) and groin (Ragland et al., 1970a; Goodrich et al., 1998; 
Martens et al., 2000). In Australia, USA and mainland Europe isolated or a small 
number of tumours have been reported, whereas in the U.K. affected animals 
more often than not have multiple lesions (Knottenbelt et al., 1995). Previous 
history of trauma or skin damage has been suggested to be a factor that 
increases susceptibility to ES (Ragland et al., 1970a; Knottenbelt, 2005b). 
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1.1.3. Clinical aspects of equine sarcoids 
1.1.3.1.  Equine sarcoid subtypes 
Equine sarcoids have a variable clinical presentation. They can present as unique 
masses or multiple lesions. They are not painful and also non-pruritic unless 
ulceration and secondary infection occur (Hamann & Grabner, 2005). 
Classification of sarcoids is based on macroscopic appearance and skin 
involvement (Knottenbelt, 2005b). This classification is useful for clinical 
decisions, for a treatment plan, to monitor progress and prognosis. In brief, 
equine sarcoids are classified as occult, verrucose, nodular (type A1, type A2, 
type B1 and type B2), fibroblastic (type 1a, type 1b and type 2), mixed and 
malignant. Examples are displayed in Figure 1.2. Occult sarcoids are the most 
benign form of ES and are thought to represent an early stage of the disease. 
Occult sarcoids are often circular alopecic lesions with a grey colour, that lack 
hair and their appearance is of a hyperkeratotic dry lesion. On palpation, skin 
feels thickened, dry and has small nodules underneath. This form is easily 
misdiagnosed as ‘ring-worm’ (dermatophytosis) or skin rubs from tack or other 
equipment (see Figure 1.2, Image 1). Verrucose sarcoids are prominent from the 
skin and they are similar to warts in appearance. The skin on these lesions is dry, 
alopecic and scaly. The margins are not well defined. Due to the ‘wart-like’ 
appearance these can be mistaken for equine papillomas. Nodular sarcoids are 
circumscribed firm subcutaneous masses that can appear as single or multiple 
lesions. Type A are characterised by no skin involvement (the skin can be freely 
moved over the nodules). If the underlying tissues are not involved it is classified 
as nodular type A1 and if there is deep tissue involvement it is named A2 
(Knottenbelt, 2005a). Nodular type B sarcoids are nodular sarcoids with visible 
and palpable skin involvement. When they have defined margins they are 
classified as B1 and if they have ill-defined margins they are named B2. 
Fibroblastic tumours have a ‘fleshy’ appearance (see Figure 1.2, Image 5). They 
are an aggressive form of sarcoids and have a tendency to ulcerate and become 
infected. Fibroblastic pedunculated sarcoids have a clear margin and a ‘neck’ 
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Figure 1.2. Examples of clinical types of equine sarcoids. 1. Occult. 2. 
Verrucose. 3. Nodular type A. 4. Nodular type B. 5. Fibroblastic pedunculated. 6. Mixed 
(Knottenbelt, 2005b) 
that separates the lesion from healthy skin. Depending on deep tissue 
involvement, fibroblastic pedunculated sarcoids are classified as type 1a with no 
deep tissue involvement, and type 1b with deep tissue involvement. Fibroblastic 
sessile sarcoids on the other hand have ill-define margins, a broader base and 
there is always involvement of underlying tissue. It can become difficult to 
macroscopically differentiate any of the fibroblastic sarcoids from fibrosarcoma 
and squamous cell carcinoma in which case biopsy will be recommended. Other 
skin diseases that fibroblastic sarcoids may be mistaken with are exuberant 
1 2 
3 4 
5 6 
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granulation tissue (‘proud flesh’), a common complication in horses in wound 
healing. Mixed sarcoids are very variable in appearance and they can combine 
two or more of the forms described above. Malevolent equine sarcoids 
sometimes called malignant, are rarely described in the literature. The tumour 
infiltrates the lymphatic system and the progression is fast. It affects extensive 
areas and it may comprise different clinical types of ES. 
1.1.3.2.  Histopathology 
Although histological findings are inconsistent, the microscopic appearance that 
defines equine sarcoids is characterized with acanthosis (epidermal hyperplasia), 
hyperkeratosis, rete peg formation (formations of superficial epidermal layers 
that run perpendicular to the skin surface, a normal finding in certain mucosae 
but it is abnormal in skin), picket fence fibroblast formation (fibroblasts sit 
perpendicular to the basal membrane) and proliferation of fibroblast-like cells 
(fusiform or spindle-shape fibroblast that form whorls) (see Figure 1.3) (Martens 
et al., 2000). The epidermal surface may be normal, thinner or have been 
ulcerated (Marti et al., 1993; Martens et al., 2000). 
 
 
 
 
 
 
 
 
Figure 1.3. 160x microscopic amplification of a haematoxylin-eosin 
histopathology cut from an equine sarcoid, where all the most common 
features can be identified (Martens et al., 2000) 
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1.1.3.3.  Diagnostic test  
Historically, clinical appearance and histological findings of sarcoids have been 
the tools to diagnose ES. For further details on histology the reader is advised to 
refer to section 1.1.3.2. 
However, histology examination is not exempt of risk. Firstly, collecting biopsy 
specimens can be counterproductive for the patient, as the procedure can 
aggravate and worsen the progression of the tumour (Roberts, 1970; Martens et 
al., 2001c). Secondly, the microscopic appearance of the lesions may be 
commonly confused with fibroma or fibrosarcoma and therefore the examination 
of the samples requires an experienced pathologist (Weiss, 1974; Taylor & 
Haldorson, 2013). Moreover, there is great variability in the histopathological 
signs and to date there are no pathognomonic features in equine sarcoids 
(Knottenbelt & Kelly, 2000). In a study based on 50 samples from five clinical 
types, Martens et al. (2000) identified increased proliferation of fibroblastic-like 
cells in all the tumours, although the occurrence of the rest of the 
histopathological features were highly variable. Differential diagnosis to consider 
when observing lesions compatible with sarcoids include excessive granulation 
tissue, granuloma, other papillomavirus lesions, fibroma/fibrosarcoma, 
cutaneous lymphoma, squamous cell carcinoma and, less commonly, habronema 
lesions, mast cell tumours, melanomas and staphylococcal folliculitis 
(Knottenbelt, 2005b).  
Although the majority of sarcoid diagnoses are based upon clinical examination 
and histopathology, detection of BPV-1/-2 genomic DNA and viral expression in 
the masses can contribute to confirm the diagnosis of ES (Nasir & Reid, 1999; 
Carr et al., 2001a; Nasir & Campo, 2008). 
1.1.3.4.  Treatment and prophylactic methods for equine sarcoids 
ES are not metastatic but often show aggressive and infiltrative growth, often 
recur following ineffective treatment and animals with isolated masses 
frequently progress to develop multiple tumours (Goodrich et al., 1998; 
Knottenbelt, 2005a). Spontaneous regression is only rarely observed (Brostrom, 
1995; Knottenbelt & Kelly, 2000). Most lesions tend to develop to a more 
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aggressive type with time, especially when exposed to trauma (Hamann & 
Grabner, 2005). 
No therapy exists that is universally effective for all cases of equine sarcoids. 
Treatment of sarcoids consists of removing the tumours through surgical excision 
(or with the use of a laser, liquid nitrogen or burning agents) followed or 
combined with cryotherapy, chemotherapy in the form of cysplatin beads or 
injections, intralesional fluoracil injection (5-FU), ‘Liverpool cream’ (marketed 
as AW3/4 ludes), immunotherapy (such as BCG or Imiquinol), local radiotherapy 
(iridium) and more recently, antiviral agents (Taylor & Haldorson, 2013). In a 
small percentage of cases, tumours spontaneously disappear and this may lead 
to the belief that the treatments were successful (Brostrom, 1995; Martens et 
al., 2001b). It is not possible to compare post-treatment recurrence rate from 
the data available in the literature due to the bias in the population selected, 
not enough follow-up time to ensure no further development of the tumour, the 
differences in the therapeutic techniques, or in some studies the lack of 
confirmation of the diagnosis using histopathology. Recurrence rates are quoted 
from 5-64% (Tarwid, 1985; Knottenbelt et al., 1995; Knottenbelt & Kelly, 2000; 
Martens et al., 2001b). Vaccination has been attempted with variable success 
(Ashrafi et al., 2008; Rothacker et al., 2015), and alternative genetic therapy 
using knock-down of a BPV-1 oncoprotein E6 has shown promising results in vitro 
(Yuan et al., 2011b). However to date, no preventative tools are available for 
equine clinicians and horse owners.  
1.1.4. Equine sarcoid pathology 
1.1.4.1. Aetiology 
Jackson (1936) was the first to postulate that equine sarcoids may be caused by 
an infectious agent, based on clinical observations and pattern of spread of 
sarcoids in South Africa. A year after this report, the link between cancer and 
papillomavirus was established in rabbits (Rous & Beard, 1935; Jackson, 1936). A 
series of epidemiological and transmission studies followed, confirming 
autologous and homologous transmission of equine sarcoids giving strength to the 
theory that a transmissible agent was involved in the disease (Olson & Cook, 
1951; Ragland et al., 1966; Voss, 1969; Ragland et al., 1970b). The transmission 
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studies used inoculation of extracts from bovine papillomas, extracts from 
naturally occurring sarcoids (NOS) and transplantation of excised tumours from 
sarcoid-bearing horses to healthy horses and donkeys. Unlike NOS, 
experimentally induced lesions were self-limiting, which indicates that 
additional factors are likely to contribute to the progression of the disease.  
Just a few years before the development of the Polymerase Chain Reaction 
(PCR), Lancaster et al. (1977) used DNA hybridisation to demonstrate the 
presence of bovine papillomavirus type 1 and type 2 genomes (BPV -1/-2) in NOS 
and artificially induced equine sarcoids. The advent of PCR led to several studies 
confirming the involvement of BPV-1/-2 in equine sarcoids and at present, there 
is strong evidence to suggest that Bovine papillomavirus types 1 and 2 (BPV-1/-2) 
are causally associated with in the disease (Angelos et al., 1991; Chambers et 
al., 2003a; Nasir & Campo, 2008; Nasir & Brandt, 2013). More recently the 
involvement of a third papillomavirus, BPV-13, has been documented in NOS 
(Lunardi et al., 2013a). Whereas BPV-1 is most commonly found in ES in Europe 
and Australia, BPV-2 has been found to be more prevalent in ES in U.S.A. and 
Canada and BPV-13 in Brazil (Otten et al., 1993; Bloch et al., 1994; Carr et al., 
2001a; Bogaert et al., 2007; Borzachiello et al., 2008; Wobeser et al., 2010; 
Lunardi et al., 2013b). 
There is an evident link between the presence of BPV-1/-2 and the development 
of ES but unfortunately many aspects of the disease remain poorly understood. 
In vitro experiments have proved that BPV-1 can transform equine primary 
fibroblasts to a phenotype seen in NOS (Yuan et al., 2008a). BPV viral DNA is 
consistently present in the tumours (Amtmann et al., 1980; Martens et al., 
2001c; Chambers et al., 2003b; Bogaert et al., 2007; Yuan et al., 2007b; 
Borzachiello et al., 2008) together with viral gene expression (Nasir & Reid, 
1999; Carr et al., 2001b; Chambers et al., 2003b; Borzachiello et al., 2008; 
Brandt et al., 2011b; Wilson et al., 2013). BPV-1/-2 DNA was undetected in 
other skin lesions including melanomas, papillomas and healthy skin (Carr et al., 
2001a; Bogaert et al., 2007; Gaynor et al., 2016) but present in equine 
inflammatory skin disease (Yuan et al., 2007c; Wobeser et al., 2012). 
Nevertheless, BPV-1/-2 DNA was detected in one case of squamous cell 
carcinoma (SCC) (Kainzbauer et al., 2012) and hoof canker (Brandt et al., 
2011a). Only one report has proven the existence of BPV-1/-2 DNA in skin swabs 
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of a small group of horses free of sarcoids but in close contact with sarcoid-
bearing animals (Bogaert et al., 2005). However, long-term epidemiological data 
from the latter study were never reported. Presence of BPV-1 DNA in visibly 
healthy skin has also been reported in the margins of ES in sarcoid-bearing 
horses, up to 16mm from the margins of the tumours (Martens et al., 2001a). 
In sarcoids, viral DNA is detected largely in fibroblasts and is present at variable 
viral loads – reported from 2 copies per cell to several hundreds (Amtmann et 
al., 1980; Yuan et al., 2007b; Haralambus et al., 2010; Brandt et al., 2011b). 
One study identified viral genomes/per unit mass of tumour as a marker for 
severity of ES (severity was measured as rapid growth rate, presence of multiple 
tumours and high recurrence when treated) but not as a marker for clinical types 
(Bogaert et al., 2007). When compared to naturally occurring tumours in cattle 
due to BPV-2, the number of BPV-1/-2 genomes per cell is substantially higher in 
equine sarcoids (Yuan et al., 2007c).  
Bovine papillomaviruses host range, classification and viral components  
Bovine papillomaviruses (BPVs) belong to a heterogeneous family of non-
enveloped circular double stranded DNA viruses, named Papillomaviridae 
(Bernard, 2006). In general papillomaviruses (PVs) are strictly species-specific 
(Smith et al., 1984) and they affect only amniotes as they have been identified 
in mammals, birds and reptiles but not amphibians (Rector & Van Ranst, 2013).  
The natural host of BPVs is cattle, in which the virus can cause benign tumours 
(papillomas and fibropapillomas) that more often than not regress, although 
occasionally they lead to malignant transformation affecting the gastrointestinal 
tract, udder, penis and bladder (Goodrich et al., 1998; Chambers et al., 2003b; 
de Villiers et al., 2004; Silvestre et al., 2009; Pangty et al., 2010; Maiolino et 
al., 2013; Roperto et al., 2013). Three types of BPVs (BPV-1, -2 and -13) have 
been linked to the development of equine sarcoids therefore equine sarcoids are 
considered the first case of cross-species infection by PVs (Otten et al., 1993; 
Nasir & Reid, 1999; Campo, 2003; Wobeser et al., 2010; Lunardi et al., 2013b). 
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 Table 1.1. Summary of the 15 BPV types and main differences between the 
genotypes grouped in four genera 
All papillomaviruses are classified by nucleotide sequence of the major capsid 
protein L1 open reading frame (de Villiers et al., 2004). To date over 316 
distinct types of PVs have been described and they are grouped into 38 genera 
(Van Doorslaer et al., 2013). The 15 types of BPVs characterised up to the 
present time (last update from 23/05/2016), are classified within four of these 
genera: Delta-, Epsilon-, Xi- and Dyoxipapillomaviruses. Details of the BPV types 
and main differences between genera are displayed in Table 1.1 (Bernard, 2006; 
Bernard et al., 2010; Van Doorslaer, 2013). 
The genome of BPV is approximately 8 kilobasepairs (Kbp) and it is enclosed in 
an icosahedral capsid of 55-60 nm in diameter (Campo, 2006). The genome is a 
double stranded circular DNA associated with histones and it is divided into 3 
canonical regions: the early genes, the late genes and the long control region 
(LCR). A schematic representation of the layout of the BPV-1 genome is 
displayed in Figure 1.4.  
Genera DeltaPVs EpsilonPVs XiPVs DyoxyPVs 
BPV types 
BPV-1 
BPV-2                    
BPV-13 
BPV-14 
BPV-5 
BPV-8 
BPV-3                   
BPV-4                  
BPV-6                   
BPV-9                     
BPV-10                
BPV-11                    
BPV-12                  
BPV-15 
BPV-7 
Target cells Fibroblasts 
Superficial layers of 
the epithelium as well 
as fibroblasts 
Superficial layers 
of the epithelium 
Superficial 
layers of the 
epithelium 
Type of 
lesion 
Fibropapillomas 
Epithelial lesions and 
fibropapillomas 
Epithelial lesions 
Epithelial 
lesions 
Genome 
length 
≈ 8 Kbp ≈ 8 Kbp ≈ 7.3 Kbp ≈ 7.3 Kbp 
Other 
features 
12 E2* protein 
binding sites in 
LCR** 
10 E2* protein binding 
sites in LCR** 
4 E2* protein 
binding sites in 
LCR** and no 
E6*** 
4 E2* protein 
binding sites in 
LCR** 
     *E2= one of the early proteins 
     **LCR=long control region of the BPVs genome 
     ***E6= one of the early proteins with oncogenic function 
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The early genes encode non-structural regulatory proteins, which are essential 
for the life cycle, as well as oncoproteins (E5, E6 and E7). The early proteins 
participate in the modulation of the immune response and host cell growth, viral 
replication and regulation of transcription. Some of the early proteins 
(oncoproteins) are responsible for the oncogenic roles of BPVs (Bergman et al., 
1988; Chambers et al., 2003b; Campo, 2006; Munday, 2014). 
 
 
 
 
 
 
 
Figure 1.4. Diagrammatic genomic organisation of BPV-1. The circular genome 
of BPV-1 is 8Kbp long and it encodes six early proteins (E1, E2, E4, E5, E6 and E7) and 
two late proteins (L1 and L2), together with a long control region (LCR) 
 
The late genes encode structural proteins for the capsid (L1 and L2) and the LCR 
is a non-coding region that contains the sequences of transcription promoters 
and enhancers, the origin of DNA replication and binding sites for cellular 
transcription factors (Spalholz et al., 1987; Chambers et al., 2003b; Nasir et al., 
2007).  
BPVs life cycle 
The viral cycle of BPVs, as for other PVs, is intimately linked to the 
differentiation of the epithelium and the virus uses the cell machinery for its 
 
 16 
viral replication. A schematic representation of the known stages of the BPV-1 
life cycle is displayed in Figure 1.5.  
 
Figure 1.5. Schematic representation of the known stages of BPV-1 life cycle 
in ES. Stages in the upper layers such as capsid synthesis and viral particle formation 
have not been demonstrated in ES yet although expression of the late proteins and 
virus-like particles have been recently reported (Brandt et al., 2008b) 
It is hypothesised that in equine sarcoids, BPV-1 and -2 access basal layers of the 
stratified epithelium (basal keratinocyte) by microtrauma on skin/mucosa. 
Interestingly there is recent evidence of the DeltaPV BPV -2 infecting and 
replicating in transitional epithelium, placenta and lymphocytes in cows 
suffering from BPV-2 induced bladder cancer, and BPV-1 and -2 have been 
detected in white blood cells of horses with and without BPV-1/-2 induced skin 
lesions, suggesting that in Delta BPVs, there may be the possibility of vertical 
transmission as well as entry through the epithelium (Brandt et al., 2008a; Hartl 
et al., 2011; Roperto et al., 2012; Silva et al., 2013b). It is thought that BPVs, 
similar to HPVs, gain access to the intracellular space through L1 protein 
interactions with extracellular sulphated sugars (Joyce et al., 1999). In other 
PVs, it is suggested that the virus is then enclosed in an endosome by interaction 
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with alpha-6 beta-4 integrin receptor (McMillan et al., 1999) and the capsid 
protein L2 initiates the liberation of the genome from the endosome and 
entrance into the nuclear space (Kamper et al., 2006).  
BPVs form paracrystaline arrays in the nucleus of infected cells, and the genome 
is maintained at a low level (10-200 copies) as an extrachromosomal element 
(episomally) using the host machinery, as PVs do not encode polymerases (Park 
et al., 1994). E1 and E2 proteins are essential during this phase. Basal cell 
replication maintains the infection but the virus needs to ascend to superficial 
layers to complete the life cycle. As infected cells from basal layers enter 
cellular division, viral DNA is evenly distributed between the two descendent 
cells and linked to the host chromosomes by the protein PV E2 (Baxter et al., 
2005); whilst one cell migrates to more suprabasal layers (spinous and granular) 
to initiate differentiation, the other cell containing the viral genome remains in 
the basal layer providing a reservoir of the viral genome. Infected basal and 
suprabasal cells express viral early proteins in the cytoplasm. Viral genome 
replication occurs in the suprabasal layers, and these cells in the absence of the 
virus are non-proliferative. Predominantly, the expression of E6 and E7 in HPVs 
and E5 in delta BPVs dysregulate the cell cycle, forcing differentiating cells into 
S phase, and allowing viral genome amplification in cells that normally would 
have exited the cell cycle (von Knebel Doeberitz, 2002; Venuti et al., 2011; 
Doorbar et al., 2012). PV oncoproteins can also activate a series of pathways 
that lead to uncontrolled proliferation, loss of differentiation of infected cells 
and loss of cell growth inhibition, and this is linked to accumulation of cellular 
mutations (persistency of S phase during mitosis) (Moody & Laimins, 2010). 
In the PV life cycle in the natural host, expression of the late proteins to form 
the capsid is confined to the most superficial layers of the epithelium. Virus 
particles are then released when cells die. In equine sarcoids there is no 
evidence of mature virus being released, as infectious virions have not been 
isolated yet within equine sarcoids (Amtmann et al., 1980). However, the 
presence of virus-like-particles (BPV-1 genome associated with L1 capsid 
formations) has been reported in a small group of ES using immunocapture PCR, 
a very sensitive technique (Brandt et al., 2008b). This is the first evidence for 
the presence of precursor viral particles in equine sarcoids. There may be two 
reasons for the lack of infectious virions in equine sarcoids. Firstly, the 
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complexes reported by Brandt et al. (2008b) may be produced at a low level. 
Secondly, as horses are not the natural host of BPV-1/-2/-13 but non-permissive 
hosts, equine sarcoids may represent an abortive form of BPV infection in horses 
(Campo, 2003; Chambers et al., 2003b). 
In equine sarcoids, BPV-1 was initially thought to be restricted to equine 
fibroblasts of the dermal-epidermal junction (Teifke et al., 1994). BPV-1 
genomes have been recently demonstrated in both dermis and epidermis – 
including keratinocytes - of naturally occurring equine sarcoids, suggesting a 
more complex pathogenesis (Bogaert et al., 2010; Brandt et al., 2011b; Wobeser 
et al., 2012).  
BPV-1/-2 transmission in equine sarcoids 
The transmission route of equine sarcoids is not yet clear. Direct transmission 
has been suggested between cattle or affected equids to other equids free of 
sarcoids (Jackson, 1936). This has been demonstrated in donkeys where close 
contact can result in the development of ES (Reid et al., 1994). The presence of 
viral DNA in the epidermis of horses with inflammatory conditions suggests the 
possibility of transmission between individuals via direct contact (Wobeser et 
al., 2012). Indirect transmission through a vector or fomites seems plausible. 
BPV-1/-2 may spread in insect vectors where it has been found (Kemp-Symonds, 
2000; Finlay et al., 2009). This hypothesis is also supported by clinical and 
epidemiological data. Some horses develop multiple tumours, ES can occur in 
intact skin and horses that have not been in contact with cattle can develop ES 
(Voss, 1969; Reid et al., 1994; Torrontegui & Reid, 1994; Knottenbelt et al., 
1995). These facts suggest that vectors may play an important role in the 
disease. Indirect transmission through fomites such as tack equipment or brushes 
is another possibility as the papillomaviruses resist desiccation for days 
maintaining infectivity (Roden et al., 1997). Vertical transmission has not been 
demonstrated in ES although BPV-1 DNA and viral expression has been reported 
in white blood cells of horses with experimentally induced ES (Brandt et al., 
2008a; Hartl et al., 2011). In cattle affected by BPV-2 bladder cancer, presence 
of the virus in placenta suggests the possibility of vertical transmission (Roperto 
et al., 2012). 
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BPV-1/-2 oncoproteins and their role in tumoural development 
As in high risk-HPV (HR-HPV) induced cancers, BPV -1/-2 presence is essential for 
the development of ES but infection alone is not sufficient for tumour 
production (Bogaert et al., 2005; Yuan et al., 2007c; Bogaert et al., 2008). 
Bradford Hill criteria for viruses as causality of cancer is a widely used guide that 
utilises certain clinical and epidemiological data to establish the link between 
viruses and human cancers (Hill, 1965); unfortunately such data is not available 
for equine sarcoids.  
In HR-HPV induced cancers the virus is thought to promote the oncogenic process 
through several mechanisms such as allowing accumulation of genetic mutations 
and expressing proteins that alter the cell cycle and promote cell proliferation 
(Moody & Laimins, 2010). In 50% of HR-HPV induced cancers, tumoural 
transformation is linked to integration of the HPV genome into the host genome 
at points of genetic instability and it is linked to overexpression of oncoproteins 
E6 and E7 (Moody & Laimins, 2010). This is not the case for BPVs, which maintain 
their genomes episomally and in which the oncogenic effect is attributed to 
three early oncoproteins (E5, E6 and E7) in both ruminant cancers and equine 
sarcoids (Yuan et al., 2011b; Corteggio et al., 2013). In equine sarcoids, E5 and 
E6 have been proven to be the major transforming oncoproteins and E7 has a 
contributing oncogenic effect (Yuan et al., 2011b).  
BPV-1/-2 E5 oncoprotein 
Compared to high risk HPV-16 E5, BPV-1 E5 is small (83 vs. 44 amino acids long 
respectively), and by itself BPV-1 E5 has a higher transforming in vitro activity, 
as it is sufficient to fully transform mouse, primary human fibroblasts and equine 
fibroblasts (Marchetti et al., 2002; Yuan et al., 2011b). BPV-1 E5 has two main 
parts: an amino-terminal domain, with a strongly hydrophobic leucine-rich 
membrane-spanning region and a small hydrophilic single amino acid (glutamine) 
residue in position 17; and a hydrophilic carboxyl-terminal domain (Venuti et al., 
2011; Corteggio et al., 2013). The hydrophilic residues at position 17 of the 
amino-terminal domain and the carboxy-terminal tail are thought to be essential 
for the transforming effect of the BPV-1 E5 protein as they facilitate 
dimerization of the E5 protein and facilitate interaction with ATPase 16 K 
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subunit C and beta-type platelet-derived growth factor receptor (PDGFβ-R) 
(Horwitz et al., 1988; Goldstein et al., 1992; Klein et al., 1999). Seven variants 
in the amino-acid sequence of E5 in equine sarcoids have been identified when 
compared to BPV-1 E5 from bovine fibropapillomas. However, the glutamine in 
position 17 was found unchanged across five equine sarcoid BPV-1 E5 variants 
(Chambers et al., 2003a).  
BPV-1 E5 is found in the Golgi apparatus, endoplasmic reticulum and inner part 
of the cytoplasmic membrane of basal cells and superficial granular cells in 
bovine fibropapillomas and BPV-1 transformed bovine primary fibroblasts 
(Ashrafi et al., 2002; Venuti et al., 2011; Corteggio et al., 2013; Bocaneti et al., 
2016). The expression of the E5 protein in both basal cells and most superficial 
granular layers, including keratinocytes in bovine fibropapillomas suggests a role 
in both early stages and late stages of the viral infection (Corteggio et al., 
2013). In the natural host, BPV-1 E5 activates PDGFβ-R and subsequently 
upregulates the phosphatidylinositol – 3 - (PI3K)–protein kinase B (known as 
AKT)-cyclin D pathway, leading to cell cycle deregulation (Araibi et al., 2004; 
Borzachiello et al., 2008; Corteggio et al., 2010). PDGFβ-R recruits growth-
factor-receptor-bound protein 2 (GRB2) and ‘son of sevenless’ gene protein 
(SOS) leading to Ras activation but not to phosphorylation of the two mitogen-
activated-protein kinases extracellular-signal - regulated (Erk) and microtubule 
associated protein (Mek or MAPK2) kinases (Corteggio et al., 2012). Based on 
this, the PI3K-AKT-cyclin D rather than Ras-Erk pathway seems to be the 
important pathway in BPV urothelial carcinogenesis. BPV-1 E5 activates the 
proto-oncogene tyrosine-protein kinase (c-src) in bovine bladder carcinoma and 
it is hypothesised to be involved in the loss contact inhibition due to 
downregulation of gap junction communication through two mechanisms, 
deregulation of conexin26 and binding to the ductin section of the 16KDa cellular 
protein (Borzacchiello & Roperto, 2008; Silva et al., 2013a; Gil da Costa & 
Medeiros, 2014). 
Expression of BPV-1 E5 in equine sarcoids has been demonstrated in both dermis 
and epidermis (Brandt et al., 2011b). At a cellular level the oncoprotein of BPV-
1/-2 was found in the cytoplasm adjacent to the nucleus (Borzachiello et al., 
2008; Altamura et al., 2013). The best studied tumorigenic effects of BPV-1 E5 in 
equine sarcoids are related to the PDGFβ-R and the equine major 
 21 
histocompatibility complex (MHC) class I. BPV-1 and -2 E5 induce tumorigenic 
transformation to cell cultures by strongly and specifically binding to its cellular 
target, PDGFβ-R in a ligand-independent manner (Borzachiello et al., 2008). 
Increased amount of activated PDGFβ-R has been found in equine sarcoids and 
human fibroblasts expressing BPV-1 E5 oncoprotein, to bind a regulatory subunit 
of PI3-K together with increased expression of AKT and cyclin D3 which results in 
mitogenic signalling activation (Borzachiello et al., 2008). Activation of PDGF-β 
receptors of the dermal fibroblasts results in mitogenesis in nearby epithelial 
cells (Carr et al., 2001b), contributing to the pseudoepitheliomatous hyperplasia 
that is typically observed in BPV infected lesions. MHC class I is an important 
part of the immunosurveillance and it is responsible for antigen presentation to 
T-cells (Garcia-Lora et al., 2003). BPV-1/-2 E5 downregulates MHC class I by 
reducing the transcription and promoting its degradation (Ashrafi et al., 2002; 
Yuan et al., 2008b). Downregulation of MHC class I through intracellular 
retention leads to immune evasion as the molecules are not presented on the 
cell surface (Chambers et al., 2003b). Intracellular retention of MHC class I is 
thought to occur as a consequence of BPV-1 E5 binding to subunit C of the 16KDa 
cellular protein and affecting intracellular pH leading to acidification 
(Borzacchiello & Roperto, 2008). Decrease in MHC class I has been reported in 
BPV bovine cancer and ES (Ashrafi et al., 2002; Marchetti et al., 2002; Yuan et 
al., 2008b). Other possible effects demonstrated of BPV-1 E5 the activation of 
p38 and MAPK that leads to increased cell proliferation, and increase of MMP-1 
(Yuan et al., 2010b; Yuan et al., 2011c). A summary of the known oncogenic 
mechanisms of BPV-1 E5 in ES is displayed in Figure 1.6.  
BPV-1/-2 oncoproteins E6 and E7 
BPV-1 E6 and E7 are also small proteins (18 and 13 KDa respectively) located in 
the nucleus and in the cytoplasmic compartment and their oncomechanisms in 
bovine and equine tumorigenesis are not fully understood (Teifke et al., 1994; 
Borzachiello et al., 2008). In high risk human papillomavirus (HR-HPV), presence 
of E6 and E7 is essential for tumoural development but not sufficient, as there 
are patients expressing these viral proteins that do not develop cancer (Moody & 
Laimins, 2010). HR-HPV E6 and E7 affect a series of cellular pathways that lead 
to DNA damage and mutation resulting in a cancerous phenotype. HR-HPV E7 
protein binds and downregulates retinoblastoma protein (pRB). pRB is a tumour 
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suppressor and it regulates E2F promoters, a series of genes that code for 
transcription factors that intervene in cell cycle regulation, cell differentiation, 
mitosis and apoptosis. HR-HPV E7 also frees up E2F promoters by disrupting pRB-
E2F complexes. The consequence of alteration of these pathways is the 
disruption of the cell cycle. A second pathway proven to be associated with 
tumoural transformation in HR-HPV is the tumour protein p53 pathway. HPV E6 
and E7 affect p53 in opposite ways. p53 repairs DNA, is a tumour suppressor and 
regulates apoptosis amongst other functions. E6 and E7 activity on the p53 
pathway makes the cells virus permissive, allowing viral genome replication and, 
as a consequence of alteration of the cell cycle, the host DNA accumulates 
mutations (Moody & Laimins, 2010). HR-HPV E6 also activates transcription of 
telomerase reverse transcriptase (TERT), an essential step for cell 
immortalisation.  
BPV-1 E6 interaction with Crebb binding protein (CBP) and protein p300 leads to 
impairment of the function of tumour suppressor p53 (Zimmermann et al., 
2000). Binding of BPV-1 E6 with paxillin leads to alterations in the actin 
cytoskeleton that are intrinsically related to tumorigenesis and BPV-1 E6 has 
recently been reported to bind mastermind-like protein1 (MAML1), delaying 
keratinocyte differentiation by impairment of the Notch signalling pathway and 
subsequently gene transcription (Tong & Howley, 1997; Brimer et al., 2012; 
Brimer et al., 2014). Little is known about the mechanisms of BPV-1 E6 in ES. 
Expression of p53 was found consistent in 4 different clinical types of ES and 
mutation of p53 seems to be an uncommon event (Nasir et al., 1999; Bogaert et 
al., 2007). At a cellular level, presence of the virus triggered p53 mislocation by 
an unknown mechanism (Martens et al., 2000; Yuan et al., 2008b). Even though 
distribution of p53 is abnormal in sarcoid fibroblasts, BPV-1 E6 in ES is thought to 
promote tumorigenesis by p53 independent mechanisms.  
BPV-1 E7 in bovine fibropapillomas is expressed in spinous layers and in basal 
layers (Bohl et al., 2001). Co-localization of E7 with BPV-1 E5 in basal layers 
suggests that E7 may have a role in cell proliferation control (Bohl et al., 2001). 
BPV-1 E7 expression in suprabasal layers is linked in bovine fibropapillomas to 
the over-expression of beta-1 integrin and proliferating cell nuclear antigen 
(PCNA) and it is thought to relate to cell proliferation and cell-cycle 
dysregulation (Cooper et al., 2006). BPV-1 E7 sensitised cells to TNF induced 
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apoptosis (Liu et al., 2000). Unlike high risk HPV E7, BPV-1/-2 E7 protein does 
not have a pRB binding domain but contributes to tumoural transformation in 
bovines by blocking pRB function by binding to a 600-kDa retinoblastoma protein 
associated factor (p600) leading to inhibition of anoikis (cancer cell apoptosis 
mechanism) (DeMasi et al., 2005; DeMasi et al., 2007).  
BPV-1 E7 is found in the cytoplasm and nucleus in equine sarcoids (Borzachiello 
et al., 2008). This protein is co-expressed with the aforementioned BPV-1 E5 
suggesting a co-operative role of the E7 protein in tumoural transformation. In 
equine sarcoid tumours, BPV-1 E7 has been demonstrated to bind protein p600 
therefore contributing to cell transformation by inhibiting anoikis (Corteggio et 
al., 2011). It is through this mechanism that BPV-1 is thought to promote 
overexpression of matrix metalloproteinases (MMPs) contributing to invasiveness 
(Corteggio et al., 2011; Yuan et al., 2011a). Additionally, BPV-E6 is thought to 
contribute to MMPs upregulation in ES as both activate activator protein -1 (AP-
1). Overexpression of MMPs is linked to alteration of mechanisms of immunity 
and inflammation, cell adhesion, motility, and integrity as well as cell cycle/cell 
proliferation and apoptosis (Yuan et al., 2008b; Yuan et al., 2011b). Another 
effect attributed to BPV-1 E7 (and shared with BPV-1 E2) is the decrease in 
expression of toll-like receptor type 4 (TLR4) in ES (Yuan et al., 2010a). 
Oncogenic mechanisms of BPV-1 E6 and E7 in ES have been summarised in Figure 
1.7.  
Since many aspects of the tumoural transformation in equine sarcoids remain 
unknown, and the diagnostic, therapeutic and prophylactic tools currently 
available do not provide sufficient help to control or prevent the disease, there 
is a particular need for further understanding of the pathogenesis of equine 
sarcoids. To aid in the discovery of new diagnostic and therapeutic tools, it is 
essential to have knowledge of the molecular mechanisms by which the virus 
leads to the tumoural transformation. Recently, miRNAs, small RNA molecules 
that are known to control essential pathways within the cell, have been 
extensively studied in disease mechanisms including cancers and HPV induced 
disease. Their biogenesis, function and known role in cancer as well as current 
knowledge of the miRNAs in the horse will be fully described in the following 
section.  
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Figure 1.6. Summary of the oncogenic mechanisms of BPV-1 E5 demonstrated 
in ES. Solid arrows indicate upregulation or activation and dashed arrows indicate 
downregulation 
 
Figure 1.7. Summary of the oncogenic mechanism of BPV-1 E6 and E7 
demonstrated in ES. Solid arrows indicate upregulation or activation and dashed 
arrows indicate downregulation 
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1.2.  microRNAs (miRNAs) 
1.2.1. Definition 
microRNAs (miRNAs) are 18-23 nucleotide, single stranded RNA molecules that 
regulate gene expression at the post-transcriptional level (Ambros, 2004). 
miRNAs were first discovered in the free-living model nematode Caenorhabditis 
elegans, with the sequencing of miRNA lin-4 (Lee et al., 1993). These molecules 
are now known to be responsible for regulation of the cell cycle, cell 
proliferation and differentiation, apoptosis and senescence in a wide range of 
organisms (Kanellopoulou et al., 2005; Hermeking, 2007; Melton & Blelloch, 
2010). Importantly, dysfunctional expression of miRNAs has been linked to 
malignancies (Calin et al., 2002; Bhardwaj et al., 2010; Zheng & Wang, 2011). 
The function of miRNAs is evolutionarily conserved and these molecules are 
receiving increasing attention as potential biomarkers for diagnosis, prognosis, 
molecular classification, monitoring progression and treatment for many diseases 
(Srivastava et al., 2013). miRNAs can be expressed in a tissue- and species-
specific manner and they are stable in body fluids, tissues and paraffin 
embedded tissue samples (Srivastava et al., 2013).  
1.2.2. Biogenesis and mechanism of action of miRNAs in 
eukaryotic cells 
A summary of the biogenesis and mechanism of action of miRNAs is presented in 
Figure 1.8. miRNAs are expressed in a primary precursor form, referred to as a 
pri-miRNA, which is the transcription product of RNA polymerase II/III. These 
molecules, of hundreds to thousands of nucleotides in length, have a 
characteristic low energy fold-back hairpin secondary structure that lacks large 
internal loops of bulges (Cai et al., 2004; Lee et al., 2004). Primary miRNAs are 
processed into secondary precursors or pre-miRNAs of approximately 70 
nucleotides in length by a class 2 ribonuclease III enzyme named Drosha, that is 
associated with the microprocessor complex subunit DiGeorge syndrome 
chromosomal (or critical) region 8 (DGCR8 protein). Pre-miRNAs are then 
exported out of the cell nucleus by Exportin-5 and subsequently processed by 
another RNAse III Dicer to form the characteristic miRNA hairpin duplex 
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structure. miRNA hairpins comprise two complementary miRNA mature 
sequences: the active miRNA (guide strand) and the complementary passenger 
strand historically referred to as the star sequence (miRNA*). The current 
annotation refers to these as the miR-5p and miR-3p referring to their location 
at the 5’ or 3’ end of the RNA transcript. The guide mature form is considered to 
be the dominant, active molecule; the star strand was thought to undergo 
degradation. Nevertheless, recent studies have demonstrated that actually the 
passenger strand (miRNA*) can have a function (Jagadeeswaran et al., 2010). 
The ratio of mature to miRNA* abundance can vary between tissues and stages, a 
process referred as arm switching, which is thought to allow functional evolution 
of miRNAs (Griffiths-Jones et al., 2011). miRNAs inhibit mRNA translation 
causing deadenylation and/or degradation of their target mRNAs (Filipowicz et 
al., 2008). The guide miRNA strand is incorporated into the RNA-induced 
silencing complex (RISC) and directs the complex to mRNA target sequences, 
leading to translational repression. Specificity is achieved by imperfect base-
pairing of the miRNA, most commonly to the 3’-untranslated region (UTR) of 
target mRNA sequences.  There is evidence to suggest that 5’-UTR base pairing 
can also occur (Grey et al., 2010). The seed sequence of a miRNA, nucleotides 
from position 2-7/8 from the 5’ end (Lewis et al., 2005; Filipowicz et al., 2008; 
Friedman et al., 2009; Kim et al., 2009) is the region thought to be crucial for 
complementary base-pairing with target mRNAs. Closely related microRNAs are 
grouped into families based on homology of the seed sequence, and miRNAs in 
the same family are believed to be functionally equivalent in certain situations. 
One mature miRNA can be encoded by multiple regions of the genome and hence 
derive from different precursors (Wang et al., 2014a). One miRNA may target 
multiple mRNAs and conversely many mRNAs may be targeted by several miRNAs 
(Filipowicz et al., 2008). These mechanisms enable microRNAs to ‘switch on’ and 
‘switch off’ pathways involved in the cell cycle, proliferation, apoptosis, and 
senescence (Lu et al., 2005; Rosenfeld et al., 2008; Wang et al., 2011; Wu et 
al., 2014). These levels of complexity of miRNA-mRNA interactions make 
functional analysis of miRNAs challenging. 
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Figure 1.8. Schematic representation of biogenesis and mode of action of 
miRNAs. The first microRNA precursor (pri-miRNA) is transcribed in the nucleus and 
subsequently cut by a RNAse (Drosha) to form a 70-110 nucleotide long precursor (pre-
miRNA). This precursor is exported to the cytoplasm and cut by another RNAse (Dicer) 
to produce the mature dominant microRNA and the miRNA*. By imperfect base pairing 
the active/dominant miRNA binds into the target mRNA as part of a protein complex 
named RISC (RNA-induced silencing complex), that contains proteins from the argonaute 
family (Ago) 
 
1.2.3. miRNAs in cancer 
Interest in miRNAs as important regulators of gene expression arose from their 
identification not only in nematodes but in the human genome (Giza et al., 
2014). Dysfunctional expression of microRNAs has been linked to multiple 
pathological mechanisms including cancer (Calin & Croce, 2006; Venugopal et 
al., 2010; Kim et al., 2011a; Baek et al., 2015). Moreover, they are located in 
fragile regions of the genome and they have been shown to bind regions of the 
genome with chromosomal instability and/or amplification (Bhardwaj et al., 
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2010; Liu, 2013). miRNAs involved in cancer are named oncomiRs (Lotterman et 
al., 2008). By repressing certain cellular processes, some miRNAs can have an 
oncogenic effect or tumour suppressor effect (Huang et al., 2015; Tutar et al., 
2015). miR-15 and miR-16 were the first two oncomiRs reported. They are 
encoded on human chromosome 13 and were found to be deleted in patients 
with B cell chronic lymphocytic leukaemia (Calin et al., 2002). Since then, 
multiple studies have detected changes in miRNA expression linked to different 
types of cancer (Calin & Croce, 2006; Kim et al., 2011a; Kim et al., 2011b; Lajer 
et al., 2012; Sharma et al., 2014). miRNAs have been proposed as biomarkers for 
cancer, signatures for diagnosis and progression, and even as therapeutic tools 
(Heneghan et al., 2010; Wittmann & Jäck, 2010; Srivastava et al., 2013; Wang et 
al., 2014b; Nagaraj et al., 2015; Roth et al., 2015).  
One of the most commonly reported dysregulated group of mature miRNAs in 
cancer are members of the let-7 family, the sequence of which is perfectly 
conserved in a wide range of animal species, but not present in plants 
(Pasquinelli et al., 2000; Hertel et al., 2012). The let-7 family is involved in 
regulating cell differentiation and limiting cell proliferation and let-7 family 
miRNAs have been identified as important tumour suppressor genes (Pasquinelli 
et al., 2000; Lee et al., 2016). Members of the let-7 family are down-regulated 
in many tumours (Li et al., 2011; Yu et al., 2015; Hung et al., 2016) and one of 
the main pathways disrupted in carcinogenesis, the Ras-mitogen activated 
protein kinase (Ras-MAPK) pathway, is directly regulated by the let-7 family 
(Johnson et al., 2005; Masliah-Planchon et al., 2015). Other examples of tumour 
suppressors are miR-15a/16, miR-26, miR-29/181, miR-39a, miR-122 miR-
143/145, miR-150, miR-200b/c (Lotterman et al., 2008; Liu, 2013; Soon & Kiaris, 
2013). 
Examples of miRNAs that promote cancer development are miR-21, cluster miR-
17-92, miR-191, miR-155, miR-372 and miR-373 (Lotterman et al., 2008; 
Heneghan et al., 2010). It is important to acknowledge that due to the nature of 
the miRNA-target mRNA interactions, the same miRNA may function as a 
suppressor or as a tumour activator (Calin & Croce, 2006). 
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1.2.4. miRNAs in papillomavirus induced cancer 
Scarce information is available on the changes in miRNA expression in 
papillomavirus cancer, except for HPV- induced cancer. The effects of miRNAs in 
high risk HPV cancer has been extensively studied and during the last couple of 
years comprehensive reviews have been published by different groups (Banno et 
al., 2014; de Freitas et al., 2014; Sharma et al., 2014; Diaz-Gonzalez et al., 
2015; Wang et al., 2016). The effect of HPV on miRNA dysregulation is discussed 
in more detail in Chapter 5. Although there is some variation in a small number 
of miRNAs, several studies have shown altered expression of miRNAs in HPV 
cervical cancer. To name a few, HPV-16 causes in vivo upregulation of miR-
16/15b, miR-21 and downregulation of miR-34a, miR-143/145, miR-203 and miR-
218 (Wang et al., 2008; McBee et al., 2011). These changes lead to an inability 
to stop cell proliferation and other mechanisms that trigger tumoural 
transformation (Zheng & Wang, 2011; Lajer et al., 2012). Some of the miRNAs 
dysregulated in HPV induced cancer, such as miR-21, miR-143/145, miR-218 or 
miR-34a, have been suggested as biomarkers for the diagnosis of the disease and 
of disease progression (de Freitas et al., 2014). 
Viruses encode miRNAs and interestingly five potential miRNA candidates have 
been reported in HPV-16 located in the E5, E1 and L1 genes, and in the LCR 
region (Qian et al., 2013). However, other groups have not reported any miRNAs 
encoded in HPV (Wang et al., 2008).  
1.2.5. miRNAs in the horse 
The horse genome (Equus caballus) was first assembled and released seven years 
ago (EquCab2.0, GenBank assembly accession reference GCA_000002305.1) and 
since then a small number of studies have started to explore microRNA profiling 
in the horse. Since the first set of 354 mature microRNAs was predicted using an 
in silico method by Zhou et al. (2009), equine microRNA research has focused on 
disease-related experiments or breeding performance (Barrey et al., 2010; da 
Silveira et al., 2012; Buechli et al., 2013; Das et al., 2013; Donadeu & Schauer, 
2013; da Silveira et al., 2014; Desjardin et al., 2014). Three experimental 
approaches have been used to date to identify potential equine microRNAs: in 
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silico prediction (Zhou et al., 2009), microRNA quantitation using real-time 
quantitative reverse-transcription polymerase chain reaction (real-time qRT-
PCR) either on a commercial platform or as individual tests (Barrey et al., 2010; 
da Silveira et al., 2012; Buechli et al., 2013; Donadeu & Schauer, 2013; da 
Silveira et al., 2014) and microRNA transcriptome analysis using high throughput 
sequencing (HTS also known as RNA-seq technology) (Desjardin et al., 2014; Kim 
et al., 2014; Platt et al., 2014). The main findings of these studies are 
summarised in Table 1.2. 
1.2.5.1. Predicted (in silico) microRNAs in the equine genome 
Zhou et al. (2009) performed the first in silico integrated comparative analysis 
of equine miRNAs and predicted 354 mature miRNA sequences in the equine 
genome using bioinformatic tools. These miRNAs were mapped to 407 genes, 
located on all 32 chromosomes except ECA19 and ECA31. Out of the 354 mature 
microRNA sequences, 75 were grouped into 32 families. This was achieved by 
comparing the entire database of animal microRNAs (miRBase) to the most 
updated version of the genome of the horse (EquCab2.0) with bioinformatic 
tools. No experimental validation was performed in the study of Zhou et al. and 
the microRNA candidates were predicted using a series of assumptions: 
- A total number of five nucleotide mismatches with microRNAs from other 
animal species was accepted. 
- The search in Basic Local Alignment Search Tool (BLAST) was modified to 
analyse smaller fragments of RNA of seven nucleotides, rather than the 
default number (11 nucleotides length). 
- Expectation value (e value) of ten was considered acceptable. 
- Structural characteristics as well as minimal folding free energy were 
taken into account for the predictions (MFold and MiPred softwares). 
 
 
 
Table 1.2. List of studies reporting equine miRNAs in the literature with a summary of the techniques and findings 
 
 
Source Species Type of study 
Number of 
horses / samples 
Type of sample 
Condition under study / 
method 
Number of 
miRNAs of 
interest / 
discovered 
Annotations of the 
miRNAs of interest 
Zhou et al., 
2009 
Equine in silico prediction 
not applicable - in 
silico study 
genomes from all 
animals and genome 
assembly of the 
horse (EquCab2) 
Descriptive, comparative and 
predictive (integrated method) 
354 mature 
miRNA 
predicted 
candidates - 
407 genes 
not applicable - in silico 
study 
Barrey et 
al.,2010 
Equine 
real-time qRT-PCR 
(Taqman®) - 
human sequences 
20 Cobs/French 
trotters including 
controls 
muscle and blood 
Recurrent exertional 
rhabdomyolysis (RER) and 
polysaccharide storage 
myopathy (PSSM) (muscular 
diseases) 
10 
miR-1, miR-23a, miR-30b, 
miR-133, miR-181, miR-
188, miR-195, miR-206, 
miR-339, miR-375 
da Silveira 
et al., 2012 
Equine 
real-time qRT-PCR 
(SYBR green) - 
human sequences 
(miRNome) 
not specified ovarian follicular fluid 
Differences between old and 
young mares (breeding 
performance) 
3 
14-signature miRNA of 
'young mares' and 5 of 'old 
mares' in exosomes. 
Differentially expressed: 
miR-181a, miR-375 and 
miR-513a-3p 
Buechli et 
al., 2013 
Equine 
real-time qRT-PCR 
(Taqman®) - 
human sequences 
not applicable - in 
vitro study 
cells 
Screening in chondrocytes 
(orthopaedic conditions) 
1 miR-140 
Das et al., 
2013 
Equine 
RNA-seq, no 
validation 
reported 
5 stallions semen 
Descriptive transcriptome 
semen in the horse (breeding 
performance) 
82 
miR-34B, miR-34C, miR-
191, miR-223, miR-1248, 
and miR-1905C are the 
most expressed miRNAs 
Donadeu 
and 
Schauer, 
2013 
Equine 
real-time qRT-PCR 
(SYBR green) - 
human sequences  
5 mares follicular exosomes 
Follicular growth (breeding 
performance) 
9 
miR-21, miR-23a, miR-145, 
miR-503, miR-224, miR-
383, miR-378, miR-132 
and miR-212 
3
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 Table 1.2. (Continuation) List of studies reporting equine miRNAs in the literature with a summary of the techniques and findings 
Source Species Type of study 
Number of 
horses / samples 
Type of sample 
Condition under study / 
method 
Number of 
miRNAs of 
interest / 
discovered 
Annotations of the 
miRNAs of interest 
Desjardin 
et al., 
2014 
Equine 
RNA-seq and 
validation using 
real-time qRT-
PCR (Taqman®) 
3 10-month old 
foals with 
osteochondrosis 
and 3 10-moth 
old foals with no 
osteochondrosis 
15 samples from 
bone and 15 samples 
from cartilage from 
each group 
Osteochondrosis (orthopaedic 
diseases) 
371 mature 
miRNA 
candidates* 
299 suggested 
novel 
miRNAs**  
DE of microRNAs in bone 
and OC was found in 
controls vs predisposed 
Buza et 
al., 2014 
Human, 
cow, 
chicken, 
pig, dog, 
equine 
In silico 
prediction 
not applicable - in 
silico study 
not applicable Comparative study 
146 miRNAs 
present in the 
horse# 
 not specified 
da Silveira 
et al., 
2014 
Equine 
real-time qRT-
PCR (SYBR 
green) -  human 
sequences 
(miRNome) 
12 mares ovary 
Different parts of the oestrus 
cycle (breeding performance 
4 
miR-27b, miR-372, miR-
382 and miR-27b 
Plat et al., 
2014 
Bat, dog, 
equine 
RNA-seq and 
validation using 
real-time qRT-
PCR (Taqman) 
not specified  1 testicular tissue Comparative study not specified not specified 
Kim et al., 
2014 
Equine 
RNA-seq, no 
validation 
reported 
8 Thoroughbred 
horses 
liver, colon and 
muscle 
Descriptive  
292 previously 
described *** 
392 novel **  
not applicable - 
transcriptome study 
*some of the miRNA annotations are not in miRBase; **miRNA sequences not submitted to miRBase (02/2016); *** miRNAs have significant variation to the sequences 
in miRBase; #present in the horse and  in humans are associated with disease in the database HDMACs (human disease microRNAs with animal counterpart) 
3
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1.2.5.2. Real-time quantitative reverse transcription PCR (qRT-PCR) 
quantification of miRNAs using human/mice sequences for the primers/probes. 
Quantification of microRNAs using qRT-PCR has been achieved either with DNA 
binding dyes (SYBR green) or probe-based chemistries (Taqman®). SYBR green I 
dye binds to any double stranded DNA (dsDNA). TaqMan® probes contain a 
fluorescent reporter dye at the 5’ end and a quencher dye at the 3’ end. During 
the PCR reaction, the dye is separated from the quencher initiating fluorescence 
liberation. SYBR green quantification is less expensive, and less specific. The 
advantage of SYBR green is the melting curve of the PCR products that allows 
examination of any non-specific amplification or contamination. On the other 
hand, Taqman® technology offers higher specificity as this dye is only liberated 
from the probe after binding to the fragment of interest. No fluorescence is 
created if no hybridisation occurs with the sequence of interest. Taqman® does 
not offer the ability of obtaining a melting curve and due to the high specificity 
is not suitable for detection of isomiRs, identical mature miRNAs that are 
generated from different genomic locations, whereas SYBR green can amplify 
isomiRs due to the lower specificity during reverse transcription and PCR stages. 
High sequence specificity of the Taqman® reverse transcription stem-loop 
primers and PCR probes, designed to bind to one unique precursor during reverse 
transcription and in the PCR phase to amplify one unique mature sequence, 
confers this specificity to Taqman®. As isomiRs are encoded in the sequence of 
different precursors in different parts of the genome, only the pair selected for 
Taqman® amplification would be quantified and therefore there is the 
disadvantage of underestimating the total amount of a mature miRNA sequence 
(including isomiRs). Fluorescence in both SYBR green and Taqman is proportional 
to the amount of sequence of interest found in the reaction. 
Exploiting the knowledge that some microRNAs are highly conserved across 
species, three groups investigated microRNA expression in equine muscular 
disease, breeding and in equine cartilage/bone disease using qRT-PCR with 
human miRNA sequences (Barrey et al., 2010; da Silveira et al., 2012; Buechli et 
al., 2013). Barrey et al. (2010) investigated the abundance of 10 of the most 
commonly dysregulated microRNAs in human muscular disease. The study 
assessed horses with and without two common muscular pathologies, recurrent 
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exertional rhabdomyolysis (RER) and polysaccharide storage myopathy (PSSM). 
From this comparison they found a correlation between increased levels of six 
microRNAs and the presence of PSSM (miR-1, miR-133, miR-23a, miR-195 and 
miR-339 (p<0.05); data was normalized to an internal control (miR-375)). In a 
separate study examining miRNAs in breeding performance, da Silveira et al. 
(2012) found differences in expression of miR-181a, miR-375, miR-523-5p in 
young mares vs. older mares. This study was performed using SYBR green 
technology with primers designed to human miRNA sequences and expression 
levels were normalized against small nucleolar RNAs (U1, U6, U43). The three 
differentially expressed microRNAs identified have been found to regulate 
mitogen-activated protein kinase (MAPK). A third study conducted on an in vitro 
model, assessed the expression of miR-140 in equine mesenchymal cells using 
Taqman® (Buechli et al., 2013). Expression levels of this microRNAs were 
normalized using U6 and results showed that the expression of this microRNA is 
linked to chondrogenic differentiation, and that mRNAs encoding C-X-C motif 
chemokine ligand 12 (CXCL12) and a disintegrin and metalloproteinase with 
thrombospondin motifs 5 (ADAMTS-5) may be targeted by miR-140. 
1.2.5.3. Experimental verification of equine miRNAs using next generation 
sequencing 
While studying the transcriptome of semen from five stallions, Das et al. (2013) 
identified 82 equine miRNAs. This was an interesting finding as library 
preparation before sequencing was not specific for miRNAs. miRNAs provided by 
the authors are annotated as pri-miRNA so it is difficult to know whether they 
identified only the precursor sequences or the mature miRNAs. Kim et al. (2014) 
used RNA seq technology to identify differences in miRNA profiles in three types 
of equine tissues (colon, muscle and liver). In total, 684 miRNA candidates were 
suggested to be present in the three tissues, of which 292 had been annotated in 
miRBase and 392 are suggested to be novel miRNAs, not present in the miRBase. 
When comparing the sequences of these putative miRNAs to the sequences 
available in miRBase, the variation in nucleotide composition and miRNA length 
is significant. Additionally, no experimental validation of the RNA seq data was 
performed by Kim et al., (2014) suggesting the likelihood of false positives in 
their list of miRNAs. Of the 292 mature miRNA candidates with annotation, 42 
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were present in all three tissues, 42 were specific to muscle, 119 of colon and 41 
to liver. 
The most recent and detailed experimental study on equine miRNAs with the 
most robust analysis to date was released soon after Kim et al. (2014) published 
their findings (Desjardin et al., 2014). In this study, miRNAs were sequenced 
from cartilage and bone samples obtained from 10 month-old foals with and 
without a common orthopaedic condition, named osteochondrosis (OC). Post-
mortem specimens were analysed while raw and after biomechanical 
experiments. In total, the authors identified 670 miRNAs of which 371 can be 
found in miRBase and 299 are suggested to be novel miRNAs. A high percentage 
of miRNAs was found in both tissues (561 miRNAs, 85%). OC had an effect on the 
miRNA expression in cartilage (49 miRNAs) and bone (41 miRNAs). Confirmation 
of the differentially expressed miRNAs was achieved by quantifying three miRNAs 
in each tissue using qRT-PCR with Taqman® technology. Although this validation 
added robustness to the study, close analysis of the annotations published in the 
paper reveals that some of the annotations given to the mature miRNA 
candidates are not present in miRBase and that some miRNA candidates have 
mismatches in sequence and length when compared to their putative 
homologues in miRBase.  
The aforementioned studies have contributed to the identification of miRNAs in 
the horse, and their expression in different tissues and in a small group of 
pathologies (OC, PSSM, RER) as well as in breeding performance. The study of 
miRNAs in other species has helped to answer scientific questions about disease 
mechanisms including tumorigenesis and this can be potentially utilised to 
improve diagnostic tools and treatment options (Iorio & Croce, 2012). In 
addition, characterising the profile of miRNAs in equine sarcoids and identifying 
their potential regulatory function will be of benefit in understanding unknown 
aspects of the pathogenesis and aetiology of equine sarcoids.  
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1.3.  Aims and objectives of the project 
As fibroblasts are the main cell type altered in ES, this project utilised a number 
of technologies to examine any changes in expression of equine miRNAs in this 
cell type, which may help understand the aetiology of ES and potentially be 
applied to aid prognosis and diagnosis. The main aims were to: 
1. Describe the miRNA profile in equine normal fibroblasts (equine primary 
fibroblasts) 
No previous studies have been performed describing the miRNA profile in equine 
fibroblasts. 
2. Study the differential expression of miRNAs in equine sarcoids using an in 
vitro model.  
Since the presence of the BPV oncoproteins cause alterations in equine 
fibroblasts promoting tumoural transformation, and knowing that other viral 
induced cancers have an abnormal microRNA expression profile, this study aimed 
to identify cellular microRNAs that may be altered in equine sarcoids. 
Comparison of miRNA profiles was carried out using three different cell samples:  
1) normal equine fibroblasts (EqPalFs), 2) cells transformed with the BPV-1 
genome, EqPalF-BPV-1 cells referred to as S6-2 cells, and 3) equine tumoural 
fibroblasts, named EqSO4bs (Yuan et al., 2008a).  
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2.1.  General laboratory practice 
Hazardous chemicals were handled as described in the Control of Substances 
Hazardous to Health (COSHH) guidelines from the University of Glasgow. 
Laboratory coat and powder-free nitrile gloves were worn at all stages. Details 
for disposables, plastic ware, reagents, other chemicals, kits and electrical 
equipment, including manufacturers/providers, are listed in this chapter in 
Tables 2.1. – 2.10.  
2.2.  Cell culture 
Cell manipulation was performed in a designated tissue culture laboratory under 
aseptic conditions. With the exception of thawing cells and cell count, all 
procedures were performed in a Class II microbiological safety cabinet, BioMat 2 
(Medical Air Technologies Ltd, Manchester, U.K.). Prior to being introduced into 
the hood and/or the incubator, the surfaces and exterior of container and vials 
were treated with 70% molecular grade ethanol (VWR International Ltd., 
Lutterworth). 
2.2.1. Cell culture media, buffers and reagents 
Cell culture media was mixed and aliquoted within a Class II microbiological 
safety cabinet and stored at 4°C. When ingredients were to be used more than 
once, these were aliquoted and stored at either 4°C or -20°C following 
manufacturer’s advice. Recipes for the different types of media and 
manufacturers are displayed in Table 2.1. Commercially prepared media and 
plastic ware are displayed in Table 2.2. and Table 2.3. respectively. 
 
 
 
Table 2.1. Description of recipes of media used in cell culture 
 
 Table 2.2. List of commercially sourced buffers and reagents used in cell culture
 
 
Name 
Final 
concentration 
Abbreviation  Ingredients Manufacturer 
Culture 
media 
88.50% DMEM 
High Glucose Dulbecco’s Modified Eagles medium with 
Pyruvate - DMEM-GlutaMAX™  
Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
10% FBS 
Foetal Bovine Serum, qualified, heat inactivated, E.U.-
approved, South America Origin  
Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
1% Pen-Strep Penicillin-Streptomycin (10,000 U/mL)  Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
0.50% Fungizone Fungizone® Antimycotic  Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
Thawing 
media 
90% DMEM 
High Glucose Dulbecco’s Modified Eagles medium with 
Pyruvate - DMEM-GlutaMAX™ 
Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
10% FBS 
Foetal Bovine Serum, qualified, heat inactivated, E.U.-
approved, South America Origin 
Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
Freezing 
media 
45% Culture media Culture media  Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
45% FBS 
Foetal Bovine Serum, qualified, heat inactivated, E.U.-
approved, South America Origin 
Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
10% DMSO Dimethyl sulfoxide Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
Phosphate - 
buffered 
saline (PBS) 
140 mM  NaCl Sodium chloride Sigma-Aldrich®, Dorset, U.K. 
2.7 mM  KCl Potassium chloride Sigma-Aldrich®, Dorset, U.K. 
10 mM  Na2HPO4 Sodium phosphate dibasic Sigma-Aldrich®, Dorset, U.K. 
1.8 mM  KH2PO4 Monopotassium phosphate Sigma-Aldrich®, Dorset, U.K. 
Name Abbreviation Use Manufacturer 
Hanks Buffered Salt Solution  HBSS Cell wash Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
0.05% Trypsin-EDTA (1x) Trypsin remove cells from monolayer Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
0.4% Trypan blue solution Trypan Blue assess cell viability and cell count Sigma-Aldrich®, Dorset, U.K. 
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Table 2.3. Plastic ware utilised in cell culture 
 
2.2.2. Description of cell lines 
 All cell lines used in this study were developed at the University of Glasgow 
(Yuan et al., 2008a) and all tissues utilised for the establishment of the cell lines 
were taken with informed owner consent. A summary of the features of the 
three cell lines is presented in Table 2.4.  
Table 2.4. Description of cell lines 
Name Abbreviation Manufacturer 
Cellstar® cell culture flasks, PS, red filter cap 
(sizes T25, T75 and T175) 
culture flask (T25, 
T75 or T175) 
Greiner-bio one, 
Gloucestershire, U.K.  
Cellstar® 15 ml PP tubes, graduated, conical 
bottom, blue screw cap, sterile 
15 ml tubes 
Greiner-bio one, 
Gloucestershire, U.K. 
1.5ml polypropylene reaction tube with cap, 
natural, free of detectable DNase and RNase 
1.5 ml tube 
Greiner-bio one, 
Gloucestershire, U.K.  
2 ml, 5 ml, 10 ml and 25 ml serological pipette, 
individually wrapped, paper/plastic packaging, 
sterile, free of detectable DNase and RNase 
Serological 
pipette 
Greiner-bio one, 
Gloucestershire, U.K.  
20 µl Graduated Filter Tips (Sterile) Tips StarLab, Milton Keynes, U.K. 
2 ml Corning® cryogenic vials, external thread 2 ml Cryovials Sigma-Aldrich®, Dorset, U.K. 
50ml Centrifuge tube, conical base, bagged, 
sterile 
50ml centrifuge 
tube 
Greiner-bio one, 
Gloucestershire, U.K.  
Name of the cell line EqPalFs  S6-2s EqSO4bs 
Description 
equine primary 
fibroblast 
equine primary 
fibroblast in vitro 
transformed with BPV-
1 genomes (from 
equine sarcoid S6) 
Equine tumoural 
fibroblast from a 
natural tumour 
BPV-1 episomal genome absent present present 
BPV-1 E5 variant Not applicable Sw I Sw I 
BPV-1 LCR variant Not applicable II VII 
Contact inhibition normal lost lost 
Life span (passage 
number) 
13 21 24 
Population doubling 
(hours) 
57.8 24 26.7 
Source 
Cell bank, University 
of Glasgow 
(described in Yuan et 
al. (2008a) 
Cell bank, University of 
Glasgow (described in 
Yuan et al. (2008a) 
Cell bank, University 
of Glasgow 
(described in Yuan et 
al. (2008a) 
40 
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EqPalFs are equine primary fibroblast cells derived from a foetal palate of an 
aborted equine foetus. EqPalFs do not contain BPV-1 episomal genomes and 
because they are primary cells, they have a limited life span of 13 passages 
(Yuan et al., 2008a). 
S6-2s are EqPalFs transformed with BPV-1 episomal genomes. The BPV-1 genome 
used to transform EqPalFs was derived from an equine sarcoid tumour (S6) by 
Rolling Circle Amplification followed by restriction digestion, purification, 
cloning and recircularization (Yuan et al., 2007c). S6-2 cells contain two BPV-1 
genomes per cell of variant Sw I for E5 and variant II for LCR (Yuan et al., 
2008a). S6-2 cells express early and late BPV-1 gene transcripts as detected by 
RT-PCR. These cells are morphologically transformed, invasive and display lack 
of contact inhibition (Yuan et al., 2008a). 
EqSO4b cells are immortal cells derived from a naturally occurring fibroblastic 
sarcoid tumour confirmed by histopathological analysis following haematoxylin 
and eosin staining (Yuan et al., 2008a). They contain eight BPV-1 episomal 
genomes per cell of the E5 variant Sw I and LCR variant VII. EqSO4b cells express 
early and late BPV-1 gene transcripts as detected by RT-PCR and they lack 
contact inhibition (Yuan et al., 2008a). 
All cell lines were kept in liquid nitrogen at -80°C in freezing media. Details of 
the freezing media can be found on Table 2.1.  
2.2.3. Cell thawing, cell count and growth 
Aliquots of 1-2 x 106 cells/ml stored in 2 ml cryovials were brought up from the 
liquid nitrogen containers taking the appropriate safety precautions. Cells were 
thawed in a 37°C water bath W6 (Grant Instruments, Cambridge) for less than 
one minute and the cryovials were then wiped with 70% ethanol and introduced 
it in the microbiological safety cabinet. The content of each cryovial was 
resuspended in 10 ml of pre-warmed thawing media prepared as described in 
Table 2.1. The cells were then centrifuged for 5 minutes at 1200 g in Heraceus® 
Multifuge® 3 SR (Thermo-Scientific, Renfrew, U.K) and the supernatant was 
completely removed. The cell pellet was then resuspended in 1 ml of pre-
warmed culture media made up as described in Table 2.1. An aliquot of 25 µl of 
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cells resuspended in culture media was mixed with 25 μl of 0.4% Trypan Blue 
solution (Trypan Blue) (Sigma-Aldrich®, Dorset, U.K.) resulting in a two-fold 
dilution. Cells were assessed under the microscope at 40x magnification for cell 
viability and cells were counted in the 16 squares of the four blocks of a 
haemocytometer to calculate the average live cells (without Trypan Blue 
uptake) taking into account the two-fold dilution: 
LC = (live cells) transparent cells in 16sq, in the 4 blocks. 
FD = Fold dilution (=2). 
vol = volume in which cell pellet was resuspended (=1ml). 
TC (total cells)/ml= LC x ¼ x 104 x FD 
Cells were seeded in a T25 culture flask at a density of 4x104 /cc2 with 10 ml of 
pre-warmed culture media and maintained in a 37°C humidified atmosphere 
with 5% CO2 in the CO2 Incubator HERAcell® 150 i / 240 i (Thermo-Scientific). 
Culture flasks were labelled with the name of the cell line, cell seeding volume, 
passage and date. When cultures became 80% confluent, cells were passaged or 
used for downstream work. 
2.2.4. Cell passaging, mycoplasma testing and sampling for DNA 
and RNA extractions 
To detach monolayer cells, firstly supernatant from flasks was aspirated and 
discarded, and cells were washed with Hanks Buffered Salt Solution (HBSS) 
(Invitrogen™-Life Technologies Ltd, Renfrew, U.K.). Cells were then exposed to 
0.25% Trypsin (Invitrogen™-Life Technologies Ltd) for less than 1 minute in the 
incubators at 37°C, and then resuspended in pre-warmed culture media. After 
centrifugation at 1200 g for 5 minutes, cells were evaluated and counted with 
Trypan Blue as previously described in section 2.2.3. (Cell thawing, cell count 
and maintenance) and seeded in flasks with 10 ml culture media of for T25 
flasks, 25 ml for T75 and 50 ml for T125 flasks. Cells were routinely sent to 
microbiology department to be tested for mycoplasma using MycoAlert™ 
Mycoplasma detection kit (Lonza Biologics plc, Cambridge, U.K.) and they were 
found to be negative.  After reaching 80% confluence cells were: 
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- Frozen in freezing media (for details on the freezing media please refer to 
Table 2.1.) to maintain the cell bank. 
- Resuspended in HBSS/ Phosphate - buffered saline (PBS) for DNA extraction and 
used immediately. 
- Resuspended in HBSS for immediate RNA extraction using the column method. 
- Resuspended in Trizol® Reagent (Invitrogen™, Life-Technologies Ltd), vortexed 
and either used immediately for RNA extraction with the phenol method or kept 
at -80°C until RNA extraction with the phenol method. 
2.3.  Molecular biology 
Details of plastic ware, kits, chemicals and electric equipment utilised in this 
section are displayed in Tables 2.5. -2.9. 
2.3.1. DNA extraction 
DNA from cells in culture (80-90% confluence in T75 flasks, approximately 
8x106cells) was isolated using a column method QIAamp® DNA Mini and Blood 
Mini Handbook (Qiagen®, Manchester, U.K.) following the manufacture’s spin 
protocol for DNA purification from blood/body fluids. In summary, cells in 
monolayer were trypsinised as described in section 2.2.4. (Cell passaging, 
mycoplasma testing and sampling for DNA and RNA extractions). Cells were 
washed with HBSS and spun for 5 minutes at 1200 g. The pellet was resuspended 
in 200 μl of PBS and cellular components, histones and other proteins associated 
with the DNA were digested using Proteinase K included in the kit (10 μl 
proteinase K per 100 μl of cells in suspension). After adding 1:1 volume of lysis 
buffer (AL buffer) and incubating at 56C for 10 minutes in a water bath Sub 36 
(Grant Instruments) and pulse centrifuging the tube, 100% molecular grade 
ethanol was added at a 1:2 ratio. The samples were collected in the column with 
the use of two buffers (AW1 and AW2), spinning the sample between buffers. 
The last buffer was added to collect the extracted DNA in a clean tube. After 
centrifuging and removing the buffer, the DNA was resuspended in 200μl of Tris 
EDTA buffer (TE buffer) (Microzone, West Sussex, U.K.).   
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2.3.2. RNA extraction 
2.3.2.1. RNA extraction using column method 
RNA from cells in culture was obtained using miRNeasy Mini Kit (Qiagen®) 
following the manufacturer’s instructions from the section ‘Purification of Total 
RNA, Including Small RNAs, from Animal Cells’. Typically, no more than 3.0 x 106 
cells in suspension of HBSS, were centrifuged and the cell pellet,after 
supernatant removal,was resuspended in 700 µl of QIAzol Lysis Reagent included 
in the kit, and homogenized by vortexing for 1 minute to lyse the cells. 
Homogenate was incubated at room temperature for 5 minutes to promote 
dissociation of nucleoprotein complexes. After addition of 0.2 volumes of 
chloroform, the sample was mixed for 15 seconds and centrifuged for 15 minutes 
at 12000 g at 4°C. Supernatant containing RNA was transferred to a fresh tube 
and 1.5 volumes of 100% ethanol was added. The mix was pipetted through a 
column to collect the RNA in the membrane of the column and washed with two 
buffers, RWT and RPE and centrifuged at 8000 g. Composition of these buffers is 
undisclosed by the manufacturer but their purpose was to wash the RNA off 
(RWT) and to prevent ethanol carry-over (RPE). The dried RNA retained in the 
column was eluted with 30-50 µl of RNAse free water provided in the kit. Total 
RNA obtained with the column method was kept at -80°C until further use. 
2.3.2.2.  RNA extraction using phenol based method 
Cells in monolayer were removed from the culture flasks using 7 ml of Trizol® 
reagent (Life Technologies) per T75 flask. Once resuspended in Trizol® reagent, 
the cells were placed in a 14 ml high speed tube (for details please seeTable 
2.5.) and vortexed for 1 minute and either: 
- Kept at -80°C until further use, in which case on the day of the RNA extraction 
they were fast-thawed in a 25°C bath and processed as described below. 
- Used immediately for RNA extraction.  
The first step after thawing or removal from the culture flasks was 5 minutes of 
incubation at room temperature to allow dissociation of nucleoprotein 
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complexes. Phenol: chloroform: isoamyl alcohol (25:24:1) (chloroform) (Sigma-
Aldrich Company Ltd., Dorset, U.K.) was added at a ratio of 0.2 volumes (1.4 ml 
per 7 ml of Trizol®) and samples were then mixed vigorously for 15 seconds and 
left at room temperature for 3 minutes. After centrifugation at 12000 g for 15 
minutes at 4°C, a three phase mixture was obtained. The upper layer, aqueous 
and transparent contained the RNA and it was approximately 40-50% of the 
volume. The aqueous phase was transferred to a clean RNAse free 14 ml high-
speed tube avoiding contact with the interphase and 100% isopropyl alcohol (IPA) 
(Sigma-Aldrich Company Ltd., Dorset, U.K.) was added (3.5 ml per 7 ml of 
Trizol®) to precipitate the RNA. Samples were then incubated at room 
temperature for 10 minutes and centrifuged for 5 minutes at 12000 g at 4°C. 
The RNA precipitate, a gel-like structure visible to the naked eye, was then 
washed. Firstly, the IPA was removed and 75% ethanol was added (7 ml of 
ethanol per 7 ml of Trizol®). Subsequently the samples were vortexed briefly 
and centrifuged at 7500 g for 5 minutes at 4°C. The ethanol was then removed 
and the samples were dried at room temperature for a maximum of 10 minutes. 
RNA was resuspended in 40-50 µl of RNAse free water (Just Water, Microzone) 
and incubated at 55°C for 5 minutes to facilitate RNA solubilisation. Samples 
were then stored at -80°C for further downstream work or temporarily kept on 
ice during assessment of integrity and quantification. 
2.3.3. Assessment of purity, integrity and quantity of nucleic 
acids 
2.3.3.1. DNA purity and quantification 
The purity and quantity of total genomic DNA were assessed using optical density 
measurements obtained with the NanoDrop® ND-1000 spectrophotometer 
(Thermo-Scientific) using the standard protocol. After selecting the settings for 
double stranded DNA measurement (DNA-50, upper limit of detection 3700 
ng/µl) and calibrating the spectrophotometer with TE buffer (running a ‘blank’), 
a volume of 1.5 µl of DNA in solution was loaded in the lower measuring 
pedestal. After closing the sampling arm (upper measuring pedestal) and 
prompting the software to perform the reading, the values of DNA concentration 
(measured at 260 nm and expressed in ng/µl), ratios of absorbance at 260/280 
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nm wavelength and 260/230 nm wavelength were obtained. Samples were 
considered acceptable for downstream work with a 260/280 nm ratio of 
approximate 1.8 (indicating good DNA purity), a ratio 260/230 higher than the 
260/280 and a unique peak of absorbance around 260 nm.  
2.3.3.2. Polymerase Chain Reaction (PCR) of equine Glyceraldehyde-3-
Phosphate Dehydrogenase (equine GAPDH) and BPV-1 E5 gene 
For identification of host genomic DNA and to confirm presence/absence of BPV-
1 episomal genomes, an aliquot of 200 ng of genomic DNA obtained from cells in 
culture was amplified by PCR using primers for an equine housekeeping gene, 
GAPDH, and for BPV-1 E5 gene. All PCR reactions were carried out in 0.2 ml 
Illustra™puReTaq Ready-To-Go PCR Beads (VWR International Ltd.) containing a 
recombinant polymerase and dNTPs All reactions were performed in the 
thermocyclers GeneAmp® PCR System 2400 and 2700 (Applied Biosystems, 
Paisley, U.K.). Each experiment with each set of primers had at least one 
negative control (all the components and Just water (Microzone Ltd.) instead of 
template) the samples of interest, and one positive control (equine GAPDH 
positive sample and BPV-1 E5 positive sample). 
Equine GAPDH PCR 
Primer sequences for equine GAPDH were obtained from Lange et al. (2013). 
Forward primer (5’ GAG CTG AAT GGG AAG CTC AC 3’) and reverse primer (5’ 
CTG AGG GCC TTTCTCCTTCT 3’) were added to each 25 µl PCR reaction to a 
final concentration of 0.2 µM. Cycling conditions suggested by Lange et al. 
(2013)  were modified as follows: 5 minutes of denaturation at 94°C, 30 cycles 
of 1 minute at 94°C, 1 minute at 57°C and 1 minute at 72°C, followed by 10 
minutes at 72°C. Samples were held at 4°C until collected from the 
thermocycler. The expected amplified DNA fragment of 393 bp corresponds to a 
segment of equine GAPDH (NCBI annotation NM_001163856, starting at 715 bp 
and ending at 1107 bp).  
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BPV-1 E5 gene PCR 
Primer sequences for BPV-1 E5 gene were obtained from Brandt et al. (2008b). 
Forward (5’ CAC TAC CTC CTG GAA TGA ACA TTT CC 3’) and reverse primer (5’ 
CTA CCT TWG GTA TCA CAT CTG GTG G 3’) were added to each 25 µl PCR 
reaction to a final concentration of 0.2 µM. Cycling conditions suggested by 
Brandt et al. (2008) were modified as follows: 5 minutes of denaturation at 
94°C, 40 cycles of 30 seconds at 94°C, 45 seconds at 58°C, 45 seconds 72°C, 
followed by 5 minutes at 72°C. Samples were held at 4°C until collected from 
the thermocycler. The expected amplified DNA fragment of 499 bp corresponds 
to a segment of BPV-1 (NCBI annotation X02346.1, starting at 3788 bp and ending 
at 4286 bp).  
2.3.3.3. Agarose gel electrophoresis of DNA fragments 
In order to visualise and verify the size of the amplified DNA, the PCR products 
were subjected to agarose gel electrophoresis. Typically 0.5g of ultra-pure 
agarose was mixed with 50 ml of Tris acetate-EDTA buffer (TAE buffer, for 
details please see Table 2.7.) and the mix was warmed until the agarose was 
fully dissolved and the solution was transparent. After the temperature 
decreases below 50°C, 2 μl of Ethidium bromide (10mg/ml) was dissolved in the 
agarose-TAE buffer mixture. The solution was allowed to solidify in a casting 
tray for 30 minutes, with a gel comb (9 to 15 wells). Once the gel solidified, the 
PCR products were loaded into a well with loading dye (for details on the loading 
dye please see Table 2.7.). The products were run at 70-80 volts over 60 minutes 
on the Mini-Sub® Cell GT Cell (Bio-rad Laboratories, Hertfordshire, U.K.), an 
electrophoresis unit, and the gel was visualised on a UV transilluminator (UVi 
tec, Thistle Scientific Ltd., Glasgow, U.K.). The size of the fragments was 
assessed in comparison to the 100 bp DNA ladder (Invitrogen™). 
2.3.3.4. Agarose gel purification and DNA sequencing analysis of the PCR 
products 
PCR products were excised from the gel and purified using QIAquickPCR 
purification kit protocol (Qiagen®). This method uses a filter that captures the 
DNA within the column and washes the rest of the components using various 
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buffer solutions (named PB and PE). Instead of collecting the eluted DNA in EB 
buffer as per manufacture’s advice, PCR products were eluted in 30-50 μl of Just 
water (Microzone Ltd.). After purification, fragments were assessed by gel 
electrophoresis again on a 1% agarose-TAE buffer gel and sent for DNA 
sequencing by a commercial company  (Source Bioscience Sequencing , Belhill, 
U.K.). Each product was sequenced using either amplicon-specific forward or 
reverse primer. Sequences were searched against the NCBI database (Altschul et 
al., 1990) using BLAST to verify the nucleotide sequence matched equine GAPDH 
(NM_001163856) or BPV-1 E5 (X02346.1) 
2.3.3.5. RNA integrity using agarose gel electrophoresis 
Integrity of total RNA was assessed using 1 % agarose gel electrophoresis in TAE 
buffer. Electrophoresis tank, tray and lid were treated with RNAse zap (Sigma-
Aldrich®) and rinsed with RNase free water. The method of preparation of the 
gel and electrophoresis, except for the initial RNAse zap treatment, is identical 
to the protocol used for PCR product visualisation (section 2.3.3.1.2. - agarose 
gel electrophoresis).  
RNA Integrity was assessed by comparing the ribosomal bands of the 28S and 18S 
to the bands from a 100 bp ladder (Invitrogen™-Life Technologies) 
Intensity of the bands, comparison and size was used to assess RNA integrity and 
level of degradation. RNA was considered of good quality when the 18S 
ribosomal unit ran at 4.5 Kb, the 28S at 1.2 Kb and the intensity of 28S band was 
twice as the intensity of 18S. The mRNA will appear as a smear from 0.5–12 kb.  
2.3.3.6. RNA quantitation using spectrophotometry (NanoDrop® ND-1000 
Spectrophotometer) 
Quantity screening of RNA was performed with the NanoDrop® ND-1000 
Spectrophotometer (Thermo-Scientific, Pailsey, U.K.). This quantification 
method cannot distinguish between DNA and RNA so RNA values can be 
artificially overestimated when using this technique. However, this method of 
quantitation aids downstream work, such as DNase treatment, where the value 
of total nucleic acid concentration is needed.  
 49 
In summary, samples (2 µl) were loaded on the spectrophotometer after 
calibration and concentration of nucleic acids was noted. Samples were 
considered acceptable when one unique peak was noted at 260 nm and when the 
260/280 ratio was approximately 2.0. A 260/280 ratio of 2.0 was considered 
acceptable. Samples with lower 260/280 and/or 260/230 ratios were discarded 
due to possible protein, phenol or ethanol contaminants that may affect 
downstream work.  
2.3.3.7. RNA quantitation using fluorometry (Qubit™ fluorometer) 
Qubit™ fluorometric quantitation (Thermo-Scientific) is a method that uses a 
fluorescent agent that specifically and uniquely binds to RNA. The samples in 
this project were measured using Qubit™ RNA BR assay following the supplier’s 
recommendations. Firstly a working solution was prepared that contains a buffer 
and a fluorescent reagent.  Secondly the working solution was distributed in 0.5 
ml Qubit tubes (for more details see Table 2.5.): the tubes labelled as standard 
(needed for calibration) contained 199 µl of working solution and 1 µl of 
standard whereas the tubes labelled for the RNA samples contained 198 µl of 
working solution and 2 µl of RNA sample. The tubes were then introduced into 
the Qubit unit and after calibration with the standards 1 and 2, fluorescence 
readings were obtained.  
When samples exceeded the range of the RNA BR kit, samples were diluted 1:6 
and the reading was repeated. RNA samples were stored at -20˚C for short term 
use or at -80˚C for long term use. RNA aliquots were diluted in RNAse free water 
to fit the concentration needed for further downstream work (SYBR and Taqman 
qRT-PCR).  
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Table 2.5. Disposables utilised during RNA extraction, DNA extraction, 
RNA/DNA quantitation/integrity assessment, cDNA first strand synthesis and 
qRT-PCR 
 
 
Table 2.6. Kits utilised during RNA extraction, DNA extraction, RNA/DNA 
quantitation/integrity assessment, cDNA first strand synthesis and qRT-PCR 
Name of the item Abbreviation Manufacturer 
14 ml polypropylene (PP) tubes, round bottom, 
two-position vent stopper, sterile, single packed 
14 ml high speed 
tubes 
Greiner-bio one, 
Gloucestershire, U.K. 
1.5ml polypropylene reaction tube with cap, 
natural, free of detectable DNase and RNase 
1.5 ml tube 
Greiner-bio one, 
Gloucestershire, U.K. 
PCR microtubes with flat cap, 0,5 ml 
0.5 ml Qubit 
tubes 
VWR International Ltd., 
Lutterworth 
2 ml, 5 ml, 10 ml and 25 ml serological pipette, 
individually wrapped, paper/plastic packaging, 
sterile, free of detectable DNase and RNase 
Serological 
pipette 
Greiner-bio one, 
Gloucestershire, UK 
10μl, 20μl, 200μL and 1000μL filter tip filtered tips StarLab, Milton Keynes, U.K.  
0.2 ml Illustra™puReTaq Ready-To-Go PCR Beads PCR beads 
VWR International Ltd., 
Lutterworth 
PCR plates - non skirted Stratagen plates  StarLab, Milton Keynes, U.K.  
MicroAmp® Optical 8-Cap Strip Cap strips 
Invitrogen™-Life Technologies 
Ltd,Paisley, U.K. 
MicroAmp® Fast Optical 96-Well Reaction Plate 7500 plates 
Invitrogen™-Life Technologies 
Ltd,Paisley, U.K. 
Name Method Provider 
QIAamp® DNA Mini and 
Blood Mini Handbook 
DNA purification Qiagen®, Manchester, U.K. 
Tris EDTA buffer (TE 
buffer) 
DNA purification and Nanodrop 
calibration 
Microzone, West Sussex, U.K. 
miRNeasy Mini Kit  miRNA purification Qiagen®, Manchester, U.K. 
QIAquickPCR purification 
kit protocol 
PCR product purification Qiagen®, Manchester, U.K. 
RNA BR fluorometric 
quantitation (Qubit™)  
Quantification of RNA 
Invitrogen™-Life Technologies 
Ltd,Paisley, U.K. 
DNA-free™ kit DNase treatment of RNA 
Invitrogen™-Life Technologies 
Ltd,Paisley, U.K. 
Mir-X™ miRNA First-
Strand Synthesis kit 
SYBR green first strand synthesis 
Clontech,  Takara Bio Europe 
SAS, Saint-Germain-en-Laye, 
France 
SYBR® qRT-PCR kit SYBR green qRT-PC master mixes 
Clontech,  Takara Bio Europe 
SAS, Saint-Germain-en-Laye, 
France 
TaqMan® MicroRNA 
Reverse Transcription Kit 
Taqman RT master mix 
Invitrogen™-Life Technologies 
Ltd,Paisley, U.K. 
TaqMan® MicroRNA 
Assays (Inventoried) 
Taqman RT primers and qPCR 
primers and probes 
Invitrogen™-Life Technologies 
Ltd,Paisley, U.K. 
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Table 2.7. Buffers, markers and carriers utilised in gel electrophoresis 
 
 
 
 
Table 2.8. Other chemicals utilised during RNA extraction, DNA extraction, 
RNA/DNA quantitation/integrity assessment, cDNA first strand synthesis and 
qRT-PCR 
 
 
 
 
 
 
Item Recipe or manufacturer 
1kbp ladder Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
100 bp ladder  Invitrogen™-Life Technologies Ltd,Paisley, U.K. 
Loading dye 
50% glycerol, 0.25% bromophenol blue, and 0.25% 
xylene cyanole in 1x TE buffer 
Tris-acetate buffer (TAE) buffer 
Tris base 484.5g, NaOAc 272.15 g, NaCl 116.8 g, 
Na2EDTA 74.45 g. pH adjusted to 8.15 with glacial acetic 
acid and made up to 2 L volume.  
Name Abbreviation Method Provider 
Trizol® Trizol® 
total RNA 
purification 
Invitrogen™-Life Technologies 
Ltd,Paisley, U.K. 
Phenol: chloroform: isoamyl 
alcohol (25:24:1) 
Chloroform 
total RNA 
purification 
Sigma-Aldrich Company Ltd. 
(Dorset, United Kingdom)  
Isopropyl alcohol (Propan-2-
ol or Isopropanol) 
IPA 
total RNA 
purification 
Sigma-Aldrich Company Ltd., 
Dorset, U.K. 
Ethanol absolute AnalaR 
NORMAPUR® ACS, Reag. Ph. 
Eur. analytical reagent 
Ethanol 
DNA and 
RNA 
purifications 
Sigma-Aldrich Company Ltd., 
Dorset, U.K. 
Just water - 1ml sterile vials Just water 
total RNA 
purification 
Microzone Ltd., West Sussex, 
U.K. 
RNAse- zap RNA-zap 
RNA 
handling 
Sigma-Aldrich Company Ltd., 
Dorset, U.K. 
Ultra-Pure agarose agarose 
Gel 
electrophor
esis 
Invitrogen™-Life Technologies 
Ltd,Paisley, U.K. 
Ethidium Bromide EB 
Gel 
electrophor
esis 
Invitrogen™-Life Technologies 
Ltd,Paisley, U.K. 
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Table 2.9. Electrical equipment 
 
 
 
 
 
 
 
 
 
 
 
2.3.3.8. RNA quantitation, integrity and sizing using automated 
electrophoresis and flow cytometry (Bioanalyzer 2100 (Agilent Technologies)) 
Total RNA samples used for microarray and for RNA-seq were assessed using 2100 
Bioanalyzer at University of Glasgow Polyomics Facility. The chip was loaded 
with 1µl total RNA and size, quantity and integrity were examined. The 
bioanalyzer determines concentration of RNA and, based on the number of peaks 
and size of the peaks as well as the graph pattern, the Bioanalyzer derives an 
integrity value named RIN. RNA samples with RIN values of less 8.5 (out of 10) 
were discarded due to the risk of poor quality RNA and/or degradation. Total 
RNA with small or undetectable peaks corresponding to the small RNA fraction 
(that includes microRNAs) were also discarded. 
 
Instrument Abbreviation Manufacturer 
Class II microbiological 
safety cabinet, BioMat 2 
Laminar flow hood 
Medical Air Technologies Ltd, 
Manchester, U.K. 
CO2 Incubator HERAcell® 
150 i / 240 i  
Incubator Thermo-Scientific, Renfrew, U.K. 
water bath W6  Bath - cell culture Grant Instruments, Cambridge, U.K. 
Heraceus® Multifuge® 3 SR  Centrifuge cell culture Thermo-Scientific, Renfrew, U.K 
water bath Sub 36  
Bath - Nucleic acids 
extraction 
Grant Instruments, Cambridge, U.K. 
CPR Centrifuge (Beckman)  
Centrifuge - DNA 
extraction 
Beckman Coulter, High Wycombe, U.K. 
Avanti® J-E High-
Performance Centrifuge  
Centrifuge - RNA 
extraction 
Beckman Coulter, High Wycombe, U.K. 
NanoDrop® ND-1000 
spectrophotometer  
Nanodrop Thermo-Scientific 
GeneAmp® PCR System 
2400  
Thermocycler Applied Biosystems, Paisley, U.K. 
GeneAmp® PCR System 
2700 
Thermocycler Applied Biosystems, Paisley, U.K. 
Mini-Sub® Cell GT Cell Electrophoresis tank Bio-rad Laboratories, Hertfordshire, U.K. 
Qubit™ fluorometer Qubit 
Invitrogen™-Life Technologies 
Ltd,Paisley, U.K. 
Bioanalyzer 2100 Bioanalyzer 2100 
Agilent Technologies UK Ltd, Edinburgh, 
U.K. 
Mx3000PTM Real-Time PCR 
System (Stratagene) 
Stratagene 
Agilent Technologies UK Ltd, Edinburgh, 
U.K. 
Applied Biosystems Fast 
7500 
Fast 7500 Applied Biosystems, Paisley, U.K. 
UV transilluminator  UV box 
UVi tec, Thistle Scientific Ltd., Glasgow, 
U.K. 
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2.4.  Microarray 
When cells grew to 80-90% confluency on a T175 flask, one total RNA sample 
from EqPalF cells and one sample from S6-2 cells was extracted using the phenol 
method. After samples being assessed for integrity, purity and quantity using 2% 
agarose gel electrophoresis and NanoDrop® ND-1000 Spectrophotometer as 
described in section 2.3.3.2.2., RNA samples were shipped on dry ice to an 
external company, Exiqon A/S (Vedbaek, Denmark) for microarray analyses. 
Upon arrival, samples were assessed again for integrity and quantity using a 
Bioanalyzer 2100. Total RNA with RIN values of 10.0 were utilised for the 
microRNA microarray. Three samples from the same RNA extraction were 
aliquoted and used as replicates for the microarray. An aliquot of 750 ng total 
RNA from both sample and reference were labelled with Hy3™ and Hy5™ 
fluorescent label, respectively, using the miRCURY LNA™ microRNA Hi-Power 
Labelling Kit, Hy3™/Hy5™ (Exiqon, Denmark) following the procedure described 
by the manufacturer. The reference sample used comprised a pooled sample of 
total RNA from both cell lines. Each well of the microarray was loaded 
simultaneously with sample and reference. The Hy3™-labelled samples and a 
Hy5™-labelled reference RNA sample were mixed and hybridized for 16 hours to 
the miRCURY LNA™ microRNA Array 7th Gen (Exiqon), using 2164 miRNA probes 
from human, equine (predicted miRNAs), viral and synthetic sequences from 
miRBase 19.0 (Griffiths-Jones et al., 2006) including repeated probes for quality 
control. Image acquisition was performed using the signal intensity of the dyes 
and the slides were scanned using the Agilent G2565BA Microarray Scanner 
System (Agilent Technologies, Inc., USA). The image analysis was carried out 
using ImaGene® 9 (miRCURY LNA™ microRNA Array Analysis Software, Exiqon, 
Denmark). Pre-processing of the data included background subtraction (Normexp 
with offset value 10) and normalisation using the global lowess regression 
algorithm. Moderated t-statistics were applied to determine differential 
expression of microRNAs between EqPalF and S6-2 cells. Following this, the 
Benjamini and Hochberg multiple testing adjustment method was applied to the 
P values (Benjamini & Hochberg, 1995). P values of 0.05 or lower were 
considered to be statistically significant. Calculations were performed with 
R/Bioconductor using the limma package (Smyth, 2004). All the data analyses 
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were performed by Exiqon and supplied as an xlx file. provided in the DVD 
contained in this thesis. 
2.5. miRNA sequencing using high throughput 
sequencing (HTS) 
Total RNA samples from EqPalF cells, EqSO4b cells and S6-2 cells extracted using 
the phenol method (section 2.3.2.2.) were assessed for integrity, purity and 
quantity using Bioanalyzer 2100. As per Illumina advice, total RNA with RIN 
values of >8.0 were utilised for microRNA sequencing. High-throughput 
sequencing (HTS) was performed on three technical replicates from the same 
RNA preparation for EqPalF cells, and on three biological replicates from three 
different RNA preparations for EqSO4b and S6-2 cells (in total three libraries per 
cell line). 
2.5.1. Library construction, cluster generation and sequencing 
Library construction was carried out using 1-2 g of total RNA and TruSeq® Small 
RNA library kit (Illumina Inc, San Diego, CA, USA) following the manufacturer’s 
advice. Firstly the 3’-end adapter was added to each sample using T4 mutant 
ligase contained in the kit. Secondly, the 5’-end adapter was ligated in a similar 
manner. The 3’-end adapter targets the hydroxyl group exposed after Dicer 
cleavage and it is the DNA binding site for the RT primers. The first strand of 
cDNA is synthesised during a reverse transcriptase reaction and it was utilised as 
a template for PCR amplification using PCR primers with indexes (tags) to 
sequence multiple samples in the same run (multiplexing). At this stage a check 
point is recommended by the manufacturer and the PCR products were run on 
the high sensitivity DNA chip to ensure the samples contained suitable quality 
and proportion of miRNAs. After amplification, the library underwent size 
selection followed by polyacrylamide gel electrophoresis (PAGE) purification. 
Fragments in the range 145-160 nucleotides, as identified by comparison to the 
ladder, were selected. This band contains mature microRNA sequences up to 30 
nucleotides together with the adaptors. After purification, microRNAs were 
precipitated with ethanol. Before sequencing, samples were run a second time 
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on a high sensitivity DNA chip on the Bioanalyzer to ensure a sufficient small RNA 
fraction was contained in the samples (band between 110 bp and 230 bp). 
Cluster generation on solid phase was performed on the libraries (Metzker, 2010) 
followed by massive parallel sequencing in the Genomic Analyzer IIx (Illumina®) 
(for EqPalF) and NextSeq500 (Illumina®) (for EqSO4b and S6-2). The samples 
were run as a multiplex on a single-index single read sequencing run as 
recommended in the protocol.  
2.5.2. Data analysis 
An overview of the steps of the data analysis is displayed in Figure 2.1. Summary 
of the pipeline for analysis of the HTS data. 
2.5.2.1. miRDeep2 
Raw data was obtained in .fastq format and the files were pre-processed before 
being analysed with miRDeep2, a tool for miRNA identification (Friedländer et 
al., 2012). The pre-processing of the files included transforming the sequencing 
files to .fasta format, removing the adapter sequences using Clip, generating a 
version of the equine genome (Equus caballus, EqCab2.0) with the appropriate 
format for miRDeep2 – downloaded from Ensembl, and formatted using BowTie. 
miRDeep2 software contains seven scripts and it is designed to process data from 
libraries removing redundant sequences (sequences that match fragments of 
SNORDs, tRNA and other non-small RNAs), removing small sequences (<18 
nucleotides long), removing ubiquitous sequences (present in more than 5 
genomic locations), aligning the results against the equine genome and equine 
miRNAs from the miRBase 20.0, predicting new miRNAs based on the folding 
energy (using RandFold) of the precursor sequence. The output from miRDeep is 
a .html file with a list of potential mature microRNA candidates together with 
their genomic location, mature and precursor sequences as well as read counts 
from the sequencer and miRDeep scores. Additional files contain graphical 
representations of the microRNAs with the predicted folding pattern in .pdf 
format.  
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Post-processing of the data obtained from miRDeep2 included harmonizing the 
data to generate a list of unique potential mature microRNA candidates from the 
three cell lines using a script and commands on command line. The following 
criteria were applied to generate a file of microRNAs: 
1. If two mature sequences were encoded on the same chromosomal location 
with a maximal deviation of location of ten nucleotides, they are defined 
as the same microRNA (tolerance for chromosomal location 10). 
2. If two mature sequences were the same length and had the same 
nucleotide sequence they were considered the same microRNA (i.e. 
tolerance for sequence composition 0). 
The genomic location condition was applied first and nucleotide sequence 
followed. This was to prevent discarding the historically named ‘star miRNA’ 
(miRNA* or passenger strand), as miRDeep2 gives priority to the guide strand (for 
more details on miRNA biogenesis and miRNA vs miRNA*, the reader is referred 
to section 1.2.2.). Each potential microRNA candidates was assigned an internal 
ID.  
2.5.2.2. Discovery of novel miRNAs 
The list of internal IDs and mature sequences were further analysed using two 
methods to assign a name for the microRNA and if no known annotation was 
found, it was attempted to group them into a known family based on the 
sequence of the seed region. An overview of the steps is displayed in Figure 2.2. 
Method 1 – BLAST 
The list of miRNA candidates and their mature harmonized sequences was 
formatted to .fasta format using TextWrangler and compared against five 
databases using BLAST + (Camacho et al., 2009) in Unix environment using Mac 
Command Line. The entire list of mature microRNAs downloaded from miRBase 
20.0 (mature), the entire list of mature equine microRNAs (downloaded from the 
miRBase 20.0 and using command line to extract the equine entries)(eca), and 
the 3 previously published lists of microRNAs in the horse (Zhou et al., 2009; 
Desjardin et al., 2014; Kim et al., 2014) were the five databases used for this 
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method. The list of potential annotations for each miRNA obtained from BLAST+ 
was processed using a script to select the top hits using maximal identity. 
Matches that had the following features were selected as ‘perfect match’: 100 % 
sequence identity, 100 % coverage with allowance of two mismatches (length of 
the query miRNA and length of the suggested annotation is either identical or up 
to two nucleotides of difference) and no internal mismatches in nucleotide 
sequence. This selection was performed on Excel. 
Method 2 – Edit distance 
The list of miRNA candidates and their mature harmonized sequences was 
compared to the same databases (mature, eca, Zhou, Kim and Desjardin) using a 
script and incorporating both nucleotide sequence and length as criteria for the 
comparison. The output generated consists of ‘edit distances’ – a number that 
reflects the number of mismatches either in length or in nucleotide composition 
- and a list of potential matches. Matches that had 2 or fewer edit distances 
were considered a ‘perfect match’. 
Seed region study 
microRNA candidates were compared to previously described miRNAs using the 
seed region in an attempt to group them into previously described families. This 
was important for potential novel microRNAs to ensure no previously annotated 
name was found. This was achieved by using the list of microRNA families in 
miRBase and TargetScan. Harmonised data obtained from both databases was 
utilised to create a family database (seed region database) containing: the name 
of the family and the annotation (name and number in the form of 
MIPF0000002), precursor annotation (name and number in the form of 
MI0000001), mature 5’ and mature 3’ annotations (name and number in the form 
of MIMAT0000001) and seed regions for each entry (nucleotide positions 2-8). 
Seed regions of the miRNAs that had no perfect match in any of the databases 
after using method 1 and method 2, were compared to the seed region database 
to group unidentified miRNAs into previously described families. 
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2.5.2.3. Descriptive analysis 
Correlation across replicates was calculated using Pearson’s coefficient. 
Calculations were performed using Microsoft Excel. Percentage of GC 
nucleotides was calculated using a matrix on Microsoft Excel and miRNA length 
and CG percentage (%) were described.  
Distribution of miRNAs across the genome was also studied and compared to data 
available from the horse (Zhou et al., 2009; Desjardin et al., 2014; Kim et al., 
2014). 
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Figure 2.1. Summary of the pipeline for analysis of the HTS data 
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Figure 2.2. Summary of the pipeline for discovery of novel miRNAs  
 
 
I. Novel miRNA discovery 
BLAST + 
1. Transform file to .fasta 
2. Download databases and blastformat them - makeblastdb 
3. Run BLAST + on command line to compare list to databases 
4. Extract top hits (max. identity) - getTopBLASTHit.pl script 
5. Select perfect matches (PM3*): 100% identity , 0 mismatches, lengthS = 
alignment, lengthS = lengthD with allowance of 2 or less - Excel 
Edit distance (ED)  
1. Transform file and databases to .txt  
2. Run script1_calc_edit_dist_RCb.pl script 
5. Select perfect matches: max ED of 2 - Excel 
Family search (seed region) 
1. Construct a list of miRNA candiates with a known annotation (using 
results from BLAST+ and ED) - Excel 
2. Consturct a list of miRNA candidates with no knowannotation - 
novel miRNAs - Excel 
3. Construct a family database with list form miRBase and TargetScan 
linking family with seed region - script 
4. Compare seed regions of list novel miRNAs to database 
list of novel miRNAs in 
equine fibroblasts 
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Figure 2.3. Summary of the steps of the analysis of differential expression of 
miRNAs in an equine sarcoid in vitro model 
 
II. Differential expression 
DESeq 
1. Rank differentially expressed miRNAs by fold change (p<0.05) 
2. Construct Venn diagrams - upregulated and downregulated in the cells 
cotaining the virus - http://bioinformatics.psb.ugent.be/webtools/Venn 
3. Construct PCA plots and heat maps - ClustVis 
Functional analysis (IPA) 
1. list of miRNA transformed to humam homologous (hsa-) 
2. Target filter study 
3. Core analysis study 
4. Links to previously dysregulatted targets in ES (MMP1, FOX P3, MHC I, 
PGDFb, RAS_MAPK, p53, cJun, Fra-1, MMP2, MMP9) 
list of differentally expressed miRNAs 
in in vitro equine sarcoid model 
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2.5.2.4. Differential expression  
The number of reads from the cell lines was normalised to 20 million and 
differential expression of miRNAs was assessed using DESeq software. 
Significance was set at padj<0.05 for each pair compared (EqSO4b vs. EqPalF and 
S6-2 vs. EqPalF).  
Differences were studied using PCA plot, heat maps and Venn diagrams. 
Functional analysis was performed using Ingenuity Pathway Analysis software 
(IPA) using core analysis, whereby pathways and networks altered as a result of 
dysregulated miRNAs, were highlighted.  
2.6.  Real-time, reverse transcription quantitative PCR 
(real-time RT-qPCR) 
2.6.1. DNase treatment 
Total RNA to be used for real time PCR analysis was treated with DNase I using a 
DNA-free™ kit (Invitrogen™-Life Technologies Ltd) following manufacturer’s 
instructions. DNase treatment is recommended to eliminate any traces of 
genomic DNA that may overestimate the level of miRNAs in the fraction of 
expressed miRNAs.  
Readings from the Nanodrop were used to dilute total RNA to a maximum of 200 
µg/µl in RNAse free water, before proceeding with the  ‘Routine DNase 
treatment’ protocol. Diluted RNA was transferred to nuclease free 0.5 ml tubes 
and 0.1 volumes of DNase buffer was added together with DNase (2 units per 10 
µg of RNA per 50 µl reaction) and samples were incubated at 37°C for 30 
minutes in the heat block. Deactivation of the DNase was achieved by adding 0.1 
volumes of DNase inactivation reagent. After mixing well and incubating for 2 
minutes at room temperature, samples were centrifuged at 10000 g for 1.5 
minutes at 4°C. This step pellets the DNase and the DNase inactivating reagent 
and the upper layer contains RNA. RNA in suspension was transferred to a fresh 
1.5 ml eppendorf without disturbing the interphase or the pellet, to prevent 
carryover of DNase inactivation reagent or DNase. Integrity of DNase treated 
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total RNA was assessed on a 1% agarose gel as described above (section 
2.2.3.1.). 
2.6.2. Relative quantitation of miRNAs with real-time qRT-PCR 
using SYBR green as a DNA dye binder (one step RT, RNA as 
template) 
Using a Mir-X™ miRNA First-Strand Synthesis kit, 300 ng of total RNA from each 
cell line, were reverse transcribed to cDNA following the manufacturer’s advice. 
In summary, during one step reaction, total RNA was polyadenylated and reverse 
transcribed. The final volume of resuspension was the only change implemented 
to the original protocol (50µl rather than 90 µl). Samples were aliquoted and 
kept at -20°C until further use. Using SYBR® qRT-PCR kit (Clontech, Takara Bio 
Europe SAS, Saint-Germain-en-Laye, France), each miRNA was amplified using a 
3’ end universal primer from the kit and a 5’-end specific primer designed 
following the advice from the manufacturer (i.e. entire sequence of the mature 
microRNA). Details of the primers are given in Chapter 3. The Master mix for 
each set of two primers, including the normalizer gene RNU6, was prepared for 
28 reactions to account for pipetting error. Changes implemented to the 
protocol were volume of water (from 9 µl to 10.36 µl), volume of 5’ and 3’-end 
primers (from 0.5 µl to 0.32µl) and volume of template (from 2 µl to 1 µl). These 
changes were introduced during optimization. Each set of primers was tested in 
each cell line in triplicate, together with two repeats of the non-reverse 
transcription (-RT) control and 5 repeats of the no-template control (NTC). Each 
plate contained RNU6 as a normalizer gene. Plates were loaded in Mx3000PTM 
Real-Time PCR System (Stratagene). Cycling conditions included a denaturation 
step of 10 seconds at 95ºC followed by 40 cycles at 95ºC for 5 seconds and 60ºC 
for 20 seconds. A dissociation curve was set at the end of the PCR for detection 
of non-specific amplification and/or primer dimer formation. Conditions of the 
dissociation curve were 60 seconds at 95ºC, 30 seconds at 55ºC and 30 seconds at 
90ºC. The threshold cycle (Ct) or cycle number at which the fluorescence 
generated within a reaction crosses the threshold line, from each miRNA from 
each cell line, were normalised to an endogenous control. Ct values together 
with melting temperature of the PCR product were analysed and results of the 
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normalised data were expressed as a relative quantitation using the delta-delta 
Ct (∆∆Ct) method (see 2.6.4) 
2.6.3. Relative quantitation with real-time qRT-PCR using probe-
based technology Taqman® (two step RT, RNA as template) 
DNase treated total RNA obtained using the phenol method was reverse 
transcribed and quantified using specific kits for microRNA from Life 
Technologies™ - Thermofisher (Taqman® microRNA assays). Each kit contains a 
specific RT stem loop primer for the microRNA of interest together with qPCR 
primers and probes, each of them specific for the mature microRNA of interest. 
In brief, 10 ng of total RNA was reverse transcribed to cDNA and then PCR 
amplified and quantified in real time using Applied Biosystems Fast 7500 real-
time PCR system following manufacture’s instruction. The initial amount of cDNA 
per PCR reaction was increased from 1.33 µl to 2 µl. PCR conditions were set at 
15 seconds at 90ºC, followed by extension and annealing during 40 cycles at 60ºC 
for 60 seconds. Each amplification was performed in triplicate and the average 
Ct value was normalized using RNU6 (for more details please refer to chapter 4 
and 5). Expression of each microRNA was quantified against the control cell line 
(EqPalF) using the ∆∆Ct method. 
2.6.4. Delta-delta Ct method (∆∆Ct method). 
The relative levels of expressed microRNAs obtained using SYBR green or Taqman 
technology were compared using the ∆∆Ct method (Winer et al., 1999a). 
Normalised Ct values (using non-coding small nucleolar RNA component of U6 or 
RNU6) were compared using EqPalF as a calibrator (or reference sample) 
assuming primer efficiencies of 2 as described in the literature (Winer et al., 
1999a). The result was a ratio between the cell line of interest and the 
calibrator per each microRNA. Results were calculated using this formula: 
Relative quantitation of a specific microRNA= 2-∆Ct
(EqSO4b or S6-2)/ 2-∆Ct
 (EqPalF)= x 
Where (∆Ct (EqSO4b or S6-2)) is the normalized Ct of a specific microRNA in one 
of the two cell lines (EqSO4b or S6-2 cells), obtained with the subtraction of the 
Ct of the microRNA minus the Ct of the normalizer for that cell line; (∆Ct 
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(EqPalF)) is the normalized Ct of that same microRNA in the primary cell line 
(named calibrator) and x is the result of this ratio.  
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3.1.  Introduction 
The mechanisms of tumoural transformation by papillomaviruses are of 
significant interest and have been well studied, particularly in human medicine. 
To date, 181 types of human papillomaviruses (HPV) have been described and 
thirteen of these, referred to as high risk HPVs (HR-HPVs) by the World Health 
Organisation (WHO), carry a risk of inducing malignancies (WHO, 2012; Van 
Doorslaer et al., 2013). Of particular importance are HPV -16 and HPV – 18, 
which belong to the group of Alpha HPVs, and are responsible for 4% of all 
cancers worldwide and 70% of cervical cancer and pre-cancerous lesions 
(Braaten & Laufer, 2008; Stanley, 2010; de Martel et al., 2012). Based on 
evidence that supports their aetiologic association with human cancer, they are 
characterised as carcinogenic to humans in the latest report of biological agents 
by WHO (WHO, 2012). HPVs induce tumoural transformation by altering 
signalling pathways of two main tumour suppressors, p53 and pRB (Moody & 
Laimins, 2010; Doorbar et al., 2015). p53 is a tumour suppressor that encodes a 
DNA binding protein that acts to decrease cell division. HPV E6 protein interferes 
with p53 function by promoting p53 degradation (through forming complexes of 
HPV E6 and cellular E3 ubiquitin ligase E6 associated protein (E6AP)) and by 
increasing p53 instability by inactivating p300 and Crebb-binding protein (CBP) 
(Münger et al., 2004; Moody & Laimins, 2010). pRB is a member of the 
retinoblastoma family of proteins that control the G1-S phase transition by 
binding and decreasing the activity of E2F factors. E2F is a family of 
transcription factors involved in cell cycle regulation (cell cycle progression, 
differentiation, mitosis and apoptosis) and DNA synthesis (Moody & Laimins, 
2010). Other factors contributing to the carcinogenic effect of HPVs are the 
alteration of telomerase, alteration of PDZ proteins and p21 and p27 and PI3K-
AKT pathways (Moody & Laimins, 2010; DiMaio & Petti, 2013; de Freitas et al., 
2014).  
It has been shown that these pathways are regulated by microRNAs (miRNAs), 
which are small non-coding RNAs and essential regulators at a cellular level 
(Gómez-Gómez et al., 2013; Honegger et al., 2015). The aberrant expression of 
miRNAs found in HR-HPVs-infected cells and cervical cancer samples has 
contributed to the understanding of the mechanisms by which the virus initiates 
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and perpetuates malignant transformation. In fact, gene expression profiling of 
miRNAs has identified aberrant expression of several miRNAs in HR-HPV-induced 
cancer in both in vitro and in vivo studies of cervical cancer and head-neck 
cancer (Wang et al., 2008; Pereira et al., 2010; Li et al., 2011; Wald et al., 
2011; Lajer et al., 2012; Wang et al., 2014b). Dysregulation of miRNAs has been 
attributed to the presence of the HPV oncoproteins E6 and E7 (Lajer et al., 
2012; Ben et al., 2015; Honegger et al., 2015).  
Several reviews have been recently published summarising the changes in miRNA 
expression in HPV induced cancer from microarray, qRT-PCR, Western Blotting 
and HTS data (Zheng & Wang, 2011; Gómez-Gómez et al., 2013; Banno et al., 
2014; Sharma et al., 2014; Wang et al., 2016). Surprisingly, the profile of 
miRNAs associated with HPV infection has shown different results across studies. 
There is also variation between in vitro and ex vivo studies which is a reflection 
of the differences between the changes that HPV induces in cell culture vs. live 
tumours. A summary of the results from in vitro and ex vivo studies is displayed 
in Table 3.1. and Table 3.2. To add more complexity, different stages of HPV 
infection have been shown to change levels of miRNAs, verified by Wang et al. 
(2014b) using qRT-PCR. Furthermore, different stages of cervical cancer have an 
effect on miRNA profiles and levels, verified by Li et al. (2011) using microarray 
and by Gocze et al. (2013) using qRT-PCR technologies. Pereira et al. (2010) also 
reported that the level of variation in normal cervical samples was a major 
challenge to generating a profile specific for HPV induced cervical cancer. 
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Table 3.1. Levels of miRNAs found in 4 in vitro studies comparing HPV-16/-18 
positive cell lines to control cells using microarray. miRNAs that show differences 
across studies are highlighted in bold in grey cells. The two rightmost rows show the 
results from ex vivo studies from HPV-induced cancer using microarray and the number 
of studies where each miRNA was reported. For details on the references from the ex 
vivo studies, the reader is referred to Table 3.2. 
miRNA 
Wang et 
al. (2008) 
Wald et 
al. (2011) 
Lajer et 
al. (2012) 
Wang et 
al. (2014b) 
Result of in vivo 
cervical cancer tissues 
Number 
of 
studies 
let-7a Low       high 2 
let-7b Low       inconsistent 2 
let-7c High       high 2 
let-7d Low       high 2 
let-7e Low   low   high 1 
let-7f High   high   high 2 
let-7g Low   high   high 1 
miR-100 High     low low 4 
miR-101 High       low 1 
miR-106b       high high 1 
miR-10b High       low 2 
miR-1180     low   not reported 0 
miR-125a-3p     low   not reported 0 
miR-125b High   high   low 3 
miR-1275     low   not reported 0 
miR-13232   low     not reported 0 
miR-142-5p   low     high 1 
miR-143 High       low 3 
miR-145 High       low 4 
miR-146a High   high   inconsistent 2 
miR-146b-5p High   high   inconsistent 2 
miR-150     high   not reported 0 
miR-155   low high   high 3 
miR-15a Low   high   high 2 
miR-15b     high   high 2 
miR-16     high high high 3 
miR-181a High low     low 1 
miR-181b High low low   low 1 
miR-181d High       low 1 
miR-191* Low       inconsistent 1 
miR-193b*     low   not reported 0 
miR-195 Low       inconsistent 4 
miR-198 low       high 1 
miR-199a high       low 3 
miR-200b low       high 1 
miR-200c low   low   high 1 
miR-203 low       inconsistent 2 
miR-205 high       high 3 
miR-20b     high   high 2 
miR-21 high   high   high 3 
miR-210       high not reported 0 
miR-214 high       low 1 
miR-218 high low     low 3 
miR-22 high     low low 1 
miR-221 high low     inconsistent 2 
miR-222 high low     inconsistent 2 
miR-223 low       high 2 
miR-224       high high 2 
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miR-23a high       high 2 
miR-23b high       high 2 
miR-24 high     low low 1 
miR-25       high high 1 
miR-26a high       low 3 
miR-26b low   high   high 1 
miR-27a low     low high 2 
miR-27b low       high 1 
miR-29a high low high low low 4 
miR-301  high       low 1 
miR-30a-5p high       low 1 
miR-30d high       low 1 
miR-30e-5p high       low 1 
miR-31     low   high 1 
miR-31*     low   high 1 
miR-324-5p     low   low 1 
miR-33   high     not reported 0 
miR-342-3p     high   not reported 0 
miR-34a high       low 1 
miR-34a*     high   low 1 
miR-34c high       low 1 
miR-363   high high   not reported 0 
miR-374a low       high 1 
miR-378 (422b)       high not reported 0 
miR-423-5p     low   not reported 0 
miR-424 high       low 3 
miR-497   high     low 1 
miR-513 low        inconsistent 2 
miR-563 low       high 1 
miR-565 low       high 1 
miR-575 low       high 1 
miR-596     high   not reported 0 
miR-598     high   not reported 0 
miR-602 low       high 1 
miR-623 low       high 1 
miR-625     high   high 1 
miR-625*     high   high 1 
miR-628 low       high 1 
miR-638 low       high 1 
miR-744     low   not reported 0 
miR-768-3p     high   not reported 0 
miR-877     low   not reported 0 
miR-92a       high high 1 
miR-93       high high 3 
miR-99b high   low   low 1 
 
Table 3.2. miRNA expression found in HPV-16/-18 cervical cancer samples by 
microarray. miRNAs which shown differences across studies are in grey cells 
  Wang et 
al. (2008) 
Wang et al. (2008) (in vitro 
HPV + raft tissues) 
Pereira et 
al. (2010) 
Li et al. 
(2011) 
Lajer et al. 
(2012) 
hsa-let-7a high high       
hsa-let-7b   high   low   
hsa-let-7c high high       
hsa-let-7d high high       
hsa-let-7e   high       
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hsa-let-7f high high       
hsa-let-7g   high       
hsa-miR-100 low low   low low 
hsa-miR-101   low       
hsa-miR-106a high   high high high 
hsa-miR-106b         high 
hsa-miR-10a     high     
hsa-miR-10b   low   low   
hsa-miR-1224-5p         high 
hsa-miR-125 low         
hsa-miR-125b   low   low low 
hsa-miR-126 low     low   
hsa-miR-127 low         
hsa-miR-130b         high 
hsa-miR-132     high     
hsa-miR-133a low         
hsa-miR-133b low         
hsa-miR-142-5p     high     
hsa-miR-143 low low low     
hsa-miR-145 low low low low   
hsa-miR-145*     low     
hsa-miR-146a high low       
hsa-miR-146b-5p   low     high 
hsa-miR-148a high   high     
hsa-miR-149         low 
hsa-miR-155 high     high high 
hsa-miR-15a high high       
hsa-miR-15b high     high   
hsa-miR-16 high   high high   
hsa-miR-17-5p high     high   
hsa-miR-17*         high 
hsa-miR-181a   low       
hsa-miR-181b   low       
hsa-miR-181c high         
hsa-miR-181d   low       
hsa-miR-182 high     high   
hsa-miR-183 high         
hsa-miR-185 high     high high 
hsa-miR-191* low high       
hsa-miR-195 low high   low low 
hsa-miR-196a     high     
hsa-miR-197     high     
hsa-miR-198   high       
hsa-miR-199a low low low     
hsa-miR-199a-3p       low   
hsa-miR-200b   high       
hsa-miR-200c   high       
hsa-miR-203   high low     
hsa-miR-205 high high high     
hsa-miR-20a high     high   
hsa-miR-20b high     high   
hsa-miR-21 high high     high 
hsa-miR-214   low       
hsa-miR-218 low low   low   
hsa-miR-22   low       
hsa-miR-221   low   high   
hsa-miR-222   low   high   
hsa-miR-223 high high       
 72 
hsa-miR-224 high     high   
hsa-miR-23a high high       
hsa-miR-23b high high       
hsa-miR-24   low       
hsa-miR-25       high   
hsa-miR-26a low low low     
hsa-miR-26b   high       
hsa-miR-27a   high high     
hsa-miR-27b   high       
hsa-miR-29a low low low low   
hsa-miR-29c       low   
hsa-miR-301    low       
hsa-miR-302b     high     
hsa-miR-30a-5p   low       
hsa-miR-30b low         
hsa-miR-30d   low       
hsa-miR-30e-5p   low       
hsa-miR-31       high   
hsa-miR-324-5p low         
hsa-miR-339-5p         high 
hsa-miR-34a   low      
hsa-miR-34c   low       
hsa-miR-374a   high       
hsa-miR-375       low low 
hsa-miR-422a low         
hsa-miR-422b (378) low         
hsa-miR-424 low low   low   
hsa-miR-450 low         
hsa-miR-455 low         
hsa-miR-497         low 
hsa-miR-512-5p     high     
hsa-miR-513   high low     
hsa-miR-522*     high     
hsa-miR-563   high       
hsa-miR-565   high       
hsa-miR-574 low         
hsa-miR-575   high       
hsa-miR-602   high       
hsa-miR-617         low 
hsa-miR-623   high       
hsa-miR-625         high 
hsa-miR-628   high       
hsa-miR-638   high       
hsa-miR-92a       high   
hsa-miR-92b       high   
hsa-miR-93 high     high high 
hsa-miR-941         high 
hsa-miR-99a low   low low low 
hsa-miR-99b   low       
 
Bovine papillomaviruses (BPVs) type 1 and 2 are recognised as causative agents 
of equine sarcoids (ES) (Nasir & Reid, 1999; Brandt et al., 2011b; Wobeser et al., 
2012). There is scarce information of a third BPV (BPV-13) which may have a role 
in ES (Lunardi et al., 2013b). The carcinogenic effects of BPV type -1 and -2 
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early proteins E5, E6 and E7 are the best characterised (Petti et al., 1991; 
Borzacchiello et al., 2006; Borzachiello et al., 2008; Marchetti et al., 2009; Yuan 
et al., 2010a; Yuan et al., 2010b; Yuan et al., 2011c; Mosseri et al., 2014). In 
fact, BPV-1 E5 alone is capable of transforming fibroblasts of mouse, human and 
equine (Bergman et al., 1988; Petti & Ray, 2000; Yuan et al., 2011b). BPV-1 E6 
has the same transforming effect on equine fibroblasts as BPV-1 E5 and both 
contribute to the invasive phenotype of tumoural cells (Yuan et al., 2011b).  
BPV-1 E7 on the other hand has a synergistic function and it has been 
demonstrated to be involved in anchorage-independent growth of transformed 
equine fibroblasts, together with BPV-1 E6 (Yuan et al., 2011b). The roles of 
BPV-1 oncoproteins have been described in detail in Chapter 1, section 1.1.4.1. 
Several studies have been conducted to identify the mechanisms by which BPV-1 
and -2 oncoproteins induce and perpetuate tumoural transformation. Activation 
of the platelet-derived growth factor  receptor (PDGF-R) signaling pathway 
and the intracellular retention of major histocompatibility complex (MHC) class 
I, both driven by the BPV-1/-2 E5 oncoprotein, are the most studied cellular 
events (Petti et al., 1991; Ashrafi et al., 2002; Borzacchiello et al., 2006; 
Borzachiello et al., 2008; Marchetti et al., 2009; Altamura et al., 2013). Other 
recognised effects of BPV-1/-2 oncoproteins in ES are activation of p38 mitogen-
activated protein kinases (p38-MAPK) (Yuan et al., 2011c), intracellular 
mislocation of tumour suppressor p53 (Yuan et al., 2008a), activation of p600, a 
member of the retinoblastoma family (Corteggio et al., 2011), downregulation of 
toll-like receptor 4 (TLR4) (Yuan et al., 2010a) and increased expression of 
forkhead box protein 3 (FOXP3) (Mahlmann et al., 2014). A summary of the 
molecules/pathways altered by BPV-1/2 during oncogenesis is displayed in Table 
3.3. However, to date, the mechanisms by which the virus activates or inhibits 
these pathways are still poorly understood.  
A previous study investigated in vitro changes to the equine fibroblast 
transcriptome induced by BPV-1 using microarray expression profiling (Yuan et 
al., 2008b). This demonstrated altered expression of genes involved in a range of 
processes including immunity and inflammation, cell adhesion, motility as well 
as cell cycle/cell proliferation and apoptosis. Currently, there is no information 
of miRNA expression changes in equine sarcoids.  
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Table 3.3. Molecules/pathways altered by BPV-1/-2 during tumoural 
transformation in equine sarcoids 
 
Microarray means small size grid (‘mikro’, which means small in Greek), of 
probes orderly arranged (‘ad- redare’, from Latin) (Trachtenberg et al., 2012). 
The probes are affixed to a surface and they are made by small size single 
stranded DNA oligonucleotides.  Utilising the affinity of single stranded cDNA to 
become double stranded, the microarray probes of DNA oligonucleotides bind to 
their complementary RNA sequences giving evidence for the presence of certain 
genes in the sample exposed to the probes. This hybridization is used to assess 
the presence of thousands of transcripts in an RNA sample.  The basic 
components in a microarray analysis are the RNA sample being analysed (and 
amplification kit if initial amount of sample is too small), microarray chip, 
labelling kit, hybridization station and chambers, scanner for image capture and 
software for data analysis (Wang & Yang, 2010; Trachtenberg et al., 2012). 
Microarray technology is widely used to examine gene expression and has been 
utilised in cervical cancer studies as a starting point to better understand the 
mechanisms of tumorigenesis induced by HPV (Wang et al., 2014b). 
The aim of this chapter was to use a novel approach to improve understanding of 
the molecular pathogenesis associated with BPV-1-induced tumorigenesis in 
sarcoids. The results presented here, obtained using microarray technology, 
identify cellular miRNAs that are differentially expressed in BPV-1-transformed 
Molecule / Pathway Effect BPV trigger Source 
Platelet derived growth factor 
beta receptor (PDGFβ-R) 
Activation BPV-1 E5 
Petti et al. (1991); 
Borzachiello et al. (2008); 
Altamura et al. (2013) 
Ras-mitogen-activated protein 
kinase pathway (Ras-MAPK) 
Activation BPV-1 E5? Altamura et al. (2013) 
PDGF-R-PI3K-AKT signaling 
cascade 
Activation BPV-1 E5 Borzacchiello et al. (2009) 
p38 mitogen-activated protein 
kinases (p38-MAPK) 
Activation BPV-1 E5? Yuan et al. (2011c) 
p53 Mislocation BPV-1 E5 Yuan et al. (2008a) 
p600 (part of the retinoblastoma 
family) 
Activation BPV-1 E7 
DeMasi et al. (2005); 
Corteggio et al. (2011) 
Matrix metalloproteinase MMP-1 Upregulation BPV-1 E7/E5 Yuan et al. (2010b) 
TLR4 Downregulation 
BPV-1 E2 and 
E7 
Yuan et al. (2008b); Yuan 
et al. (2010a) 
MHC class I Downregulation BPV-1 E7 Marchetti et al. (2009) 
Transcription factor forkhead box 
protein 3 (FOXP3) 
Upregulation ? Possibly E5 Mahlmann et al. (2014) 
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equine fibroblasts that may lead to BPV-1-induced tumorigenesis. 
3.2. Materials and methods 
3.2.1. Cell culture and RNA isolation 
Equine primary fibroblasts (EqPalFs) and BPV-1 transformed cells (S6-2) have 
been previously described (Yuan et al., 2008a). RNA was isolated using a phenol 
based method, a variation of the classic phenol/chloroform extraction and 
ethanol precipitation, with the use of Trizol® reagent. For details on the cell 
lines, cell culture conditions, RNA isolation, quantification and quality 
assessment of RNA, the reader is referred to Chapter 2, sections 2.2. (Cell 
culture) and 2.3. (Molecular biology). One RNA extraction was performed per 
cell line, and the RNA sample from each cell line was divided in 3 aliquots 
(technical replicates) for the microarray. 
3.2.2. miRNA microarray 
miRNA expression profiling was performed using the commercial array platform 
miRCURY LNA™ microRNA Array 7th Gen (Exiqon, Vedbaek Denmark) probed with 
total RNA isolated from EqPalF cells (normal equine fibroblast) and S6-2 (BPV-1 
transformed fibroblast) cells. This array comprised 2,164 probes that contain 
human (1651 probes, 76.3%), viral miRNA sequences (146, 6.75%), predicted 
equine microRNA sequences derived from miRBase 19.0. (350, 16.2%) (Griffiths-
Jones et al., 2006) and SNORDs (17, 0.8%). A detailed description of the 
technique is given in Chapter 2 (Materials and methods) in section 2.4. (miRNA 
microarray) and a list of probes is included in the file ‘master file 
microarray.xlsx’ supplied in the DVD. 
3.2.3. Validation of miRNA expression using real-time quantitative 
reverse transcription polymerase chain reaction (real-time qRT-
PCR) 
Eleven miRNAs were selected for validation of the microarray results. The list of 
miRNAs selected and qRT-PCR primer sequences are shown in the results section 
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(Table 3.7). miRNAs were quantified using SYBR® green qRT-PCR technology 
(Takara Bio Europe, St Germaine en Laye, France), however due to problems 
with non-specific amplification and low efficiency for some primer sets, a panel 
of miRNAs were examined using TaqMan® MicroRNA Assays (Life Technologies 
Ltd, Paisley, United Kingdom). Primers used for amplification were supplied as 
part of the kits with the exception of the 5' primers for SYBR green and these 
are listed in Table 3.4. Each amplification reaction was performed in triplicate 
and the average Ct value was used for subsequent analysis. Expression of each 
miRNA was normalised using RNU6 and differential expression was calculated 
using the ∆∆Ct method (Winer et al., 1999b; da Silveira et al., 2012; Buechli et 
al., 2013). Further details of the qRT-PCR technique are included in Chapter 2, 
section 2.6. (Real-time quantitative reverse transcription polymerase chain 
reaction). 
3.3.  Results   
3.3.1. Quality control of RNA samples 
Triplicate samples of RNA isolated (three technical replicates per cell line) from 
EqPalF and S6-2 cells were subjected to NanoDrop® ND-1000 analysis to measure 
RNA concentration from optical density readings. In addition, on arrival at the 
microarray service provider, the RNA integrity number (RIN) of samples was 
assessed using the Bioanalyzer 2100. This tests the quality of RNA. The results 
from these measurements (concentration, optical densities and RIN value) are 
displayed in Table 3.4. 
Table 3.4. Quality control and quantification of RNA extracted for microarray 
analysis. Values of concentration and optical density were obtained using NanoDrop® 
ND-1000 Spectrophotometer and RIN values were obtained using automated 
electrophoresis and flow cytometry (Bioanalyzer 2100, Agilent Technologies). Each 
replicate was obtained by dividing one RNA sample in three aliquots (technical 
replicates) 
 
Concentration 
(ng/μl) 
Optical density 
(O.D.) 260/280 
Optical density 
(O.D.) 260/230 
RIN value 
EqPalF-1 1455 1.88 2.22 10 
EqPalF-2 1455 1.89 2.20 10 
EqPalF-3 1455 1.83 2.16 10 
S6-2-1 901 1.87 2.10 10 
S6-2-2 901 1.88 2.10 10 
S6-2-3 901 1.85 2.12 10 
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In addition, agarose gel electrophoresis of the samples revealed minimal 
degradation of the RNA samples as shown by the clear 18S and 28S bands in  
 
Figure 3.1. 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Agarose gel electrophoresis of RNA samples from EqPalF and S6-2 
cells. Ribosomal bands 28S (bigger arrow) and 18S (small arrow) were well defined 
indicating limited degradation of the RNA 
 
3.3.2. Microarray data 
3.3.2.1. microRNAs expressed above background signal 
Of the 2,164 probes present in the microarray, 492 probes shown signal intensity 
above the background. The background threshold was calculated for each 
individual microarray slide as 1.2 times the 25th percentile of the overall signal 
intensity of the slide (Exiqon, Vedbaek Denmark). Only miRNAs with intensities 
above threshold in more than one of the samples were included in the expression 
analysis dataset. 
Principal component analysis (PCA) was used to investigate the relationship 
between the S6-2 and EqPalF microarray readings. PCA allow complex multi-
dimensional datasets to be transformed to reveal underlying patterns of 
variation. Microarray expression data for the 492 probes was subjected to PCA 
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and clear separation was evident between the cell lines that containing BPV-1 
(S6-2) and the control cell line (EqPalF) (see Figure 3.2.), with replicates of the 
same cell-type forming clusters. Replicates of S6-2 and EqPalF were 
discriminated by the first principal component, which accounted for more than 
60% of the variation in the dataset. This indicated that the differences in 
microRNA expression profile of the two types of sample were pronounced and 
that a good level of biological replication was evident 
 
 
 
 
 
 
 
 
Figure 3.2. Principal component analysis (PCA) plot with 492 probes found 
above the background signal. Unit variance scaling is applied to rows; singular value 
decomposition with imputation is used to calculate principal components. The X and Y 
axes show the 1st and 2nd principal components, which explain 60.2 % and 15 % of the 
total variance, respectively. N = 6 data points (graph obtained using online tool Clustvis) 
 
3.3.2.2. Data refinement  
Of the 2,164 probes on the array, 492 were above the background signal 
(average signal intensity from three replicates) in both cell lines. Of those, 90 
probes were excluded for the data analysis for various reasons, as detailed 
below. Twenty-three probes were duplicates, identified on the basis of their 
annotation or mature sequence name. The data from duplicated probes was 
averaged to produce a value for each individual mature miRNA sequence. 
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Another 67 probes were removed as they were included in the array design for 
quality control purposes. These included 19 human-targeted probes known to 
give false positive readings, 27 non-papillomavirus sequences, 9 human synthetic 
sequences and 12 small nucleolar RNA. Thus, in total, analysable data was 
generated representing 402 microRNA sequences. Of those, 124 were equine 
predicted sequences and 278 were human sequences. The contribution of each 
group of probes to the total is represented in Figure 3.3. and a summary of the 
data refinement is displayed in Figure 3.4. A detailed list of the miRNAs and 
sequences is included in the file ‘master file microarray.xlsx’ in the DVD 
supplied. 
 
 
 
 
 
 
Figure 3.3. Pie chart displaying the distribution of the probes/sequences 
found in equine fibroblasts using miRNA microarray. 278 sequences were human 
mature miRNAs, 124 sequences were equine predicted sequences, 90 probes were 
excluded as they were repeats, false positives, synthetic sequences, non-PV viral 
sequences and SNORDs 
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Figure 3.4. Summary of the steps of the analysis of differential expression of 
miRNAs between BPV-1 transformed cells (S6-2 cells) and EqPalFs using 
microarray. *human ‘false-positive’ probes are used as part of the quality control 
process and are discarded in the analysis. ** The Benjamini and Hochberg multiple 
testing adjustment method was applied on the data to obtain the adjusted p values  
miRCURY LNTM microRNA array 7th Gen - 
2164 probes 
Background subtraction: -1672 probes 
below threshold 
492 probes  
Removal of repeats (23), human probes false 
positives*(19), viral probes (27), human synthetic 
probes (9), SNORDS (12): - 90 probes 
402 probes 
402 miRNAs that are present in equine fibroblasts: 124 
equine sequences and 278 human sequences. Applied 
moderated t-statistics, adjusted p value** <0.05: 
206 differentially expressed miRNA (S6-2 vs EqPalF) 
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3.3.2.3. Differential expression of miRNAs 
Just over 50% of the 402 sequences were found to be differentially expressed 
between the two cell types after applying moderated t-statistics (206, adjusted 
p value < 0.05 using the Benjamini and Hochberg multiple testing adjustment 
method). In total 62 (15%) miRNAs were found to be upregulated in S6-2 cells 
compared to EqPalFs, 144 (36%) miRNAs were downregulated and 196 (49%) were 
not significantly different (p<0.05). The distribution of up- and downregulated 
miRNAs is displayed in Figure 3.5. Log2 fold change in the 206 differentially 
expressed miRNA ranged from -2.13 to 0.61 and signal intensity ranged from 5.81 
to 13.53. The list of the top 30 downregulated miRNAs in S6-2 relative to EqPalF 
cells (ranked by FC) is displayed in Table 3.5. The list of top 30 upregulated 
miRNAs (ranked by FC) is presented in Table 3.6. 
 
 
 
 
 
 
 
 
Figure 3.5. Distribution of up- and down-regulated miRNAs in S6-2 cells vs. 
EqPalFs. The majority of the dysregulated miRNAs were downregulated in S6-2 cells. In 
total 144 miRNA candidates were found downregulated (72 human sequences and 72 
equine predicted sequences, 70% of the differentially expressed miRNAs) and 62 were 
found upregulated (49 human sequence and 13 equine predicted sequences, 30% of the 
differentially expressed miRNAs) 
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Table 3.5. Top 30 downregulated miRNA candidates in S6-2 cells compared to 
EqPalF cells (adjusted p value <0.05; ranked by FC) 
Annotation FC AvgHy3 adj. p value 
eca-miR-127 -4.38 5.92 1.34E-08 
hsa-miR-4732-5p -2.98 9.47 1.34E-08 
eca-miR-132 -2.79 5.81 2.79E-07 
eca-miR-181a -2.41 8.21 3.65E-08 
eca-miR-409-3p -2.25 5.83 5.36E-07 
hsa-miR-663a -2.18 9.1 9.81E-08 
hsa-miR-3158-5p -2.03 6.51 2.79E-07 
eca-miR-15b -2.00 9.34 2.20E-07 
eca-miR-106a/ eca-miR-17 -1.97 6.87 3.70E-07 
hsa-miR-199a-3p  -1.95 9.2 5.02E-07 
hsa-miR-675-5p -1.91 6.63 3.16E-07 
hsa-miR-455-3p -1.88 7.27 3.13E-07 
eca-miR-199b-5p -1.86 8.69 2.20E-07 
eca-miR-16 -1.86 9.63 1.40E-06 
eca-miR-181b -1.83 6.51 2.20E-07 
eca-miR-199a-5p -1.83 8.56 3.70E-07 
eca-miR-23a -1.80 11.98 7.60E-07 
hsa-miR-106a-5p -1.80 6.66 1.14E-06 
eca-miR-24 -1.80 11.14 1.54E-05 
eca-miR-93 -1.77 7.89 5.02E-07 
hsa-let-7b-5p -1.77 10.91 1.32E-06 
eca-miR-23b -1.76 12.37 5.53E-07 
eca-miR-487b -1.71 5.84 1.98E-06 
eca-miR-214 -1.71 10.22 5.80E-07 
eca-miR-27a -1.68 8.12 1.14E-06 
hsa-miR-181d -1.68 6.93 1.74E-06 
hsa-let-7i-5p -1.66 8.42 1.31E-05 
eca-miR-432 -1.66 6.64 5.77E-06 
eca-miR-25 -1.66 7.27 4.54E-07 
eca-miR-20a -1.65 6.73 7.04E-07 
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Table 3.6. Top 30 upregulated miRNA candidates in S6-2 cells compared to 
EqPalF cells (adjusted p value <0.05) ranked by FC 
Annotation FC AvgHy3 Adj.P.Val 
eca-miR-1902 1.53 6.48 1.14E-05 
hsa-miR-493-5p 1.48 8.99 8.20E-06 
hsa-miR-4484 1.41 5.93 1.28E-05 
hsa-miR-1285-3p 1.40 8.02 1.54E-05 
hsa-miR-3121-5p 1.40 7.12 8.04E-06 
hsa-miR-639 1.39 7.64 1.70E-04 
eca-miR-193b 1.37 7.44 1.46E-05 
hsa-miR-4742-3p 1.32 7.47 6.63E-05 
eca-miR-1248 1.29 7.05 3.94E-05 
eca-miR-99a 1.27 6.78 5.15E-05 
hsa-miR-630 1.27 6.37 3.57E-04 
hsa-miR-3676-5p 1.27 6.75 9.50E-05 
hsa-miR-3161 1.25 6.18 1.87E-03 
eca-miR-122 1.23 7.55 3.22E-02 
hsa-miR-4301 1.23 11.81 1.39E-03 
hsa-miR-1321 1.23 6.37 2.72E-04 
eca-miR-187 1.22 6.82 7.58E-04 
hsa-miR-514a-5p 1.21 6.32 3.61E-04 
hsa-miR-5684 1.19 11.8 2.59E-03 
hsa-miR-4791 1.19 6.9 1.51E-03 
hsa-miR-377-5p 1.19 6.31 5.25E-03 
hsa-miR-877-5p 1.19 7.15 4.86E-04 
hsa-miR-636 1.19 6.5 2.25E-03 
hsa-miR-4646-3p 1.18 6.31 3.90E-03 
hsa-miR-4712-3p 1.17 6.61 4.15E-03 
hsa-miR-4780 1.17 9.85 4.84E-03 
hsa-miR-4475 1.17 7.92 2.11E-03 
hsa-miR-4299 1.16 7.13 7.24E-04 
hsa-miR-4682 1.17 6.68 5.00E-03 
eca-miR-532-3p 1.17 6.31 2.85E-03 
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A two-way hierarchical clustering of miRNAs and samples showed that the EqPalF 
replicates are closer to each other than they are to S6-2 and equally the 
replicates of S6-2 are closer to each other than they are to EqPalF (Figure 3.6). 
Additionally, the clustering indicates, based on the distance of the tree 
branches, that there is a clear discrimination between the two cell lines. The 
heat map also highlights that the majority of differentially expressed miRNAs in 
S6-2 cells are downregulated. 
Figure 3.6. Heat map representing the top 50 miRNAs (with the highest 
standard deviation) out of 206 differentially expressed miRNAs between 
EqPalF and S6-2 cells using microarray. The complete-linkage method was used to 
define clusters together with a euclidean distance measure. Each row represents a 
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microRNA and each column represents a sample. The microRNA clustering tree is shown 
on the left. The colour scale illustrates the relative expression level of microRNAs (each 
replicate compared to the reference). Red represents an expression level below the 
reference channel and green represents expression higher than the reference 
 
3.3.3. Real-time qRT-PCR data 
To validate the S6-2 versus EqPalF microarray results, 11 differentially expressed 
miRNAs were assessed by qRT-PCR using RNA prepared from three biological 
replicates of the same cell lines. RNA preparations were obtained from other 
batches of cells, different from those used in the microarray analysis, and were 
extracted using the same method as described above. The miRNAs were chosen 
based on two of the following thresholds advised by Exiqon: absolute fold-
change of ≥2, microarray signal intensity between 7.5 and 14.5 and biological 
significance, i.e. previously shown to be implicated in human papillomavirus-
associated cancer. The list of miRNAs selected for validation with the results 
from the microarray and sequence is displayed in Table 3.7.   
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Table 3.7. List of 11 miRNAs selected for real-time qRT-PCR validation of microarray data. Four criteria were used to select the miRNAs 
differentially expressed between BPV-1 transformed equine fibroblasts (S6-2 cells) and normal equine fibroblasts (EqPalF cells) with significance of 
p<0.05 (adjusted p value); fold change between the two cell lines (FC) outwith 2.0 and -2.0, signal intensity on the microarray (AvgHy3) between 
7.5 and 14.5 and biological significance (b.s.) (previously found dysregulated in cancer and or HPV induced cancer) 
Annotation FC 
AvgH
y3 
Adj. p 
value 
Criteria Sequence 
miRBase 
accession number 
Biological significance (b.s.) 
eca-miR-15b -2.0 9.34 2.20E-07 
Hy3, FC 
criteria and 
b.s. 
TAGCAGCACATCATGGTTTACA MIMAT0012954  
Reported to be upregulated in HR-HPV (Wang et 
al., 2008; Li et al., 2011; Lajer et al., 2012) and 
downregulated in glioma cells (Sun et al., 2014) 
hsa-miR-663a -2.17 9.1 9.81E-08 
Hy3, FC 
criteria and 
b.s. 
AGGCGGGGCGCCGCGGGACCGC MIMAT0003326 
Promotes switch to abnormal phenotype in 
proliferative cardiac disease model (Liu, 2013).  
 
 
eca-miR-181a -2.41 8.21 3.65E-08 
Hy3, FC 
criteria and 
b.s. 
AACATTCAACGCTGTCGGTGAGT MIMAT0013178  
High in HPV + monolayer culture but low in HPV + 
raft tissues using microarray (Wang et al., 2008);  
low in HPV-16 cell line using microarray and qRT-
PCR (Wald et al., 2011), low in HPV-16/18 cell 
line using microarray and qRT-PCR (Lajer et al., 
2012). Encoded in ECA25, region associated with 
equine sarcoids (Jandova et al., 2012). 
hsa-miR-4732-5p -2.97 9.47 1.34E-08 
Hy3, FC 
criteria and 
b.s. 
TGTAGAGCAGGGAGCAGGAAGCT MIMAT0019855 
Regulates abundance of tumour suppressor p53 
(Pouladi et al., 2013). 
eca-miR-127 (hsa-
miR-127-3p) 
-4.38 5.92 1.34E-08 
FC criteria 
and b.s 
TCGGATCCGTCTGAGCTTGGCT MIMAT0013126  
Downregulated in HPV induced cancer (Zheng & 
Wang, 2011). 
eca-miR-409-3p -2.25 5.83 5.36E-07 
FC criteria 
and b.s 
GAATGTTGCTCGGTGAACCCCT MIMAT0013151 
Downregulated in HPV-positive cells in 
pharyngeal SCC (Lajer et al., 2011). It suppresses 
cancer cell growth in breast cancer (Zhang et al., 
2016) 
eca-miR-106a / 
eca-miR-17 
1.97 6.87 3.70E-07 
FC criteria 
and b.s 
CAAAGTGCTTACAGTGCAGGTAG MIMAT0013194 
Upregulated in HPV16 cervical cancer (Zheng and 
Wang, 2011; Li et al., 2011) 
eca-miR-132 (hsa-
miR-132-3p) 
-2.79 5.81 2.79E-07 
FC criteria 
and b.s 
TAACAGTCTACAGCCATGGTCG MIMAT0013021  
Upregulated in HPV cervical cancer (Pereira et al., 
2010) 
hsa-let-7b-5p 
-1.77 10.91 1.32E-06 
Hy3 criteria 
and b.s. 
TGAGGTAGTAGGTTGTGTGGTT MIMAT0000063 
 Overexpression of let-7b inhibits invasion and 
migration in gastric cancer (Han et al., 2015) 
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(Table 3.7 Continuation) 
Annotation FC AvgHy3 
Adj. p 
value 
Criteria Sequence 
miRBase 
accession number 
Biological significance (b.s.) 
eca-miR-23b -1.77 12.37 5.53E-07 
Hy3 criteria 
and b.s. 
ATCACATTGCCAGGGATTACC MIMAT0013113   Reported to be downregulated in HPV-16 via E6 
(Yeung et al., 2011). Encoded in ECA23, region 
associated with equine sarcoids (Jandova et al., 2012). 
eca-miR-143 
-1.31 
 
10.1 1.79E-04 
Hy3 criteria 
and b.s. 
TGAGATGAAGCACTGTAGCTC 
MIMAT0013063 
Lajer et al., 2012 - suppresses cell growth in HPV 
cancer. It is downregulated in hpv infected cells. 
Cluster 143/145 frequently mentioned as tumor 
suppressors. Mentioned in the majority of the HPV 
cancer related papers (summary Zheng and Wang, 
2011) 
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Real-time quantification showed that 6 of the 11 microRNAs tested had 
significantly higher expression in EqPalF than in S6-2 cells, as expected (let-7b, 
miR-17, miR-23b, miR-132, miR-143, miR-181a) (Figure 3.7.), confirming the 
results from the microarray. Pearson’s correlation coefficient between 
microarray and qPCR data was 0.68 (Figure 3.8.). One miRNA (miR-663a) showed 
no significant difference between the cell types, whilst two miRNAs had an 
inverse expression pattern to the microarray data (miR-15b and miR-127). Two 
miRNAs (miR-409 and miR-4732) could not be quantified due to low efficiency 
and/or non-specific amplification. 
 
 
Figure 3.7. Relative quantification of the six miRNAs that validated 
microarray data using real-time qRT-PCR. The mean expression value of target 
miRNA was normalised against the expression of endogenous control U6 snRNA and 
values were calibrated against expression levels of calibrator (EqPalF). Error bars 
represent the standard error of the mean. Statistical significance is represented by 
asterisks, *P < 0.01 
 
 
 
 
miRNA validated using qRT-PCR 
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Figure 3.8. Correlation between microarray and qRT-PCR data. The differential 
expression of miRNAs in control equine fibroblasts (EqPalF) and BPV-1 transformed 
equine fibroblasts (S6-2 cells) was calculated by microarray (x-axis, S6-2/EqPalF ratio) 
and qRT-PCR (y-axis, log2 fold-change of S6-2 versus EqPalF) 
 
3.4. Discussion 
In total, 206 miRNAs were found to be significantly dysregulated in BPV-
transformed equine primary fibroblasts when compared to control primary 
fibroblast using miRNA microarray (adjusted p<0.05). The results indicated a 
clear difference in miRNA expression between EqPalF and S-62 cells: replicates 
of the same cell line are located in the same region of the PCA plot and there is 
a clear separation between the two cell lines within the PCA plot. The strong 
correlation between microarray results and qRT-PCR is good supporting evidence 
indicating that the microarray results are a reliable estimate of relative miRNA 
expression. 
Research and interest in the role of microRNAs in virus-host interactions has 
increased in recent years (Gupta et al., 2012; Buggele & Horvath, 2013; Chang 
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et al., 2013). Viruses are able to remodel cellular miRNA expression networks 
impacting on the pathogenesis of virally induced cancers (Greco et al., 2011; 
Yeung et al., 2011; Wang et al., 2014b). To date, there are few studies on 
equine miRNAs and no studies have investigated the impact of viral infection on 
miRNA expression in equine cells. For further details on equine miRNA studies 
the reader is advised to refer to Chapter 1, section 1.2.5. 
miRNAs are highly conserved across species (Lee et al., 2007) and phylogenetic 
conservation of the mature sequence was utilised in the first report on equine 
miRNAs (Zhou et al., 2009). Using an integrated comparative genomic approach 
to the human genome and other animal genomes, a total of 354 mature 
sequences of miRNA candidates were computationally predicted in the horse 
(Zhou et al., 2009). The results from the microarray comparing miRNA 
expression levels in EqPalF and S6-2 cells confirmed that 124 of these predicted 
miRNA are indeed encoded within the equine genome and expressed in equine 
fibroblasts. 
Pathway analysis to group the candidate miRNAs into functional processes was 
attempted however, due to the low number of mRNA in the transcriptome 
dataset (Yuan et al., 2008b) and the low number of microRNAs from the 
microarray identified in the Ingenuity Pathway Analysis database, the analysis 
was insufficient to provide information on canonical pathways 
(http://www.ingenuity.com/products/ipa). 
An interesting observation in our study was that most of the miRNAs (70%) were 
downregulated in transformed cells. Pereira et al. (2010) assessed samples of 
human cervical cancer linked to HPV-16/-18 and found a general pattern of 
miRNA downregulation in tumour samples. However, it needs to be considered 
that the scope of the miRNA microarray performed in the current study was 
limited to 402 mature miRNA candidates so there is the possibility of a bias in 
the data due to the probe selection and the inherent problem of working with 
human sequences and equine predicted sequences. A general dowregulation of 
cellular miRNAs has also been observed in other cancers and some of the miRNAs 
found downregulated in S6-2 cells by both microarray and qRT-PCR in this study 
have been previously found to be downregulated in HPV-induced cancers either 
in cell culture or from in vivo tumours. These include let-7b, miR-23b and miR-
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143 (Wang et al., 2008; Pereira et al., 2010; Li et al., 2011; Yeung et al., 2011; 
Liu et al., 2012) and the data shown here indicate that these same miRNAs can 
be downregulated by PV in different host species. 
Real-time qRT-PCR successfully validated differential expression of six of 11 
selected microRNAs (let-7b, miR-17/miR-106a, miR-23b, miR-132, miR-143, miR-
181a). For two of the selected miRNAs PCR reactions could not be optimised due 
to low efficiency and/or non-specific amplification (miR-4732-5p and miR-409-
3p). miR-663a was shown to be significantly downregulated by microarray 
analysis (fold change of -2.17), however real-time qRT-PCR showed no difference 
in expression.  Similarly, it was not possible to reproduce the results for miR-15b 
and miR-127 as they showed an inverse relationship by quantitative PCR 
compared to the microarray. No non-specific amplification was recorded for 
those miRNAs and the differences between both methods could have been 
related with presence of isomiR forms not detected by the microarray.  
In this study let-7b was significantly downregulated by BPV-1 expression. In most 
human cancers, let-7b is considered to function as a tumour suppressor 
inhibiting cancer cell proliferation and tumour growth (Li et al., 2011; Hung et 
al., 2015; Yu et al., 2015). miRNAs from the let-7 family reduce cancer cell 
proliferation and tumour development by controlling the expression of a number 
of oncogenes, such as RAS and MYC (Gomez-Gomez et al., 2013). Let-7b has 
been shown to be downregulated in HPV-16/-18 infected keratinocytes, HPV-16 
squamous cell carcinomas and HPV-18 cell cultures (Wang et al., 2008; Li et al., 
2011). Since let-7b can function as a tumour suppressor, the downregulation of 
let-7b expression by BPV-1 may contribute to the tumoural transformation of 
equine cells.  
miR-17/106a expression was also significantly downregulated in S6-2 cells. miR-
17 has been reported to promote cell proliferation, to reduce apoptosis and to 
participate in the immune response to HPV-induced cervical cancer (Gomez-
Gomez et al., 2013). Wang et al. (2008) and Li et al. (2011) have shown that 
miR-17 is upregulated in HPV 16 cervical tissues when compared to normal 
cervix.  The observed downregulation in S6-2 cells suggests that miR-17 can be 
modulated differently by distinct papillomaviruses.   
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Analysis of miR-23b by real-time qRT-PCR demonstrated that this miRNA is also 
downregulated.  miR-23b has been shown to be involved in a wide range of 
cellular processes (Zhu et al., 2012; Iaconetti et al., 2015) and aberrant 
expression of miR-23b has been reported in many types of cancers (Goto et al., 
2014; Ma et al., 2014; Avci et al., 2015). Zhang et al. (2011a) showed that miR-
23b suppressed invasion and metastasis both in vitro and in vivo and an 
independent study shown that this miRNA is linked to metastasis and 
invasiveness (Yeung et al., 2011). HPV-16/-18 E6 protein has been reported to 
downregulate expression of miR-23b via expression of urokinase type 
plasminogen activator (uPA) and through a p53 dependent mechanism (Yeung et 
al., 2011; Honegger et al., 2015) although in a different study it has been 
reported to be upregulated in HPV-positive cell types (Wang et al. 2008). We 
have previously shown that BPV-1 oncogene E5 and E6 induced invasion of equine 
cells (Yuan et al., 2008b) and the downregulation of miR-23b by viral oncogenes 
may represent a pathway by which this occurs. miR-23b has been predicted to 
be encoded within ECA 23 in a chromosomal region  linked to the development 
of sarcoids (Jandova et al., 2012).  
The results from microarray and qRT-PCR show that miR-132 is significantly 
downregulated in S6-2 cells compared with EqPalF cells. This miRNA has been 
shown to be upregulated in HPV cervical cancer (Pereira et al., 2010) and gastric 
cancer (Liu et al., 2014). However, in other types of cancer such as breast 
cancer, osteosarcoma and pancreatic cancer miR-132 has been found to be 
downregulated (Zhang et al., 2011b; Li et al., 2013; Yang et al., 2013). It is 
likely that the mechanisms of dysregulation of miR-132 by BPV-1 in ES may differ 
to those present in HPV induced cancer.   
miR-143 is downregulated by BPV-1. miR-143 has been shown to be dysregulated 
by HPV-16 leading to inability to stop proliferation in cervical cancer via the p53 
pathway. It has been claimed that miR-143 is an anti-tumoural miRNA and is 
consistently shown to be downregulated in HPV-induced cancer (Wang et al., 
2008; Witten et al., 2010; Li et al., 2011; Lajer et al., 2012; Liu et al., 2012). In 
the human genome miR-143 is encoded in a region that is deleted in prostate 
cancer (Pereira et al., 2010). 
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Wald et al. (2011) showed that the presence of the oncogene HPV-16 E6 and E7 
results in down-regulation of miR-181a in human cells. Roles attributed to this 
miRNA are inhibition of virus infection and replication in porcine reproductive 
and respiratory syndrome virus, activation of anti-inflammatory pathways, a 
tumour-suppressor role and as a prognostic biomarker in leukaemia patients and 
non-small cell lung cancer patients (Gao et al., 2010; Schwind et al., 2010; Fei 
et al., 2012; Guo et al., 2013; Xie et al., 2013). This miRNA has been predicted 
to be encoded in a chromosomal region that has been linked to the development 
of sarcoids in Warmblood horses (Jandova et al., 2012). 
miR-663a was found to be significantly downregulated in S6-2 cells using 
microarray but this could not be reproduced with the use of qRT-PCR, as both 
EqPalF and S6-2 cells showed the same level of expression with the latter. SYBR 
green technology, rather than Taqman probe, was utilised for quantification of 
this miRNA so there may be the possibility of amplification of a highly similar 
miRNA in EqPalF cells. 
miR-15b was shown to be downregulated in S6-2 cells in the data from the 
microarray although real-time qRT-PCR showed that in this cell type there was 
upregulation of this miRNA. This may have been related to the presence of 
isomiRs, which may have been quantified during qRT-PCR but not detected by 
the microarray probes. In HR-HPV induced cancer, miR-15b has been found to be 
consistently upregulated in cervical cancer tissue, HPV-16 squamous cell 
carcinoma lesions and in HPV-16 cell culture plates (Wang et al., 2008; Li et al., 
2011; Lajer et al., 2012; Wang et al., 2014b). Further tests would be required to 
ascertain the level of miR-15b in BPV transformed cells and the role of this 
miRNA in ES.   
miR-127 was found to be downregulated in the microarray data and upregulated 
in the qRT-PCR data in S6-2 cells. Quantification of this miRNA was performed 
using SYBR green technology using a predicted miRNA sequence for this miRNA. 
It is therefore possible that the amount of miRNA may have been overestimated 
as the specificity of the SYBR green method is lower compared to other qRT-PCR 
technologies and the possibility of isomiRs being picked up during qRT-PCR and 
not by the microarray probes. miR-127 has been found to be downregulated in 
cervical cancer tissues (Wang et al., 2008). Similar to the finding with miR-15b, 
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further tests would need to be performed to ascertain the level and potential 
function of this miRNA in BPV transformed cells. 
In summary, this is the first report of equine miRNAs that are differentially 
regulated by BPV-1. Future work using high throughput sequencing will be 
necessary to verify the equine miRNA sequences identified here, however this 
study should provide a basis for further studies investigating detailed roles on 
miRNAs in BPV-1 induced transformation and in the pathogenesis of equine 
sarcoid tumours.   
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Chapter 4. Identification of microRNAs in equine 
primary fibroblasts using high-throughput 
sequencing 
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4.1. Introduction 
MicroRNAs (miRNAs) are single-stranded RNA molecules 18-23 nucleotides in 
length that regulate gene expression at the post-transcriptional level (Ambros, 
2004). Understanding of microRNA biogenesis has challenged the central dogma 
of biology, since these molecules are the proof that many genes have a 
regulatory rather than protein coding function (Kim et al., 2009). Through 
partial sequence complementarity, mature microRNAs bind to their target 
mRNA, leading to direct mRNA degradation, acceleration of mRNA degradation 
via deadenylation and/or suppression of protein translation (Filipowicz et al., 
2008). The same microRNA can target multiple mRNAs and the same mRNA can 
be the target of more than one mature microRNA. This mechanism enables 
microRNAs to ‘switch on’ and ‘switch off’ pathways involved in the cell cycle, 
proliferation, apoptosis, and senescence (Lu et al., 2005; Rosenfeld et al., 2008; 
Wang et al., 2011; Wu et al., 2014). Dysfunctional expression of microRNAs has 
been linked to multiple pathological mechanisms including cancer (Calin & 
Croce, 2006; Venugopal et al., 2010; Kim et al., 2011a; Baek et al., 2015). 
Through activating or repressing certain cellular processes, some microRNAs can 
have an oncogenic effect or tumour suppressor effect (Huang et al., 2015; Tutar 
et al., 2015). 
The horse genome (Equus caballus) was first assembled in 2007 (EquCab2.0, 
GenBank assembly accession reference GCA_000002305.1, 
http://www.ncbi.nlm.nih.gov/assembly/286598/) and since then a small 
number of studies have started to explore microRNA profiling in the horse. 
Currently there are 35,828 miRNAs in the official database miRBase 20.0 
(www.mirbase.org) (Kozomara & Griffiths-Jones, 2014) of which 711 are 
annotated as equine miRNA precursors, which encode 690 mature miRNAs. More 
than half of the equine miRNAs in the database – 359 sequences - are in silico 
predicted (Zhou et al., 2009), and prior to this study there was no data available 
to confirm that these are expressed miRNAs in the horse. The rest – 331 
sequences – were obtained using high throughput sequencing (HTS) from a single 
testicular sample of a horse as part of a genetic study undertaken in large bats 
(Eptesicus fuscus), whereby the miRNA profiles from testicular samples from one 
bat, one dog and one horse were compared (Platt et al., 2014). Although these 
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331 sequences are included in the official database, no details regarding data 
validation, such as real-time, reverse transcription quantitative PCR (real-time 
qRT-qPCR), are reported in the paper. Nonetheless, there have been studies 
attempting to describe miRNAs in the horse using HTS (Das et al., 2013; 
Desjardin et al., 2014; Kim et al., 2014). These are summarised in Table 4.1. 
Table 4.1. Summary of experimental design and main finding of previous 
studies on equine miRNAs identified by HTS 
 
Although empirical evidence of expression of some equine microRNAs has been 
documented, this has not been validated further and there is inconsistency in 
length and nucleotide composition of miRNA candidates across theses studies. An 
example of this disparity is eca-let-7a. This mature miRNA, with the annotation 
identifier MIMAT0012979 in the official database, has been predicted to be 
encoded in the horse in two genomic locations, chromosome 7 (from a precursor 
eca-let-7a) and chromosome 28 (from the precursor eca-let-7a-1). This mature 
miRNA is listed in Desjardin et al. (2014) and Kim et al. (2014) but both the 
name and nucleotide composition are dissimilar to those listed in miRBase. In 
Figure 4.1 the alignment of the three sequences shows that there is one 
nucleotide missing in the 5’ end of the miRNA reported by Desjardin et al. 
 Das et al. (2013) Desjardin et al. (2014) Kim et al. (2014) Platt et al. (2014) 
Tissue / 
sample 
Semen Bone and cartilage 
Liver, colon and 
muscle 
Testicular sample 
Number of 
samples 
8 
3 for each condition 
and tissue 
8 from each 
tissue 
1 
Type of 
samples 
Healthy 
Healthy vs. with 
osteochondritis 
Healthy Not reported 
Validation Not reported 
qRT-PCR Taqman: 6 
miRNA tested. 2 failed 
Not reported Not reported 
Number of 
mature 
miRNAs with 
annotation 
91 371 292 1 
Suggested 
novel miRNAs 
0 299 329 330 
Remarks 
6 miRNAs most 
abundant: miR-
34b, miR-34c, 
miR-191, 
miR-223, miR-
1248, 
miR-1905c 
49 miRNAs in cartilage 
and 41 in bone 
differentially expressed 
between conditions (5 
and 8 known 
respectively) 
Specific mature 
miRNAs: 
- colon: 99 
- muscle: 36 
- liver: 3 
Phylogenetic-
comparative study. 
No detailed 
information on 
equine miRNAs 
given 
Included in 
miRBase 
No No No Yes 
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(2014), and 1 and 4 extra nucleotides at the 5’ and 3’ ends respectively in the 
miRNA reported by Kim et al. (2014) when compared to the miRNA annotated in 
miRBase.  
 
 
 
Figure 4.1. Alignment of the mature miRNA eca-let-7a (MIMAT0012979) with 
the sequences of this miRNA reported by two HTS studies. It is noticeable that 
the length of the miRNA is different in the three datasets and additions and deletions 
are evident (highlighted in pink). This affects the definition of the seed region (from the 
2nd to the 7th nucleotide from the 5’ end) and consequently any target search performed 
using the seed region (Manzano et al., 2015) 
Variations in miRNA length or sequence can give rise to isomiRs (Morin et al., 
2008; Guo & Chen, 2014), which can make precise naming and comparison across 
studies difficult. IsomiRs can arise due to slight variations in miRNA precursor 
trimming at the 5’ or the 3’ end by Drosha and/or Dicer and also by addition of 
nucleotides to the 3’ end of miRNAs (Neilsen et al., 2012). The former most 
likely explains the extra sequence in eca-let-7a described by Kim et al. (2014) 
shown in Figure 4.1 as the four nucleotides ‘UAGA’ are part of the stem loop of 
the predicted precursor eca-let-7a (MI0012731) deposited in miRBase.   
There is therefore a need for improved characterisation of miRNAs in the horse. 
In addition, no studies to date have sequenced miRNAs present in equine skin or 
fibroblast cells, both of which are relevant to the study of equine sarcoids. Thus, 
a goal of the present study is to produce a detailed catalogue of mature 
sequences expressed in equine fibroblast cells.  
The comparative study of microRNAs using microarray technology (Chapter 3) 
supports the view that there is a high degree of sequence conservation across 
species. The probes utilised in the microarray were designed using mainly human 
microRNA sequences (1651 probes, 76.3%) and equine in silico predicted miRNA 
sequences from Zhou et al. (2009) (350 probes, 16.3%), and yet 22.7% of the 
probes (492) successfully hybridised (see Chapter 3, section 3.3.2.2. Data 
refinement). Microarray analysis is a relatively inexpensive platform that 
Desjardin et al.      - eca-let-7a-5p    -GAGGUAGUAGGUUGUAUAGUU---- 
Kim et al.            - eca-let-7a       UGAGGUAGUAGGUUGUAUAGUUUAGA 
miRBase (MIMAT0012979)- eca-let-7a       UGAGGUAGUAGGUUGUAUAGUU---- 
                                          *********************   
 99 
requires very small amounts of RNA and allows a large number of genes to be 
interrogated from the same sample (Wang & Yang, 2010; Trachtenberg et al., 
2012). However, the recent introduction of HTS is beginning to supercede 
microarray technology. HTS allows absolute quantification of microRNA levels 
and this is reflected in its much higher dynamic range than microarray (Metzker, 
2010). Another advantage of HTS over microarray analysis is that it does not 
depend on previous knowledge of the sequences of the miRNAs and is therefore 
an excellent tool for discovery of novel miRNAs (Wang et al., 2009; Witten et 
al., 2010). Sequence-based technologies have become more popular to profile 
microRNAs in different tissues. The drawback of HTS is mainly technical; 
compared to microarray analysis, more RNA is needed and this has to be of high 
quality for small RNA library preparation and sequencing. In addition, the output 
data requires greater analysis involving mapping to the genome of interest and 
removal of non-miRNA sequences to focus on miRNA expression. 
Fibroblasts are found in a wide range of animals and primary fibroblasts 
represent a good example of a control for in vitro models of diseases such as 
Parkinson’s disease and cardiomyopathies (Auburger et al., 2012; Castaldo et 
al., 2013). EqPalFs are equine primary fibroblasts and, in previous work at the 
University of Glasgow (Yuan et al., 2008a), were used for BPV-1 transformation 
to create a robust in vitro model of equine sarcoids, As the focus of my PhD 
project was on miRNA expression in equine sarcoids, a first step in this study was 
to establish baseline expression of miRNAs in horse fibroblast cells. The main 
aim of the work detailed in this chapter was to use high-throughput sequencing 
technology (HTS) to obtain a detailed profile of microRNAs expressed in equine 
primary fibroblasts (EqPalFs).  
4.2. Materials and methods 
4.2.1. RNA extraction, quantitation and assessment of RNA 
integrity (RIN) 
Chapter 2 (General materials and methods) contains details of cell culture, RNA 
extraction and RNA quality/quantity assessment. In summary, RNA was prepared 
using a phenol extraction method (with Trizol®) from equine primary fibroblasts 
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(EqPalF). Quantity and integrity were assessed and only when the sample had 
RIN values greater than 9.0 was it utilised for sequencing. The RNA obtained was 
divided into three samples for three library preparations.  
4.2.2. Library construction, cluster generation and sequencing 
A detailed explanation of library construction, cluster generation and sequencing 
is given in Chapter 2, Materials and Methods, section 2.5.1. In summary, libraries 
were prepared in triplicate using TruSeq® Small RNA (Life Technologies). Library 
preparation specific for miRNAs involves adaptor ligation and size selection so 
that only miRNAs are selected for further sequencing. After library construction, 
cluster generation on solid phase was performed followed by massive parallel 
sequencing in the Genomic Analyzer IIx from Illumina® (GA-IIx). 
4.2.3. Data analysis 
Data analysis of the HTS data is fully explained in Chapter 2 Materials and 
methods, section 2.5.2. A diagram explaining the steps in the pipeline can be 
found Chapter 2 (Figure 2.1). A summary is displayed in Figure 4.2. 
In brief, the files obtained from the GA-IIx sequencer were pre-processed 
(removal of adaptor sequences), fed into miRDeep 2, software designed for 
microRNA identification and discovery. Sequences were mapped against the 
equine genome (EqCab.2.0) and the list of miRNA from the database 
(www.miRBase.org), following removal of redundant sequences and sequences 
smaller than 18 nucleotides in length, a list of equine predicted miRNAs was 
generated de novo based on RNA folding energy potential. Data was then 
harmonised using nucleotide composition and genomic location. Tolerance for 
nucleotide composition was set at 0, and tolerance for genome location was set 
as 10 (for more details please refer to section 2.5.2.1). Putative miRNA 
candidates were filtered during post-processing to increase robustness of the 
data, so that only miRNAs present in at least two of the three replicate EqPalF 
RNA libraries were retained for analysis.  
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Figure 4.2. Summary of the steps of the analysis of the HTS data 
 
As part of the descriptive analysis, the following parameters were calculated: 
length of mature miRNAs, percentage of GC nucleotides (GC content), 
chromosomal distribution and clustering, and relative abundance of the 3p or 5p 
arm of each miRNA. These were calculated using Microsoft Excel. When 
comparing the data to previous studies, t-test was applied and statistical 
significance was set at p<0.05. Statistical differences were calculated using 
Raw data sequencing (.fastq) 
Pre-processing: 
Sqquence data files were converted to the appropriate format (.fasta) and 
databases were downloaded (equine genome and list of equine miRNAs from 
miRBase) 
miRDeep2:  
Deep sequencing reads were mapped to the equine genome and list of mature 
miRNAs listed in miRBase 20.0 (www.mirbase.org) 
Reads that mapped to multiple loci (5 or more) or to other types of RNA were 
discarded (rRNA, mRNA, tRNA, etc...) 
Using sequence reads potential precursors were excised from the genome and 
unlikely precursors were discarded on the basis of their predicted folding energy 
miRDeep2 algorithm was used to predict novel miRNAs 
Post-processing: 
Data was filtered for presence in more than one replicate and harmonised using 
genomic location and nucleotide sequence 
List of known and novel miRNA 
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SPSS. Figures were generated using Excel, ClustVis 
(http://biit.cs.ut.ee/clustvis/) and the Genome Decorator Page online tool 
(NCBI). 
To verify if the miRNAs were novel or had been described before, the list of 
miRNA candidates was analysed using two methods (BLAST+ and Edit distance) 
using the list of miRNAs from miRBase 20.0 and the list of equine miRNAs 
available in the literature. Full details of both methods are explained in Chapter 
2, section 2.5.2.2. and a summary is displayed in Figure 4.3. Functional analysis 
was performed using Ingenuity Pathway Analysis (IPA) software with the list of 
non-novel miRNAs.  
 
 
Figure 4.3. Summary of the pipeline for discovery of miRNAs in equine 
primary fibroblast (EqPalF) 
 
list of miRNAs from miRDeep2 output 
BLAST+ 
Perfect matches : 100% identity , 0 mismatches, lengthS = alignment, 
Difference in lengthS and lengthD ≤ 2 
Edit distance (ED)  
Perfect matches: 2 or less nucleotides difference (length or nucleotide 
composition) 
Family search (seed region) 
Compare seed regions of list of novel miRNAs (miRNAs with no match in any 
database) to in-house miRNAfamily database built from miFam and TargetScan 
list of novel miRNAs in equine fibroblasts 
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4.3. Results 
4.3.1. RNA quality, integrity and library quality control 
Total RNA extracted from a flask of EqPalF cells maintained in culture showed 
good integrity as observed by electrophoresis on 1% agarose gel (Figure 4.4a). 
The A260/A280 ratio was 2.07 and the RIN value was 9.90, obtained using the 
Bioanalyser 2100 (Figure 4.4b) indicating suitable RNA for sequencing.  
 
Figure 4.4. a) RNA sample from EqPalF visualised in a transilluminator on a 
1% agarose gel. Good demarcation of the 28S (orange arrow) and 18S (white arrow) 
bands indicates high integrity of the RNA sample. b) Electrophenogram obtained 
with Bioanalyzer 2100 of EqPalF RNA. Single clear peaks correspond to the 18S and 
28S fraction and no signs of RNA degradation are present as indicated by a high RIN 
value of 9.9. 
 
The RNA extracted from the cultured EqPalF cells was divided into three samples 
for three technical replicates for RNA sequencing. During library preparation, 
two of the replicates, EqPalF.1 and EqPalF.3, demonstrated a unique peak of 
small RNAs in the DNA high specificity chip (band between 110 bp and 230 bp) 
(Figure 4.5a.). The second library, EqPalF.2 showed secondary peaks indicating 
possible contamination (Figure 4.5b). Preparation of this library was 
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subsequently repeated and the repeated DNA high sensitivity chip demonstrated 
a discrete small RNA peak on this second occasion (Figure 4.5c). 
 
Figure 4.5. Image from the DNA high sensitivity chip showing the fraction of 
small RNA from the libraries. a) EqPalF.1 and EqPalF.3 both produced the same 
image on the DNA high sensitivity chip, showing a single peak around 150 bp signifying 
the fraction of small RNAs. b) EqPalF.2 had additional small peaks associated to the 150 
bp peak which was compatible with contamination (grey arrow). c) EqPalF.2 library was 
repeated at a later time and the repeated DNA high sensitivity chip showed a single 
peak around 150 bp corresponding to the small RNA fraction with no contamination 
 
4.3.2. Characterisation of RNA read data - correlation across 
replicate libraries, read count and number of mature miRNA 
candidates 
The number of reads obtained from RNA sequencing ranged from 7.81 x 106 to 
10.70 x 106 per library. After adaptor-trimming sequence reads were fed into 
miRDeep2. miRDeep2 mapped the sequencing reads to the databases (equine 
genome and equine miRNAs included in miRBase), removed redundancy and 
performed miRNA predictions based on a core algorithm and folding energy. 
Sequences that were not mapped to the equine genome, or mapped to other 
types of RNA such as tRNA, sequences that mapped to five or more loci in the 
genome, and sequences that did not meet the folding energy criteria set for 
miRNA in the Randfold script were removed. The number of reads retained after 
miRDeep2 and harmonisation ranged from 3.82 x 106 to 6.72 x 106 per library 
(see Table 4.2). Applying the filter of a candidate miRNA being present in at 
least two replicates of the cell line, a total of 593 unique sequences of putative 
mature miRNAs were identified in EqPalF RNA. Not all replicates expressed the 
593 miRNA candidates. Library Replicate 2 (EqPalF.2) had a smaller number with 
534 miRNAs in total, whereas Replicates 1 and 3 expressed 560 and 566 miRNAs, 
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respectively. The full list of miRNAs before and after data analysis is included in 
the file ‘master file EqPalF.xlsx’ in the DVD enclosed. 
Table 4.2. Summary of reads and number of miRNAs per replicate library 
prepared from EqPalF cells 
 Replicate 1 
(EqPalF.1) 
Replicate 2 
(EqPalF.2) 
Replicate 3 
(EqPalF.3) 
Number of reads from the sequencer 10,697,659 7,811,655 9,508,226 
Number of reads after miRDeep2 6,716,925 3,820,310 6,125,119 
Number of miRNA candidates from miRDeep2 638 583 628 
Number of miRNA candidates after filtering 
for “at least present in two replicates” 
560 534 566 
 
The correlation between the number of reads for each miRNA between each 
replicate was calculated as part of quality control analysis of the data. The 
correlation between the three libraries was good as indicated by a Pearson’s 
coefficient that ranged from 0.96-1.00 (see Table 4.3. and Figure 4.6.) 
Pearson’s coefficient is a measurement of linear correlation and the values 
range from -1.00 to +1.00. Two replicates with a correlation coefficient close to 
1.00 indicates that the relative values of microRNA expression within each 
replicate are very similar, whereas closer to 0.00 would indicate that the two 
datasets are highly dissimilar.  
Table 4.3. Pearson’s correlation coefficient for EqPalF replicate libraries. 
Coefficients were obtained by comparing the number of reads of each mature miRNA 
candidate in the three library replicates from EqPalF cells 
 
Read counts were obtained using the average value from the three replicates. 
Level of expression measured by read counts was variable from 1 read to 
800,297 reads. Forty one per cent of the miRNA candidates had at least 100 
reads. The 20 most highly expressed miRNAs in each replicate ranked by number 
of reads, are displayed in Table 4.4.The top 20 most highly expressed miRNAs in 
EqPalF using the average from the three replicates is presented in Table 4.5. 
  EqPalF.1 EqPalF.2 EqPalF.3 
EqPalF.1 1 0.96 1 
EqPalF.2 0.96 1 0.96 
EqPalF.3 1 0.96 1 
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Figure 4.6. Correlation of miRNA expression in EqPalF replicates. The 
number of reads of each miRNA, expressed in log2 values from each of the three 
replicates was compared in a pair-wise manner. Each dot represents one miRNA with 
the log2 number of reads on the x axis from one replicate and on the y axis from a 
different replicate. Pearson’s coefficient for each pair is displayed as ‘r’ and it shows 
that the linear relationship in the three pair comparisons is positive and strong (as 
values are close to +1.0)
 Table 4.4. Top 20 highly expressed miRNAs in each replicate ranked by expression levels (number of reads) 
 
 
 
 
 
 
 
 
 
 
Internal ID 
miRBase 
annotation 
Expression in 
EqPalF.1 
Internal ID miRBase annotation 
Expression in 
EqPalF.2 
Internal ID 
miRBase 
annotation 
Expression in 
EqPalF.3 
U0_3p eca-miR-143 913,516 U0_3p eca-miR-143 643,975 U0_3p eca-miR-143 843,400 
U4_5p eca-miR-181a 445,006 U1_5p eca-miR-21 300,211 U2_3p eca-miR-22 423,803 
U2_3p eca-miR-22 431,534 U4_5p eca-miR-181a 161,312 U4_5p eca-miR-181a 420,779 
U1_5p eca-miR-21 391,725 U2_3p eca-miR-22 150,179 U1_5p eca-miR-21 385,487 
U5_3p eca-miR-27b 248,699 U9_3p eca-miR-127 124,283 U5_3p eca-miR-27b 227,871 
U8_5p eca-miR-26a 247,455 U5_3p eca-miR-27b 117,996 U8_5p eca-miR-26a 226,812 
U9_3p eca-miR-127 222,673 U10_3p eca-miR-92a 117,017 U9_3p eca-miR-127 197,266 
U10_3p eca-miR-92a 202,203 U3_5p eca-miR-10b 115,856 U10_3p eca-miR-92a 177,459 
U12_3p eca-miR-28-3p 179,825 U11_5p eca-miR-191a 90,970 U11_5p eca-miR-191a 172,656 
U11_5p eca-miR-191a 177,942 U15_5p eca-miR-100 84,807 U12_3p eca-miR-28-3p 161,028 
U13_3p eca-miR-222 173,475 U8_5p eca-miR-26a 83,335 U14_5p eca-miR-125a-5p 135,190 
U14_5p eca-miR-125a-5p 167,581 U12_3p eca-miR-28-3p 77,051 U13_3p eca-miR-222 130,282 
U3_5p eca-miR-10b 139,752 U13_3p eca-miR-222 73,142 U3_5p eca-miR-10b 130,248 
U15_5p eca-miR-100 116,157 U14_5p eca-miR-125a-5p 71,908 U19_5p eca-miR-30d 110,425 
U19_5p eca-miR-30d 116,048 U17_3p eca-miR-221 70,097 U18_5p eca-let-7a 95,835 
U18_5p eca-let-7a 102,475 U18_5p eca-let-7a 65,586 U6_3p eca-miR-199a-3p 88,258 
U21_5p eca-miR-125b-5p 98,581 U6_3p eca-miR-199a-3p 64,069 U21_5p eca-miR-125b-5p 84,015 
U6_3p eca-miR-199a-3p 89,846 U19_5p eca-miR-30d 62,668 U17_3p eca-miR-221 75,235 
U17_3p eca-miR-221 83,314 U22_5p eca-miR-145 54,596 U16_5p eca-miR-16 74,513 
U16_5p eca-miR-16 73,835 U24_3p eca-miR-23b 49,473 U22_5p eca-miR-145 52,295 
1
0
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  Table 4.5. Top 20 highly expressed miRNAs in EqPalF, ranked by average of expression in three replicates 
 
Internal ID Mature sequence Annotation (BLAST-ED method) Average number of reads 
U0_3p UGAGAUGAAGCACUGUAGCUC eca-miR-143 800,297 
U1_5p UAGCUUAUCAGACUGAUGUUGA eca-miR-21 359,141 
U4_5p AACAUUCAACGCUGUCGGUGAGU eca-miR-181a 342,366 
U2_3p AAGCUGCCAGUUGAAGAACUGU eca-miR-22 335,172 
U5_3p UUCACAGUGGCUAAGUUCUGC eca-miR-27b 198,189 
U8_5p UUCAAGUAAUCCAGGAUAGGCU eca-miR-26a 185,867 
U9_3p UCGGAUCCGUCUGAGCUUGGCU eca-miR-127 181,407 
U10_3p UAUUGCACUUGUCCCGGCCUGU eca-miR-92a 165,560 
U11_5p CAACGGAAUCCCAAAAGCAGCUG eca-miR-191a 147,189 
U12_3p CACUAGAUUGUGAGCUCCUGGAG eca-miR-28-3p 139,301 
U3_5p UACCCUGUAGAACCGAAUUUGU eca-miR-10b 128,619 
U13_3p AGCUACAUCUGGCUACUGGGUCUC eca-miR-222 125,633 
U14_5p UCCCUGAGACCCUUUAACCUGUGA eca-miR-125a-5p 124,893 
U19_5p UGUAAACAUCCCCGACUGGAAGCU eca-miR-30d 96,380 
U18_5p UGAGGUAGUAGGUUGUAUAGUU eca-let-7a 87,965 
U15_5p AACCCGUAGAUCCGAACUUGUG eca-miR-100 82,070 
U6_3p ACAGUAGUCUGCACAUUGGUU eca-miR-199a-3p 80,724 
U21_5p UCCCUGAGACCCUAACUUGUGA eca-miR-125b-5p 76,852 
U17_3p AGCUACAUUGUCUGCUGGGUUUC eca-miR-221 76,215 
U16_5p UAGCAGCACGUAAAUAUUGGCG eca-miR-16 63,372 
1
0
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4.3.3. Mature sequence length and GC content 
The sequences of the putative miRNAs in EqPalF ranged between 18 and 26 
nucleotides in length and the median length was 22 nucleotides (see Figure 
4.7.a). The percentage of GC nucleotides in the putative miRNA sequences 
varied, ranging from 19.05% -100.00% (average 51.63%, median 50%, Figure 
4.7.b). The length distribution of mature miRNA candidates in this study was 
consistent with the distribution of equine miRNAs in miRBase 20.0 (in silico 
predicted and HTS) (Zhou et al., 2009; Platt et al., 2014) as well as 
experimental data from other species (Ji et al., 2012; Shukla et al., 2015). With 
the data available from the two previous HTS equine studies it is not feasible to 
compare miRNA by miRNA but overall, the length distribution was also similar to 
that described for miRNAs in equine bone and cartilage (Desjardin et al., 2014) 
and to colon, liver and muscle in the horse (Kim et al., 2014) when including 
both known miRNAs and ‘novel miRNAs’ reported in both studies. GC content 
was consistent with previous studies in equine miRNAs (Zhou et al., 2009; 
Desjardin et al., 2014; Kim et al., 2014).  
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Figure 4.7. Length distribution of miRNAs and GC nucleotide content (%) of 
593 miRNAs found in EqPalF cells 
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4.3.4. Distribution of microRNAs within the equine genome and 
distribution of 5p/3p miRNA arms 
The equine genome comprises 32 chromosomes 
(http://www.ncbi.nlm.nih.gov/genome?term=equus%20caballus). All 
chromosomes but one (ECA 31) encoded putative microRNAs. Chromosomes 24, 
X, 11 and 7 had the highest number of microRNAs with 99, 64, 47 and 41 entries 
respectively, whereas chromosomes 18, 21, 27 and 29 had the lowest number of 
miRNA candidates, seven, four, four and one, respectively. No miRNAs were 
found on chromosome 31. A histogram showing the number of miRNAs encoded 
on each chromosome is shown in Figure 4.8. 
The majority of the mature miRNA candidates mapped to a single genomic locus 
(545 miRNAs, 91.95%), whereas a small proportion were found in two (40 
miRNAs, 6.75%), three (6 miRNAs, 1.01%) and four loci (2 miRNAs, 0.34%). As 
stated above, miRNAs mapping to five or more loci were removed by the 
miRDeep2 software. The chromosomal distribution of miRNAs in EqPalFs was in 
accordance with the equine miRNAs included in the miRBase (Zhou et al., 2009; 
Platt et al., 2014) and similar to previous studies undertaken in colon, liver and 
muscle (Kim et al., 2014) and bone and cartilage in horses (Desjardin et al., 
2014) (Figure 4.9). A notable exception is the abundance of miRNAs identified on 
chromosome 24 in the current study. 15.21% of total miRNAs (99 miRNA 
candidates) from EqPalF RNA sequencing were identified on chromosome 24, 
which far exceeds that in previous equine miRNA studies.  
 
 
 
  
Figure 4.8. Histogram representing 593 miRNA candidates mapped to the 32 chromosome in the horse. miRNAs that were found in 
more than one locus have been included in all locations that they were mapped to (593 miRNAs, 636 loci). miRNAs which mapped to the non-
characterised areas of the genome (“Un”, for more details see horse genome assembly EqCab2.0 in 
http://www.ncbi.nlm.nih.gov/genome?term=equus%20caballus) were omitted (15 miRNAs)  
1
1
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Figure 4.9. Histogram representing the comparison of chromosomal distribution of 593 miRNA candidates sequenced from EqPalF 
cells mapped to 636 loci to miRBase 20.0 and two equine HTS studies. The average distribution from three EqPalF replicates was 
compared to equine miRNAs from the miRBase 20.0 (690 mature sequences, 771 loci), and from two HTS studies on equine miRNAs (Desjardin et al. 
(2014) with 669 mature sequences, 371 known and 298 suggested as novel, mapped to 669 loci; and Kim et al. (2014) with 292 mature sequences 
mapped to 310 loci as no information is provided about the genomic location of the suggested novel miRNAs in the latest study
1
1
3
 
Interestingly, several miRNAs were found to be located in close proximity to one 
another, suggesting that these may be encoded as polycistronic miRNAs. This can 
be appreciated by the close chromosomal positioning of some miRNAs shown in 
the ideogram in Figure 4.10. A total of 255 miRNAs (43%) were found forming 43 
clusters. Clusters were defined as groups of miRNAs encoded in the same strand 
at not more than 3 Kb apart (Zhou et al., 2009; Kim et al., 2014). The 
distribution of miRNA clusters was found to be similar to previous studies 
although in the current study no clusters were found on ECA 1 (Zhou et al., 
2009), and ECAs 16, 18, 20 and 28 (Kim et al., 2014) (see Figure 4.11). ECAs 24 
and X had the highest density of miRNA clusters identified from EqPalF cells and 
in particular two main areas of ECA 24 with high density of miRNAs were 
identified and are shown by intense red bands in Figure 4.10. 
On multiple occasions, miRNAs identified by sequencing mapped to the same 
genomic location and were encoded by either the 3’ or 5’ arm of the precursor 
miRNA. In total, 302 miRNAs mapped to the 3p end of the precursors (50.93%) 
and 291 miRNAs mapped to the 5p end of the precursors (49.07%).  
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Figure 4.10. Ideogram showing the distribution and density of miRNA candidates in EqPalF cells when mapped to the 32 equine 
chromosomes. The broader the red band, the higher number of miRNAs that are encoded in the region. In total 255 were found in 43 clusters 
(<3Kb genomic distance). The chromosome with highest number of miRNAs (ECA24) had a high density of miRNAs, encoded in three areas of the 
chromosome. miRNAs which genomic location mapped to the non-characterised areas of the genome of the horse (named as “Un”, for more details 
see horse genome assembly EqCab2.0. in http://www.ncbi.nlm.nih.gov/genome?term=equus%20caballus) were omitted (15 miRNAs)  
         miRNAs 
1
1
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Figure 4.11. Histogram representing miRNA candidates from EqPalF cells mapped in clusters compared to those from Zhou et al. 
(2009) and Kim et al. (2014) 
1
1
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4.3.5. Characterisation of miRNAs in EqPalF cells: expression 
levels and novel miRNAs 
Using a sequential method (first BLAST+ and then Edit distance), out of 593 
miRNAs sequenced from EqPalF cells and mapped to the horse genome, 258 
sequences were found to be already present in miRBase 20.0 as equine miRNAs 
(eca-miRs). Of the remaining 335 miRNAs sequenced, 71 matched human 
annotations, 18 matched mouse annotations, 73 matched other species and 173 
had no match in any database and therefore are considered novel miRNAs. A 
small proportion of the novel miRNAs (22) could be grouped into miRNA families 
by aligning the seed region (nucleotides 2-7)(see Chapter 2). The full list of 593 
miRNAs expressed in EqPalF cells is supplied in this thesis as a digital copy under 
the file of EqPalF_HTS_data.xlsx. 
miRNAs were ranked by level of expression (average number of reads from the 
three replicate libraries). The top 20 most expressed miRNAs showing their 
miRBase annotation and level of expression (in number of reads, average from 
three replicates) is displayed in Figure 4.12.  This histogram highlights the 
abundance of eca-miR-143 which represents 17% of the total number of reads 
from EqPalF cells. No novel miRNAs were amongst the top 20 most expressed 
miRNAs. 
 
 
 
 
 
 
 
 
Figure 4.12. Histogram representing the top 20 most expressed miRNAs in 
equine primary fibroblasts (EqPalF cells) ranked by number of reads. Results 
are expressed as the average of reads from three replicate libraries 
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Out of 593 miRNA candidates obtained in the current study, 334 had been 
previously assessed using microarray (please see Chapter 3 for more details). Of 
those, 143 were also found to be present in EqPalF cells during the microarray 
analysis. The remaining 191 were indeed interrogated during the microarray 
although they produced signals below the background level. Over half of those 
miRNAs (58%, 109 miRNAs) had low expression (≤100 reads) on the HTS data, 
whereas over one third (36%, 69 miRNAs) had medium expression (101-1000 
reads) and the remaining 6% (13 miRNAs) were expressed at least in 1000 reads 
(13 miRNAs). 
Amongst the top 50 most expressed miRNAs there were three miRNAs that had 
never been reported in the horse, but previously described in other species: ssc-
miR-151-3p, bta-miR-6119-5p and cgr-miR-140-3p with average read counts of 
33361, 26381 and 12304, respectively. Notably, the level of expression of the 
novel miRNAs was low and ranged from 1 read to 3576 reads. The top 12 most 
expressed novel miRNAs ranged from 100 to 3576 reads. 
4.3.6. Functional analysis 
The list of 593 miRNAs sequenced from EqPalF cells were transformed to their 
human, mouse or other species counterparts where possible (up to a maximal 
difference of 2 nucleotides either in length or in sequence composition) and 
uploaded onto Ingenuity Pathway Analysis software (IPA) for functional analysis. 
This software does not list equine miRNA per se and is based on a generic 
mammalian database, thus this adaptation was necessary to facilitate functional 
analysis. In total, 256 miRNAs were present in the IPA database. The core 
analysis function, which tests for enrichment of a gene-set within the various 
forms of database contained in IPA provided no usable results and therefore 
pathways of interest and upstream regulators could not be identified. The 
Target filter analysis tool recognised 149 miRNAs, which can potentially target 
15967 targets. The top diseases and functions highlighted by this analysis were 
ranked by score and number of molecules identified: cancer of the reproductive 
system, immunological disease of muscular disorders, cellular development, 
proliferation and growth, cancer of the gastrointestinal system, cell cycle 
dysregulation. Results are displayed in Table 4.6.
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Table 4.6. List of networks that were highlighted in EqPalF using IPA software. Data obtained from using as input 593 miRNAs, of which 
256 were listed by the software as “mapped” and 149 had allocated targets. Core analysis includes not only miRNAs present in the data set but 
other genes/miRNA targets that are directly or indirectly linked to those miRNAs 
Score Focus Molecules Top Diseases and Functions 
55 28 Cancer, Organismal Injury and Abnormalities, Reproductive System Disease 
36 21 Organismal Injury and Abnormalities, Reproductive System Disease, Cancer 
29 16 Cell Death and Survival, Skeletal and Muscular Disorders, Immunological Disease 
23 16 Organismal Injury and Abnormalities, Reproductive System Disease, Cancer 
21 14 Cellular Development, Cellular Growth and Proliferation, Cell Death and Survival 
21 14 Organismal Injury and Abnormalities, Reproductive System Disease, Developmental Disorder 
21 14 Cancer, Gastrointestinal Disease, Organismal Injury and Abnormalities 
20 14 Cellular Development, Cellular Growth and Proliferation, Cancer 
18 13 Cancer, Organismal Injury and Abnormalities, Cell Cycle 
18 13 Developmental Disorder, Hereditary Disorder, Organismal Injury and Abnormalities 
17 12 Cancer, Organismal Injury and Abnormalities, Reproductive System Disease 
17 13 Cancer, Organismal Injury and Abnormalities, Reproductive System Disease 
15 11 Cancer, Organismal Injury and Abnormalities, Cellular Development 
4 2 Neurological Disease, Psychological Disorders 
4 2 Cancer, Gastrointestinal Disease, Hepatic System Disease 
4 2 Cardiovascular Disease, Congenital Heart Anomaly, DNA Replication, Recombination, and Repair 
2 1 Endocrine System Disorders, Organismal Injury and Abnormalities, Reproductive System Disease 
2 1 Cancer, Gastrointestinal Disease, Organismal Injury and Abnormalities 
2 1 Cancer, Organismal Injury and Abnormalities, Hematological Disease 
2 1 Cancer, Organismal Injury and Abnormalities, Reproductive System Disease 
2 1 Connective Tissue Disorders, Inflammatory Disease, Inflammatory Response 
2 1 Cellular Response to Therapeutics, Connective Tissue Disorders, Inflammatory Disease 
2 1 Dermatological Diseases and Conditions, Hereditary Disorder, Organismal Injury and Abnormalities 
1
1
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4.4. Discussion 
To begin to understand the roles of miRNAs in equine sarcoids, the miRNA 
transcriptome of equine primary fibroblasts was characterised. In the current 
chapter, expression and abundance of 593 putative miRNA candidates in EqPalF 
cells were described using the bioinformatic analysis of HTS data. Of those, 258 
had previously been described from the horse, with sequences available in 
miRBase 20.0. Amongst the remaining 335 miRNA candidates, 162 were 
homologous to miRNAs identified in other species and 173 have not been 
reported before in the horse or other species. All novel miRNAs made a stable 
hairpin structure as predicted by miRDeep2 using the prediction algorithm. 
Therefore this represents the first report of novel miRNAs found in equine 
primary cells using HTS. 
Currently HTS is used as a tool for the identification and discovery of miRNAs in 
various organisms as it has several advantages compared to previous methods 
including high throughput, high repeatability, low background noise, ability to 
detect miRNAs expressed at low levels, and identification of previously 
uncharacterised miRNA sequences (Morozova & Marra, 2008; Yan et al., 2011; 
Chen et al., 2012; Gunaratne et al., 2012). Successful RNA extraction and library 
construction are two of the most crucial steps required for a suitable set of 
sequencing data (Metzker, 2010; Pritchard et al., 2012). In the current study the 
integrity and quality of RNA prepared from equine primary fibroblasts was good. 
During library construction one of the replicates, EqPalF.2 had to be repeated at 
a later time due to suspected contamination. This led to small differences in the 
sequencing data obtained as seen in the marginally lower correlation 
coefficients (0.96) and marginally lower number of miRNAs identified in this 
replicate (534 vs. 560 and 566 for EqPalF.2 vs. EqPalF.1 and EqPalF.3 
respectively). However, despite differences being observed between the other 
two replicates and EqPalF.2, the correlation between all three replicates was 
excellent (0.96 – 1.0), indicating that the results are robust.  
The length distribution of mature miRNA candidates (18-26 nucleotides) and the 
GC nucleotide content were in agreement with previously predicted equine 
miRNAs in miRBase and very similar to that previously predicted and reported by 
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HTS from equine bone, cartilage, colon, liver and muscle (Zhou et al., 2009; 
Desjardin et al., 2014; Kim et al., 2014) and to miRNAs in other species (Ji et 
al., 2012; Shukla et al., 2015). This comparison was made with the full list of 
miRNAs provided by the publishers that include ‘known miRNAs’ as well as ‘novel 
miRNAs’. It needs to be stated that a considerable number of miRNAs from 
Desjardin et al. (2014) (298 mature miRNA sequences) and Kim et al. (2014) (329 
mature miRNA sequences) were not included in the official database at the time 
the analysis was performed but were nevertheless included in my calculations 
for length and nucleotide composition comparisons. Dissimilarities in length, 
nucleotide composition and precise nomenclature were found between these 
studies and the official database. These differences restricted some of the 
comparisons during the data analysis, as by definition a difference in one or 
more nucleotides between sequences can result in them being considered as 
distinct miRNAs (Griffiths-Jones et al., 2006).  
The chromosomal distribution of the miRNAs expressed in equine primary 
fibroblasts was very similar to that reported in equine tissues and predicted in 
the equine genome (Zhou et al., 2009; Desjardin et al., 2014; Kim et al., 2014). 
However, the results from these comparisons are to be taken with caution due 
to the same reasons as stated above when comparing length and nucleotide 
sequence. Additionally, one of the studies, Kim et al., (2014), only provided 
details of chromosomal coordinates for the known miRNAs (292 miRNAs encoded 
in 310 loci).  
An interesting finding from examination of the chromosomal distribution of 
miRNAs in EqPalFs was that 48 miRNA candidates (6.75% of the total number of 
miRNAs) mapped to multiple locations. One of the assumptions made when 
processing the data using miRDeep2 is that sequences found five or more times 
along the genome are discarded and therefore the maximum number of loci that 
a miRNA could be encoded was limited to a maximum of four. From a 
computational perspective, these are considered repetitive DNA sequences 
rather than real miRNAs and excluded from the analysis.  
Although the average expression for the miRNAs encoded by multiple loci was 
higher than the average expression of single locus miRNAs (7150 vs. 1593), the 
difference was not statistically significant. It can be hypothesised that some of 
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the miRNAs that are encoded in multiple parts of the equine genome regulate 
crucial pathways and therefore the multi-copy nature of the loci encoding these 
miRNAs may be viewed as a defence mechanism whereby if any damage or 
deletions occur to those loci, there is the possibility for the cellular machinery 
to switch the expression to alternative loci.   
miRNAs are frequently found in clusters and these clustered miRNAs are believed 
to share a common primary transcript and have hence been suggested to be co-
regulated and co-expressed (Altuvia et al., 2005; Baskerville & Bartel, 2005). 
Clusters that contain miRNAs from the same family, as they share the same seed 
region, have been suggested to be gene duplication events with the purpose of 
regulating the same mRNA function (Maher et al., 2006; Berezikov, 2011; Marco 
et al., 2013). Interestingly miRNA clusters can contain miRNAs from different 
families and this is thought to be again a duplication event but with a slightly 
different purpose: instead of targeting the same mRNA, clustered miRNAs from 
different families may regulate a pathway by targeting multiple molecules that 
intervene in the pathway (Berezikov, 2011). It is thought that miRNAs encoded in 
distances shorter than 50 Kb derive from the same transcript and therefore may 
be co-expressed (Baskerville & Bartel, 2005). miRNA clusters are defined as 
miRNAs that map to adjacent chromosomal loci within a distance that ranges 
from approximately 1 Kbp to 10 kbp (Altuvia et al., 2005; Zhou et al., 2009; Kim 
et al., 2014; Shukla et al., 2015). For the analysis of clusters expressed in EqPalF 
cells, I used the criteria from Zhou et al. (2009) and Kim et al. (2014) as there 
are the only two studies that evaluated miRNA clusters in the equine genome 
and the sequences from Zhou et al. (2009) are present in the miRBase database. 
Using this criteria, 255 miRNA candidates from EqPalF cells were found to form 
43 clusters. Unfortunately there was not a sufficient number of clustered 
miRNAs recognised by the IPA software to perform functional analysis. Further 
studies of equine miRNA clusters transcribed in the same transcripts will be 
required to evaluate target identification and co-regulation of functional 
pathways.  
One of the most challenging aspects of the data analysis was to annotate the 
mature miRNA candidates. Nucleotide composition and length were utilised to 
ascertain whether the miRNA candidates found in EqPalFs had been reported 
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before in the horse or in any other species. Due to the quality of data available 
from the two studies that specifically assessed miRNAs in equine tissues using 
high throughput sequencing (HTS) (Desjardin et al., 2014; Kim et al., 2014), the 
results from the comparisons using nucleotide composition and length were 
inconsistent. When allocating a name/annotation to each miRNA candidate 
found in EqPalF cells, if a match was found in either the official database 
miRBase 20.0 (Zhou et al., 2009; Platt et al., 2014) or previous HTS studies of 
equine miRNAs (Desjardin et al., 2014; Kim et al., 2014), the annotation present 
in the official database was considered the most accurate. There is no consensus 
on what is sensible or acceptable when determining if two relatively similar 
sequences are indeed two distinct miRNAs. Two miRNA with differences in the 
nucleotide composition and/or length will have variation in the seed region and 
therefore their function may be affected (Berezikov, 2011). In the current study, 
I used a maximum deviation of two nucleotides in length for the BLAST+ method 
and a maximum deviation of two nucleotides in either length or composition for 
the ED method. This cut-off point was set after assessing the differences 
between the dataset obtained from equine primary fibroblasts, the official 
miRNA database and the list of miRNAs from two previous equine HTS studies 
(Desjardin et al., 2014; Kim et al., 2014) and after learning that commercial 
sequencing services use two as the cut-off to define the difference between two 
distinct miRNAs. This approach has the limitation that isomiRs may be 
mistakenly assigned different annotations, as additions or deletions to the 3’ and 
5’ ends may simply be a variation during the biogenesis of a particular miRNA 
and unequivocally this will have an effect on the miRNA function (Manzano et 
al., 2015). 
In total, 143 miRNAs expressed by EqPalF cells were identified by both HTS and 
microarray methods (for details on microarray results, the reader is referred to 
Chapter 3). However, out of the 334 sequences that were common to the two 
assays (identified by HTS / oligos included in the microarray chip design), 191 
were found in the sequencing data but did not produce a signal above 
background noise on the microarray. More than half of those were expressed at a 
low level in EqPalF cells in the HTS dataset (58%, 109 miRNAs, ≤100 reads). The 
probes in the microarray were designed with miRNA sequences from the miRBase 
from the horse (predicted miRNAs) and from the human datasets. Of the miRNAs 
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expressed at >1000 reads in HTS but not detected during microarray (6%, 13 
miRNAs), it is likely that mismatches in the nucleotide composition between the 
miRNA sequence in EqPalF and the microarray probe could explain the presence 
of those miRNAs in the HTS set and low or undetectable levels in the microarray. 
Moreover, HTS methods can detect miRNAs present at a low level that may be 
overlooked using other techniques. Additionally, 259 miRNAs were sequenced 
that were not included in the microarray design. Again, this highlights another 
advantage of the HTS over microarray, as it does not rely on previous knowledge 
of miRNA sequences. 
Amongst the expressed miRNAs in equine primary fibroblasts, the miRNAs 
provisionally named as eca-miR-21, eca-miR-22, eca-miR-26a, eca-miR-27b, eca-
miR-28-3p, eca-miR-92a, eca-miR-127, eca-miR-143, eca-miR-181a and eca-miR-
191a were the 10 most abundantly expressed miRNA candidates. Bioinformatic 
analysis identified five of these miRNAs to be encoded in clusters in the equine 
genome: cluster miR-143/145, cluster miR-181f/a/b, cluster miR-24/27b/23b, 
cluster miR-433/127/432/136 and cluster miR-17/106/18/19/20/92. miRNAs 
encoded by these clusters have been reported to be expressed in equine colon, 
liver and muscle tissue (Zhou et al., 2009; Kim et al., 2014). Therefore, the 
current study represents the first experimental verification of the presence of 
those miRNAs in equine primary fibroblasts and contributes to the knowledge of 
miRNA clustering in the horse. 
The most highly expressed miRNA, eca-mir-143, was found to represent 17.2% of 
the total reads. Significant upregulation of miR-143 has been reported in 
fibroblasts and smooth muscle cells in a colorectal cancer model when compared 
to other types of cells using HTS technology (Kent et al., 2014). Interestingly, 
the orthologue of this miRNA in the goat has been found to be the most 
abundant miRNA in the mammary gland (Ji et al., 2012). Downregulation of miR-
143/145 has been reported in colorectal cancer, breast cancer and cervical 
cancer, and an anti-tumoural role has been attributed to these miRNAs through 
regulation of MAPK and p53 signalling pathways and hexokinase 2 (Suzuki et al., 
2009; Fang et al., 2012; Liu et al., 2012; Pagliuca et al., 2013; Das & Pillai, 
2015). Further investigations will be required to ascertain the roles of miR-143 in 
equine primary fibroblasts.  
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In summary, the results presented in this chapter reveal the expression profile of 
equine miRNAs in primary fibroblast cells. This provides experimental 
verification of the existence of 258 equine miRNAs and the presence of an 
additional 335 novel miRNAs in the horse.  Out of the 335, 173 of the miRNAs 
identified here were not only novel for the horse but for any other species, as no 
annotation match is available in miRBase. Having established the expression 
profile of miRNAs in normal equine fibroblast cells, this information can be 
applied to examine any changes in miRNA expression in BPV-1 transformed cells 
and sarcoid cell lines. This can be achieved using HTS and qRT-PCR, as detailed 
in the next chapter.   
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Chapter 5. Differential expression of miRNAs in 
equine sarcoids: high-throughput sequencing of 
the miRNAs in equine primary fibroblasts, equine 
sarcoid fibroblasts and equine fibroblasts 
transformed in vitro with Bovine Papillomavirus 
type 1 genome 
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5.1. Introduction 
Equine sarcoids (ES) are a recognised health and welfare concern in horses and 
other Equidae and represent the most common cutaneous tumour in horses, 
donkeys, and mules (van Dyk et al., 2009; Wobeser et al., 2010; Schaffer et al., 
2013; Sanchez-Casanova et al., 2014; NEHS, 2015). The aetiology is intrinsically 
linked to bovine papillomavirus (BPV) types 1 and 2 (Nasir & Reid, 1999; Yuan et 
al., 2007a; Brandt et al., 2011b; Wobeser et al., 2012). Risk factors such as age, 
breed, equine leucocyte antigen haplotype and other genetic influences (single 
nucleotide polymorphisms and DNA deletions and duplications) have also been 
identified (Meredith et al., 1986; Brostrom et al., 1988; Mohammed et al., 1992; 
Brostrom, 1995; Wobeser et al., 2010; Jandova et al., 2012; Bugno-Poniewierska 
et al., 2016; Staiger et al., 2016). An in-depth review of the current knowledge 
of equine sarcoids was presented in Chapter 1. 
BPV types associated with ES belong to a family of heterogeneous viruses that 
can give a great variety of clinical presentations from benign lesions to 
malignant cancer (Silvestre et al., 2009; Pangty et al., 2010; Maiolino et al., 
2013; Roperto et al., 2013). The oncogenic effects of papillomaviruses have 
been extensively studied and recently reviewed for HPV and BPV (Moody & 
Laimins, 2010; Venuti et al., 2011; DiMaio & Petti, 2013; Banno et al., 2014; de 
Freitas et al., 2014; Gil da Costa & Medeiros, 2014; Munday, 2014; Doorbar et 
al., 2015; Bocaneti et al., 2016). The oncogenic activity in high-risk HPVs -16 
and -18 (HR-HPVs) is attributed to oncoproteins E7, E6 and to a lesser extent, 
E5, whereas in BPV-1/-2 it is primarily attributed to E5 and E6 and to a lesser 
extent, E7 (Moody & Laimins, 2010; Yuan et al., 2011b). The best-studied 
oncogenic mechanisms for HR-HPVs are the downregulation of p53 tumour 
suppressor protein and pRB pathway by E6 and E7 respectively, whereas for BPV-
1/-2 it is the activation of PDGFβ-R by BPV E5 (Borzacchiello et al., 2009; 
Marchetti et al., 2009; Moody & Laimins, 2010; Altamura et al., 2013). Both HR-
HPVs and BPV-1/-2 prevent expression of MHC class I on the cell surface, 
promote activation of the MAPK-p38 cascade, affect expression of p53 and 
stimulate anchorage-independent growth (Ashrafi et al., 2002; Yuan et al., 
2008a; Venuti et al., 2011; Yuan et al., 2011c; Altamura et al., 2013; de Freitas 
et al., 2014). Interestingly, some of the mechanisms that lead to tumorigenesis, 
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are induced and modified differently in HR-HPV than in BPV-1/-2 (Moody & 
Laimins, 2010). 
miRNAs are non-coding small RNAs with essential roles in a great variety of 
cellular processes and play an important role in HPV oncogenesis (Gómez-Gómez 
et al., 2013; Banno et al., 2014; Sharma et al., 2014; Wang et al., 2016). 
Certain miRNAs have been shown to be consistently dysregulated in HPV-induced 
cancer, such as miR-218 and clusters miR-143/145 and miR-302~367. These 
miRNAs participate in inhibition of apoptosis (miR-218 and miR-143/145 cluster) 
and metastasis pathways (miR-218 and miR-302~367 cluster), and during HPV 
induced cancer they are downregulated by HPV E6 via inhibition of p53 pathways 
(Wang et al., 2008; Li et al., 2011; McBee et al., 2011; Wald et al., 2011; Ben et 
al., 2015). Other miRNAs have been reported to be upregulated during HPV 
tumorigenesis, such as miR-196a and miR-21. These two miRNAs participate in 
migration, invasion pathways and appear to be dysregulated due to the effect of 
HR-HPV E7 on PI3K/Akt signalling pathway (Pereira et al., 2010; Gocze et al., 
2013; Wang et al., 2016). Nevertheless, several studies have shown 
discrepancies in the expression of some miRNAs in both in vitro and ex vivo 
studies of HPV-induced cancer and this was initially highlighted by Pereira et al. 
(2010) and recently discussed in the review by Sharma et al. (2014). Examples of 
this are hsa-let-7b (Wang et al., 2008; Li et al., 2011), miR-146a and miR-146b-
5p (Wang et al., 2008; Lajer et al., 2012), which have shown different levels of 
expression across studies. Variation in the control samples used in ex vivo 
studies and in clinical samples may be a reason for these disparities (Pereira et 
al., 2010; Sharma et al., 2014). Additionally, expression of miRNA changes over 
time after HPV transfection, and therefore differences found in the 
aforementioned studies, may be due to the dynamic changes occurring during 
viral infection and neoplastic development (Greco et al., 2011; Li et al., 2011). 
A summary of miRNAs that have been linked to expression of oncoproteins E5, E6 
and E7 in HPV-16/-18 is displayed in Table 5.1. 
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Table 5.1 List of miRNAs dysregulated in HPV cancer linked to expression of oncoproteins E5, E6 and E7 
miRNA Oncoprotein Pathway 
Level of 
expression 
in HPV+  Effect of miRNA dysregulation Source 
miR-106b E6/E7 E2F1 up Cell migration 
McBee et al. (2011); Gómez-
Gómez et al. (2013) 
miR-129-5p - Targets E6 via SP1 down Decreases E6 and increases p53 Zhang et al. (2013) 
miR-129-5p - Targets E7 down Inhibits E7 expression Zhang et al. (2013) 
miR-129-5p E6/E7 Unknown down Dysregulation of the cell cycle Gómez-Gómez et al. (2013) 
miR-145 E6 p53  down Prevents apoptosis Shi et al. (2012) 
miR-146a E5 Unknown up 
Decrease of target PDZD2. Increases dramatically after 
HPV transfection due to HPV16 E5 protein. 
Consequence is decrease in p38 and ERK1. miR-146a is 
involved in cytokine signalling. 
Greco et al. (2011); Gómez-
Gómez et al. (2013) 
miR-15/16 cluster E7 c-Myc up Metastasis and angiogenesis Myklebust et al. (2011) 
miR-196a E7 PI3K up Promotes cell migration and invasion Pereira et al. (2010) 
miR-203 E6 unknown down Decreases p53 promoting cell proliferation McKenna et al. (2010) 
miR-203 E7 MAPK down Dysregulation of the cell cycle Melar-New and Laimins (2010) 
miR-205 E6/E7 pRb? up Promotes cell proliferation McKenna et al. (2010) 
miR-21 E6 Unknown up 
Promotes increase of phosphorylated Akt inhibiting 
PTEN (a tumour suppressor) and increasing cell 
proliferation Ben et al. (2015) 
miR-218 E6 LAMB3 down Promotes tumorigenesis 
Martinez et al. (2008); Ben et al. 
(2015) 
miR-23b E6 p53  down Increases uPA and promotes cancer development Yeung et al. (2011) 
miR-24 E6/E7 Unknown up Promotes cell proliferation McKenna et al. (2010) 
miR-324-5p E5 Unknown down 
Increase of target N-cadherin. It is a negative regulator 
of the oncogenic Hedgehog pathway 
Greco et al. (2011); Gómez-
Gómez et al. (2013) 
miR-34a E6 p53  down Cell cycle disruption that leads to cell transformation Wang et al. (2008); Li et al. (2010) 
miR-375 - targets E6 down Decreases E6 and increases p53 Li et al. (2011); Jung et al. (2014) 
miR-375 - targets E7 down Inhibits E7 expression Li et al. (2011); Jung et al. (2014) 
miR-92 E6 PTEN protein up Tumour development Yu et al. (2013) 
1
2
9
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Using microarray analysis, differences in miRNA expression were found in BPV-1 
in vitro transformed equine primary fibroblasts (S6-2) compared to equine 
primary fibroblasts (EqPalF) (Chapter 3). In the current study, differences in 
miRNA expression in two equine cell lines containing the BPV-1 viral genome and 
equine primary fibroblasts were explored in more depth using high throughput 
sequencing (HTS). HTS has become the tool of choice for quantification and 
annotation of miRNAs due to the ability to discover novel miRNAs, as previous 
knowledge of the sequences is not necessary, and to the high dynamic range that 
allows identification of less abundant miRNAs. Using HTS, a catalogue of the 
miRNA profile in equine cells using equine primary fibroblast was performed 
(detailed in Chapter 4). In this chapter, the differences in miRNA expression 
between three cell lines from an equine sarcoid model developed in the 
University of Glasgow (Yuan et al., 2008a) were studied with the use of HTS to 
contribute to the understanding of the tumorigenesis mechanisms of BPV-1/-2 
oncoproteins in equine sarcoids.  
5.2. Materials and methods 
5.2.1. RNA extraction, quantitation and assessment of RNA 
integrity (RIN) 
Chapter 2 (General materials and methods) contains details of RNA extraction 
and RNA quality/quantity assessment. In summary, RNA was prepared using a 
phenol extraction method (with Trizol®) from equine primary fibroblasts (EqPalF 
cells), equine primary fibroblasts transformed in vitro with BPV-1 genomes (S6-2 
cells) and equine fibroblasts obtained from an equine sarcoid tumour (EqSO4b 
cells) maintained in culture (Yuan et al., 2008a). Features of the cell lines is 
displayed elsewhere (Table 2.4, Chapter 2). In summary, EqPalF cells do not 
contain the BPV-1 genomes or express viral proteins whereas S6-2 cells are 
EqPalF cells in vitro-transformed with 2 BPV-1 genomes per cell and EqSO4b are 
equine fibroblasts obtained from naturally occurring equine sarcoids that contain 
8 BPV-1 genomes per cell (Yuan et al., 2008a). Both S6-2 and EqSO4b cells 
express BPV-1 E5 protein (Sw I variant) (Yuan et al., 2008a). Quantity and 
integrity of the extracted RNA were assessed and samples with RIN values 
greater than 9.0 were utilised for sequencing. One RNA sample was obtained 
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from EqPalF cells and the RNA was divided in three to construct three libraries. 
For EqSO4 and S6-2 cells, RNA was extracted from three individual cultures and 
used to prepare three independent libraries for each cell line. The experimental 
design is summarised in Figure 5.1.
 
 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Diagram of the HTS experimental design. RNA from each cell line of the equine sarcoid in vitro model was obtained, followed by 
library preparation and sequencing in two platforms (GAIIx and NextSeq500) 
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5.2.2. Library construction, cluster generation and sequencing 
A detailed explanation of library construction, cluster generation and sequencing 
is given in Chapter 2, section 2.5.1. In summary, libraries were prepared using 
TruSeq® Small RNA (Life Technologies). Library preparation involves adaptor 
ligation and size selection. At two different stages of the library construction, 
the TruSeq® Small RNA kit requires quality control checks to quantify the 
fraction of potential miRNAs. If the check-points fail, the library preparation is 
repeated and if enough miRNA fraction is recorded by the DNA high sensitivity 
chip, the library is highly likely to produce enough fraction to retrieve good 
quality data. After library construction and cluster generation, massive parallel 
sequencing was performed in the Genomic Analyzer IIx from Illumina® (GA-IIx) 
for EqPalF cells and in the NextSeq 500 from Illumina® for EqSO4b and S6-2 
cells. The reason for the change of sequencer was due to discontinuity of the use 
of the GA-IIx machine and reagents. All sequencing was carried out at the 
University of Glasgow Polyomics facility. 
5.2.3. Data analysis 
Analysis of the high throughput sequencing data is fully explained in Chapter 2, 
section 2.5.2. and a summary is displayed in Figure 5.2.  
In brief, the files obtained from the GA-IIx and NextSeq500 sequencers were pre-
processed (removal of adaptor sequences) and fed into miRDeep 2, software 
designed specifically for microRNA discovery. During miRDeep2 processing, 
sequences were mapped against the equine genome (EqCab.2.0, GenBank 
assembly accession reference GCA_000002305) and equine miRNAs from miRBase 
20.0, redundant sequences identified and sequences smaller than 18 nucleotides 
in length were removed. Following this, RNA folding energy potential was used 
to identify putative novel miRNAs. The output from miRDeep2, containing the 
list of sequences of mature miRNA candidates, their genomic location, precursor 
sequences and number of reads, was harmonised across replicates. To harmonise 
the data and generate a list of unique miRNA candidates, the following criteria 
were applied: 
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1. If two mature sequences were encoded on the same chromosomal location 
with a maximal deviation of location of 10 nucleotides, they are defined 
as the same microRNA (tolerance for chromosomal location 10). 
2. If two mature sequences were the same length and had the same 
nucleotide sequence they were considered the same microRNA (i.e. 
tolerance for sequence composition 0). 
The genomic location condition was applied first and nucleotide sequence 
followed. This was to prevent discarding the historically named ‘star miRNA’ 
(miRNA* or passenger strand), as miRDeep2 gives priority to the guide strand 
Each potential microRNA candidates was assigned an internal ID in the form of 
U_number_location in the precursor (3p or 5p). miRNA candidates were then 
filtered during post-processing to increase robustness of the data, so that only 
the miRNAs present in at least two of the three replicate libraries of each cell 
line were included in the analysis.  
 
          Figure 5.2. Summary of the steps of data analysis of HTS data 
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To verify if the miRNAs were novel or had been described before, the list of 
miRNA candidates were analysed using two methods, BLAST + and Edit distance 
using the list of miRNAs from miRBase 20.0 and the list of equine miRNAs 
available in the literature. Full details of both methods are explained in Chapter 
2, section 2.5.2.2.  
To study the differences of miRNA profile between cell lines, the data from the 
three cell lines (9 replicates in total) was analysed using DESeq R package 
(Anders & Huber, 2010) from Bioconductor 
(http://bioconductor.org/packages/release/bioc/html/DESeq.html). With this 
package, firstly reads from each cell line were normalised to the level of the 
sample with the highest read number and the differences in fold change 
between the cell lines were calculated in a pair-wise manner (EqPalF vs. 
EqSO4b, EqPalF vs. S6-2 and EqSO4b vs. S6-2 cells). The p-value for differential 
expression of each putative miRNA was calculated; following this, an adjusted p-
values was also obtained using Benjamini-Hochberg procedure to control for 
multiple tests (Anders & Huber, 2010). An adjusted p-value of less than 0.05 was 
taken to be statistically significant. Data was subsequently explored using heat 
maps, MvA plots (also known as Bland-Altman) and principal component analysis 
(PCA). Figure showing the data for differential expression analysis were 
constructed in Microsoft Excel, ClustVis and R. Functional analysis was 
performed using Ingenuity Pathway Analysis (Qiagen) where identified miRNAs 
could be mapped to their human or mice equivalent. Biomarker analysis was 
performed using LefSe, implemented using Galaxy. 
5.2.4. Validation using real-time quantitative Reverse-
Transcription Polymerase Chain Reaction (qRT-PCR) with 
Taqman technology 
Real-time Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-
PCR) was used to quantify differential expression for a subset of miRNAs 
identified as differentially expressed by the HTS approach. Six miRNAs were 
selected as they fulfilled all the following criteria: 
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1. Differentially expressed between EqPalF vs. EqSO4b, EqPalF vs. S6-2 or 
EqSO4b vs. S6-2 cells (p<0.01) and present in the top 60 miRNAs ranked by 
absolute fold change in each pair-wise comparison. When a miRNA was 
present in more that one comparison, only one entry for that miRNA was 
kept. 
2. Showed a perfect match to equine miRNAs included in miRBase using 
BLAST (see Chapter 2 for more details), setting the values of identity at 
100% and coverage at 100%. 
3. Commercial availability of Taqman® probes for the miRNA sequence (Life 
technologies). 
4. Biological significance (i.e. having being previously reported to be 
dysregulated in cancer and/or HPV).  
5.3. Results 
5.3.1. RNA quality, integrity and library quality control 
Total RNA extracted from EqPalF (equine primary fibroblasts), S6-2 (equine 
primary fibroblasts in vitro transformed with BPV-1 genomes) and EqSO4b cells 
(equine fibroblasts from naturally occurring sarcoids) maintained in culture 
showed good integrity as observed by electrophoresis on 1% agarose gel. The 
A260/A280 ratio ranged from 2.02 to 2.07 and the RIN value ranged from 9.90 to 
10.0, obtained using the Bioanalyzer 2100, indicating suitable RNA for 
sequencing (see Figure 4.3 for details on EqPalF and see Figure 5.3 for details on 
EqSO4b and S6-2 RNA). During library preparation, EqSO4b and S6-2 RNA samples 
shown a discrete peak on the DNA chip as expected for the miRNA content, 
whereas one of the libraries from one of the replicates from EqPalF had to be 
repeated due to suspected contamination (see Chapter 4, section 4.3.1.). 
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Figure 5.3. Electrophenogram obtained with the Bioanalyzer 2100 of RNA 
samples from EqSO4b (left) and S6-2 (right). No signs of RNA degradation were 
noticed and RIN values were 10 for both RNA samples 
 
5.3.2. Characterisation of RNA read data - read count, number of 
mature miRNA candidates and correlation across replicate 
libraries 
The number of reads obtained from EqPalF cells from the GAIIx sequencer 
ranged from 7.81 x 106 - 10.70 x 106 whereas reads obtained from EqSO4b and 
S6-2 cells from NextSeq500 ranged from 22.4 x 106 – 29.5 x 106. The differences 
in read counts between EqPalF and the other two cell lines can be explained by 
differences in the sequencing platforms. Sequencing reads after adaptor-
trimming were fed into miRDeep2. This mapped the sequencing reads to the 
databases (equine genome and equine miRNAs included in miRBase 20.0), 
removed redundancy and performed miRNA predictions based on a core 
algorithm and folding energy of the miRNA precursor candidates. Sequences that 
were not mapped to the equine genome, mapped to other types of RNA such as 
tRNA, mapped to five or more loci in the genome, and sequences that did not 
meet the folding energy criteria set for miRNA in the Randfold script were 
removed. The number of reads retained after miRDeep2 and harmonization 
ranged from 3.82 x 106 – 6.72 x 106 in EqPalF, 14.2 x 106 – 18.0 x 106 in EqSO4b 
and 12.0 x 106 - 15.1 x 106 in S6-2 cells. Combining the output of the three cell 
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lines reads were normalised to 20 x 106 reads in each cell line. A Perl script was 
used to harmonise the data between cell lines and 1336 potential miRNA 
candidates were found.  The list of 1336 miRNA candidates is included in the file 
‘master file DESeqdata.xlsx’ in the DVD enclosed. Harmonisation of the data was 
performed with the following assumptions: two sequences were considered the 
same mature miRNA if they were in the same genomic location (with a maximum 
deviation of ten nucleotides) and if the nucleotide composition was exactly the 
same (tolerance 0 for nucleotide sequence). When these criteria were followed 
and there were differences in length either at the 3’ or 5’ end, the longest 
sequence was used for further analysis. To add robustness to the results, the list 
of mature miRNA candidates was filtered by occurrence. All miRNAs that were 
sequenced in at least two of three the libraries of each of the three cell lines, 
independently of the read count, were included for further analysis. The list was 
therefore shortened from 1336 to 752 mature miRNA candidates. In total, 593, 
558 and 585 mature miRNAs were found in EqPalF, EqSO4b and S6-2 cells 
respectively. Of those, 433 miRNAs were commonly expressed in the three cell 
lines, 84 were exclusive to EqPalF, 65 and 52 were exclusive to EqSO4b and S6-2 
respectively (see Figure 5.4.). 
 
 
 
 
 
 
 
Figure 5.4. Venn-diagram indicating the number of miRNAs present in each 
cell line. EqPalF expressed 593 miRNAs while EqSO4b and S6-2 expressed 558 and 585 
respectively. A substantial number of miRNAs (433) was present in all three cell lines. 
Presence of a miRNA in each cell line was defined as ‘at least present in two of the 
three replicates of that cell line’ 
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Pearson’s correlation coefficient (r) was 0.96-1.00 for EqPalF replicates, 0.98-
0.99 for EqSO4b replicates and 0.99 for S6-2 replicates, indicating that the 
replicates were very similar in miRNA expression pattern and miRNA repertoire 
within each cell line, as the values are closer to 1 rather than closer to 0. As r 
coefficient is higher than 0, the direction of the linear relationship is positive in 
all cell lines. Graphical representation of the correlation of miRNA expression 
between replicates from S6-2 and EqSO4b is displayed in Figure 5.5. Correlation 
of replicates for EqPalF was displayed elsewhere (Chapter 4, section 4.4.2., 
Figure 4.4.). After normalisation, data was also assessed using MA plots (Blant-
Altmant plots), whereby differences in expression of miRNAs in each cell line 
pair were plotted against average expression. Figure 5.6. shows the distribution 
of the data of cell lines in pairs. The most differentially expressed miRNAs are 
located to the higher side of the x axis (average expression) and away from “0” 
on the y axis (Log2FC of expression).  
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Figure 5.5. Correlation of miRNA expression in EqSO4b (above) and S6-2 cells (below). The number of reads of each miRNA, 
expressed in Log2 values from each of the three replicates, was compared pair-wise. Each dot represents one miRNA with the Log2 read 
number in x axis from one replicate and in y axis from a different replicate. Pearson’s coefficient for each pair is displayed as ‘r’ and shows a positive 
and strong linear relationship in the three pair comparisons (as values are close to +1.0) 
1
4
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Figure 5.6. MA plots of miRNA expression in EqPalF vs. EqSO4b (above) and 
EqPalF vs. S6-2 (below). miRNAs that were differentially expressed with an adjusted 
p value <0.05 are represented in red 
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The difference in the miRNA expression levels was also small within each cell 
line as observed in the PCA plots. This was particularly noticeable in EqPalF 
replicates 1, 2 and 3 where the replicates sit very close to each other in the PCA 
plot (see Figure 5.7). EqSO4b and S62 dissimilarities were also small but not as 
small as EqPalF. This may be explained by the fact that the three EqPalF 
libraries were prepared from the same RNA preparation. Nevertheless, the 
majority of the differences were found between each cell line: almost 84% of 
the variation between EqPalF and EqSO4b, and almost 80% of the variation 
between EqPalF and S6-2 is due to the inherent biological differences between 
cell lines (see Figure 5.8). 
Differences between the three cell lines were explored using a three-way PCA 
plot with the list of miRNAs expressed in each cell line and levels of expression. 
Differences between the cells containing BPV-1 genomes were smaller when 
compared with each other and were bigger when compared to EqPalF cells (see 
Figure 5.8). Almost 50% of the variation in miRNA expression between EqPalF 
and cells containing BPV-1 genomes (S6-2 and EqSO4b) can be attributed to the 
biological differences in the cell lines due to the presence of BPV-1 viral 
genomes. 
Out of the 752 miRNA candidates found, 280 had an equine match in miRBase 
20.0 (eca-miR-xxx, where “x” are the number or letters that have been used to 
annotate each miRNA), 187 had a match in miRBase 20.0 from other species (of 
which, 80 were a perfect match to human miRNAs or hsa-miR-xxx) and 285 had 
no match in the database and therefore are considered novel miRNAs to the 
horse and to other species. Novel miRNAs, which annotation is referred to as 
U_number_-5p/3p in this chapter, were excluded from any functional analysis as 
for the analysis either miRBase annotation name (eca-miR-xxx) or miRBase 
number (MIMAxxxxxxx) is required. For details on those miRNAs (i.e. mature 
sequence, levels of expression, precursor sequence, genomic location, DESeq 
data) please see file ‘master file DESeqdata.xlsx’ in the accompanying DVD. 
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Figure 5.7. Principal Component Analysis (PCA) plot of list of miRNAs, their expression in number of reads and presence in each 
cell line (pair comparisons). Unit variance scaling is applied to rows (3 replicates per cell line). Singular value decomposition (SVD) with 
imputation was used to calculate principal components. Axis x and y show principal components 1 and 2 that explain 79.5% and 8.3% of the total 
variance respectively in S6-2 vs. EqPalF (right) and explain 83.7% and 7.6% of the total variance respectively in EqSO4b vs. EqPalF (left). Prediction 
ellipses are such that a new observation from the same cell line would fall inside the ellipse (based on 6 data points, probability 0.971) 
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Figure 5.8. Principal Component Analysis (PCA) plot of list of miRNAs, their 
expression indicated by number of reads and presence in the three cell lines 
(three-way comparison). Singular value decomposition (SVD) with imputation was 
used to calculate principal components. Axis x and y show principal components 1 and 2 
that explain 48% and 16.5% of the total variance respectively (based on 9 data points, 
probability 0.92).The plot demonstrates that the biggest differences between the cell 
lines are across PC1, showing that S6-2 cells are closer to EqSO4b cells than to EqPalF 
cells 
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5.3.3. Differential expression of miRNAs between equine primary 
fibroblasts in vitro transformed with BPV-1 genomes (S6-2 cells) 
and equine primary fibroblasts (EqPalF) 
DESeq results 
In total, 251 mature miRNA candidates were found significantly dysregulated in 
S6-2 (fibroblasts transformed in vitro with BPV-1 genome) compared to EqPalF 
(primary fibroblast) cells (adjusted p<0.05). Of these differentially expressed 
miRNAs, 19% (49) have not been previously reported neither in the horse nor any 
other species and are therefore considered novel miRNAs. Novel miRNAs were 
not included in the functional analysis because of the reasons mentioned in 
section 5.3.2. Just over half of the differentially expressed miRNAs (52%, 131 
miRNAs) were found to be upregulated in cells containing the BPV-1 genomes. 
Differences in expression of miRNA candidates between S6-2 and EqPalF cells 
ranged from 0.61-10.82 (Log2FC). The top 10 most up - and down-regulated 
miRNA candidates in S6-2 compared to EqPalF are displayed in Table 5.2. and 
their differences are presented in Figure 5.9. Interestingly, 14 of those had no 
match in miRBase 20.0 (novel miRNAs). In addition, in the top 50 most 
dysregulated miRNA candidates, 31 miRNAs in total did not have a match in the 
miRBase. While this limited the use of the data for automated functional 
analysis, it is an interesting finding. The two most dysregulated miRNAs were 
U147_5p (novel miRNA) and hsa-miR-1249-3p (U140-3p) with Log2FC of 10.82 and 
-10.55 respectively (see Table 5.2). The top 50 most dysregulated miRNA 
candidates (top 25 upregulated in S6-2 and top 25 downregulated compared to 
EqPalF) are presented in Figure 5.10). Hierarchical clustering positions the three 
replicates from EqPalF together and the three replicates from S6-2 together, and 
highlights a difference between the two cell lines as shown by the separation of 
the branches of the clustering tree.  
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Table 5.2. List of the 10 most upregulated and 10 most downregulated miRNAs in S6-2 when compared to EqPalF ranked by log2FC. 
When no match for a miRNA was found in the database (miRBase) the internal identifier generated after harmonising the data, was used instead 
(U**number_3p/5p). Log2FC represents the difference in expression between the two cell lines calculated as the average expression in each cell line 
after normalising read counts to 20 x 106 reads. Fourteen of the 20 most dysregulated miRNA candidates have no annotation in the miRBase 20.0 and 
therefore are novel miRNA candidates 
 
 
 
 
 
 
 
 
 
ID Mature sequence Length Annotation p-adj Log 2 fold change 
U147_5p AUCCUGCCGACUGCGCCA 18 U147_5p 3.10E-92 10.82 
U174_3p CUAGAAUGAAGCUCCUAGAGG 21 U174_3p 2.56E-63 9.95 
U142_5p UAGGGGUAUGAUUCUCGCU 19 U142_5p 7.96E-06 9.89 
U201_3p UUGCCUGGGCCUCUGGAACCAU 22 U201_3p 7.99E-58 9.76 
U183_3p AAGUUUCUCUGAACGUGUAGAGC 23 U183_3p 1.27E-05 9.75 
U207_3p UCAAGGAGAUCACAGUCUAGU 21 U207_3p 6.43E-41 9.11 
U230_5p UCAGUAACAAAGAUUCAUCCUUG 23 eca-miR-802 8.96E-40 9.05 
U238_5p UGAGAUGAAGCACUGUCAC 19 U238_5p 5.94E-05 8.43 
U301_5p AGCCAGCUUGAGCCCACCUACAU 23 U301_5p 3.63E-08 6.51 
U316_3p ACAAAAGUCUGCACAUUGGA 20 U316_3p 8.29E-04 6.49 
U279_3p CUGACCCCCUGCCCCCCCCAUC 22 U279_3p 1.66E-04 -5.86 
U310_3p UGGACGGAGAACUGAUAAGGGU 22 eca-miR-184 1.15E-04 -5.91 
U290_5p UGGCUCUCCUCUGCCUGCUGUGC 23 U290_5p 1.27E-04 -5.93 
U286_3p GACCCCCAGCCCCAGCCCUGGA 22 U286_3p 3.46E-05 -6.07 
U277_5p UGAGAACUGAAUUCCAUGGGUU 22 eca-miR-146a 9.60E-07 -6.48 
U263_3p UCUGCCUCUUGUUUCCUUCCAGC 23 U263_3p 3.50E-03 -6.49 
U275_3p AUUUCCACCACGUUCCCG 18 U275_3p 3.27E-09 -6.95 
U154_5p GAGGGCCCCCCCCAAUCCUGU 21 ssc-miR-296-5p 2.87E-20 -8.88 
U154_3p AGGGUUGGGUGGAGGCUUUCCU 22 eca-miR-296 8.16E-41 -9.39 
U140_3p ACGCCCUUCCCCCCCUUCUUCA 22 eca-miR-1249 3.50E-22 -10.55 
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Figure 5.9. Top most differentially expressed miRNAs in S6-2 vs. EqPalF (p 
adjusted <0.05) ranked by Log2FC (ten most upregulated and ten most 
downregulated). When no match was found in miRBase, the miRNA maintained the 
internal annotation (U_number_3p/5p). The x-axis denotes the Log2FC between reads 
from S6-2 and EqPalF: overexpressed miRNAs in S6-2 have values >0 and underexpressed 
miRNAs have values <0 
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Figure 5.10. Heat map and hierarchical clustering of the top 50 most 
differentially expressed miRNAs in S6-2 vs. EqPalF (Adjusted p<0.05) ranked 
by Log2FC (25 most upregulated and 25 most downregulated). When no match 
for a miRNA was found in the database (miRBase) the internal identifier generated after 
harmonising the data, was used instead (U”number”_”3p/5p”). Hierarchical clustering 
was performed using correlation as clustering distance with average as the linkage 
criteria; the tree was ordered by the tightest cluster first. Each column represents one 
replicate (EqPalF_1,_2 and _3 for EqPalF and S6-2_1,_2 and _3 for S6-2). Note that 
through hierarchical clustering the replicates from each cell line are closer to each 
other than to the counterpart cell line, shown by the short branch lengths within both 
clusters (red arrows) 
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Comparison of DESeq data with miRNA microarray  
Of the 251 miRNAs found dysregulated in S6-2 cells when compared to EqPalF, 
42% (105 miRNAs) had been previously interrogated using microarray (for details 
see Chapter 3). Of those, just over half had shown signal intensity above the 
background level during microarray (55%, 57 miRNAs) and the rest were found 
below the background level (45%, 48 miRNAs). Out of the 57 with signal above 
background level, 37% (21 miRNAs) showed the same pattern of expression 
between HTS and microarray (either upregulated or downregulated), 18% (10 
miRNAs) were not differentially expressed by microarray but were on the HTS 
dataset and the rest (26 miRNAs, 46%) showed disagreement in the direction of 
the dysregulation (up or down). miRNAs found differentially expressed in both 
HTS and microarray with agreement in the direction of dysregulation, are 
displayed in Table 5.3. Three of those miRNAs (U72-5p, U4-5p and U44-5p) were 
found to be encoded in regions of the equine genome previously reported to be 
linked to equine sarcoids (Jandova et al., 2012; Bugno-Poniewierska et al., 
2016). 
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Table 5.3. List of 21 miRNAs that show agreement in the comparison of S6-2 cells vs. EqPalF by HTS and microarray (p<0.05). 
Differences are displayed as Log2FC between S6-2 and EqPalF. In bold the three miRNAs encoded in regions of the equine genome linked to higher 
susceptibility to equine sarcoids have been highlighted 
HTS Microarray   
ID Mature sequence ECA Annotation Log2FC Log2FC Result (HTS and microarray) 
U9_3p UCGGAUCCGUCUGAGCUUGGCU 24 eca-miR-127 -4.44 -2.13 downregulated in BPV-1 + 
U108_3p GUCAUACACGGCUCUCCUCUCU 24 eca-miR-485-3p -3.50 -0.53 downregulated in BPV-1 + 
U105_5p UGGUUUACCGUCCCACAUACAU 24 hsa-miR-299-5p -2.88 -0.35 downregulated in BPV-1 + 
U34_3p GAAUGUUGCUCGGUGAACCCCU 24 eca-miR-409-3p -2.77 -1.20 downregulated in BPV-1 + 
U96_5p UCUUGGAGUAGGUCAUUGGGUGG 24 eca-miR-432 -2.49 -0.73 downregulated in BPV-1 + 
U58_5p UAGCAGCACAUCAUGGUUUACA 5 eca-miR-15b -1.99 -1.00 downregulated in BPV-1 + 
U72_5p UUCCCUUUGUCAUCCUAUGCCU 23 eca-miR-204b -1.81 -0.16 downregulated in BPV-1 + 
U64_3p UAACAGUCUACAGCCAUGGUCG 11 eca-miR-132 -1.79 -1.48 downregulated in BPV-1 + 
U10_3p UAUUGCACUUGUCCCGGCCUGU 17 eca-miR-92a -1.73 -0.40 downregulated in BPV-1 + 
U104_5p UUAAUGCUAAUCGUGAUAGGGGU 26 eca-miR-155 -1.67 -0.17 downregulated in BPV-1 + 
U148_5p GAAGUUGUUCGUGGUGGAUUCG 24 eca-miR-382 -1.51 -0.53 downregulated in BPV-1 + 
U30_5p UGAGGGGCAGAGAGCGAGACUUU 11 eca-miR-423-5p -1.41 -0.14 downregulated in BPV-1 + 
U4_5p AACAUUCAACGCUGUCGGUGAGU 25 eca-miR-181a -1.36 -1.27 downregulated in BPV-1 + 
U50_3p ACAGCAGGCACAGACAGGCAGU 5 eca-miR-214 -1.30 -0.77 downregulated in BPV-1 + 
U11_5p CAACGGAAUCCCAAAAGCAGCUG 16 eca-miR-191a -1.29 -0.46 downregulated in BPV-1 + 
U44_5p AACAUUCAUUGCUGUCGGUGGGU 25 eca-miR-181b -1.27 -0.87 downregulated in BPV-1 + 
U73_5p UGGGUCUUUGCGGGCGAGAUGA 11 eca-miR-193a-5p -1.17 -0.12 downregulated in BPV-1 + 
U17_3p AGCUACAUUGUCUGCUGGGUUUC X eca-miR-221 -0.61 -0.32 downregulated in BPV-1 + 
U76_5p AACCCGUAGAUCCGAUCUUGUG 26 eca-miR-99a 1.86 0.35 upregulated in BPV-1 + 
U158_3p UGUGACAGAUUGAUAACUGAAA X eca-miR-542-3p 2.03 0.12 upregulated in BPV-1 + 
U100_3p UAGCACCAUUUGAAAUCAGUGUU 4 eca-miR-29b 2.67 0.11 upregulated in BPV-1 + 
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5.3.4. Differential expression of miRNAs between equine tumoural 
fibroblasts (EqSO4b) and equine primary fibroblasts (EqPalF) 
In total, 329 mature miRNA candidates were found differentially expressed 
between EqSO4b and EqPalF cells (p adj<0.05). Differences between levels of 
expressions ranged from -16.5 to 13.34 (measured as Log2 fold change (Log2FC) 
of expression in EqSO4b compared to EqPalF). Of the 329 miRNAs, 82% (271 
miRNAs) had an annotation allocated in miRBase 20.0 and 18% (58 miRNAs) had 
not been reported in the horse or any other species (novel miRNAs). Novel 
miRNAs were excluded from the functional analysis because of the reasons 
mentioned in section 5.3.2. Out of the 329 differentially expressed miRNAs, 51% 
(168 miRNAs) were upregulated in EqSO4b and 49% (161 miRNAs) were found 
downregulated when compared to EqPalF cells, very similar to the comparison 
between S6-2 and EqPalF cells presented above. The 20 most dysregulated 
miRNAs (top 10 upregulated and top 10 downregulated), ranked by Log2FC, are 
displayed in Table 5.4. Their differences in Log2 FC are represented in Figure 
5.11. The top most dysregulated miRNAs were eca-miR-23a (U29_3p) and eca-
miR-615-3p (U88_3p) with Log2FC -16.50 and 13.34 respectively (see Table 5.4).  
Differences in expression between the top 50 most dysregulated miRNAs (top 25 
upregulated and top 25 downregulated in EqSO4b compared to EqPalF), ranked 
by Log2FC is displayed in Figure 5.12. It is worth noting that the hierarchical 
clustering of this heat map puts the replicates of each cell line close to each 
other as the branches of the clustering tree are tight, whereas there is a marked 
difference between the two cell lines as seen by the separation of the main 
branches of the clustering tree. It is also apparent that for less abundant 
miRNAs, the differences in expression between replicates are visually more 
obvious in the heat map. This occurs with miRNAs such as U307_5p, U202_3p, 
U301_5p and efu-miR-219 to name a few. For these miRNAs, the level of 
expression in all three replicates of EqSO4b is low or cannot be detected in one 
of the replicates, and therefore the fold change of the average expression of 
each cell line is indeed significant although there was variation across 
replicates.  
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Table 5.4. List of the 10 most upregulated and 10 most downregulated miRNAs in EqSO4b when compared to EqPalF ranked by 
Log2FC. When no match for a miRNA was found in the database (miRBAse 20.0) the internal identifier generated was used instead. Log2FC 
represents the difference in expression between the two cell lines calculated as the average expression in each cell line after normalising read 
counts to 20 x 106 reads 
 
ID Mature sequence Length Annotation p adjusted value Log 2 fold change 
U88_3p UCCGAGCCUGGGUCUCCCUCU 21 eca-miR-615-3p 4.26E-44 13.34 
U97_5p UAGGUAGUUUCCUGUUGUUGGG 22 eca-miR-196b 1.20E-126 13.19 
U120_5p UAGGUAGUUUCAUGUUGUUGGG 22 eca-miR-196a 1.10E-107 12.37 
U7_5p UACCCUGUAGAUCCGAAUUUGU 22 eca-miR-10a 7.32E-145 11.09 
U174_3p CUAGAAUGAAGCUCCUAGAGG 21 U174_3p 3.78E-69 10.82 
U178_3p CACUAGAAUGUGAGCUAC 18 U178_3p 8.62E-06 10.00 
U7_3p CAAAUUCGUAUCUAGGGGAAU 21 oan-miR-10a-3p 5.00E-46 9.82 
U201_3p UUGCCUGGGCCUCUGGAACCAU 22 U201_3p 2.49E-45 9.79 
U207_3p UCAAGGAGAUCACAGUCUAGU 21 U207_3p 1.20E-41 9.61 
U197_5p UAUAUAUAUAUAUGUACGUAUG 22 tch-miR-1277-5p 2.18E-16 9.43 
U233_3p CACAAUACACGGUCGACCUCU 21 U233_3p 4.26E-17 -8.14 
U130_3p CACAUUACACGGUCGACCUCU 21 eca-miR-323-3p 6.35E-60 -8.42 
U223_3p CAACCUGGAGGACUCCAUGCUGU 23 eca-miR-490-3p 2.36E-20 -8.44 
U108_5p AGAGGCUGGCCGUGAUGAAUUC 22 eca-miR-485-5p 9.38E-37 -8.53 
U9_3p UCGGAUCCGUCUGAGCUUGGCU 22 eca-miR-127 4.43E-106 -8.62 
U214_3p AACACACCUAGUUAACCUCUUU 22 eca-miR-329a 6.31E-24 -8.72 
U160_5p UGUGACUGGUUGACCAGAGGGG 22 eca-miR-134 2.09E-05 -9.95 
U175_3p AUCAUGAUGGGCUCCUCGGUGU 22 eca-miR-433 2.92E-45 -9.98 
U140_3p ACGCCCUUCCCCCCCUUCUUCA 22 eca-miR-1249 8.10E-24 -10.55 
U29_3p AUCACAUUGCCAGGGAUUUCC 21 eca-miR-23a 2.67E-09 -16.50 
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Figure 5.11. Top most differentially expressed miRNAs in EqSO4b vs. EqPalF 
(p adjusted <0.05) ranked by Log2FC (ten most upregulated and ten most 
downregulated). When no match was found in miRBase 20.0, the miRNA maintained 
the internal project annotation (U_number_3p/5p). The x-axis denotes the Log2FC 
between reads from EqSO4b and EqPalF: upregulated miRNAs in EqSO4b have values >0 
and downregulated miRNAs have values <0 
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Figure 5.12. Heat map and hierarchical clustering of the top 50 most 
differentially expressed miRNAs in EqSO4b vs. EqPalF (Adjusted p<0.05) 
ranked by Log2FC (25 most upregulated and 25 most downregulated). When no 
match for a miRNA was found in the database (miRBase) the internal identifier 
generated after harmonising the data, was used instead (U”number”_”3p/5p”). 
Hierarchical clustering was performed using correlation as clustering distance with 
average as the linkage criteria; the tree was ordered by the tightest cluster first. Each 
column represents one replicate (EqPalF_1,_2 and _3 for EqPalF and EqSO4b_1,_2 and 
_3 for EqSO4b). Note that through hierarchical clustering the replicates from each cell 
line are closer to each other than to the counterpart cell line, shown by the short 
branch lengths within both clusters (red arrows) 
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5.3.5. Validation of HTS data using real-time quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) 
To validate the findings from the RNA seq data, qRT-PCR of a subset of miRNAs 
was carried out. Of the 1336 miRNAs (raw data), those that were found to be 
differentially expressed with adjusted p<0.01 in either of the pair-wise 
comparisons were ranked by absolute fold change. A more stringed adjusted p 
value was selected on this occasion as the aim of the qRT-PCR was validation of 
the HTS data. The top 60 differentially expressed miRNAs from each of the three 
pair-wise comparisons were merged into an Excel file. After 59 duplicates (i.e. 
miRNAs present on two or more lists) were removed, the remaining 121 miRNAs 
compared to the miRNAs in miRBase using in BLAST+ method described in 
Chapter 2. The criteria for perfect match was more restrictive than the criteria 
selected for discovery of novel miRNAs due to the importance of perfect match 
sequence inherent to the Taqman primers and probes. Only miRNAs with 100% 
identity and 100% coverage to a miRNA in the database within the list of equine 
miRNAs, were selected. Of the 44 miRNAs that had a perfect match to an equine 
miRNA, 37 had a commercially available Taqman® kit. Six miRNAs were selected 
from this list based on biological significance (i.e. associated with other tumours 
and/or linked to HPV-induced cancer) and most representative of changes 
between the three cell lines (i.e. number of reads, presence/absence in the 
three cell lines). For four miRNAs, data on fold changes between EqPalF and S6-2 
obtained using microarray were also available (see Chapter 3; a summary of the 
microarray results for the miRNAs selected for validation is displayed in Table 
5.5). For the other two miRNAs, microarray data were discarded as they were 
regarded as having expression below the background level. The list of six miRNAs 
selected for validation is displayed in Table 5.5. 
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Table 5.5. List of six miRNAs selected for qRT-PCR validation of HTS data 
High throughput sequencing data  Microarray data 
(S6-2 vs. EqPalF) Biological significance 
ID and mature sequence BLAST match* 
EqSO4b vs. EqPalF S6-2 vs. EqPalF S6-2 vs. EqSO4b 
Log2FC  p-adj  Log2FC  p-adj Log2FC  p-adj  Log2FC  p-adj  
U29_3p    
AUCACAUUGCCAGGGAUUUCC eca-miR-23a -16.50 2.67E-09 -0.16 1.00E+00 15.64 1.23E-08 -0.85 7.60E-07 
Exclusive to non tumoural 
equine fibroblasts (EqPalF 
and S6-2). Downregulated in 
HPV induced cancer 
(Honegger et al., 2015) 
U9_3p 
UCGGAUCCGUCUGAGCUUGGCU eca-miR-127 -8.62 4.43E-106 -4.44 5.52E-61 3.50 2.12E-14 -2.13 1.34E-08 
Highly abundant. 
Downregulated in EqSO4b 
and S6-2. Reported 
downregulated in HPV-16 
cervical cancer (Li et al., 
2011) 
U97_5p 
UAGGUAGUUUCCUGUUGUUGGG eca-miR-196b 13.19 1.20E-126 0.00 NA
#
 -12.30 4.00E-96 BBL** BBL** 
Exclusive to EqSO4b. Linked 
to tumorigenesis and 
invasion (Lu et al., 2014) 
U34_3p 
GAAUGUUGCUCGGUGAACCCCU eca-miR-409-3p -6.84 2.21E-76 -2.77 1.06E-26 3.40 2.94E-09 -1.17 5.36E-07 
High read count. Present in 
all cells. Reported 
downregulated in HPV-
16/18 samples (Lajer et al., 
2011) 
U77_3p     
AAUAUAACACAGAUGGCCUGU eca-miR-410 -6.01 1.15E-57 -2.37 4.06E-18 2.98 3.52E-03 BBL** BBL** 
High read count. Present in 
all cells. Reported 
downregulated in HVP-
16/18 samples (Lajer et al., 
2011) 
U140_3p     
ACGCCCUUCCCCCCCUUCUUCA eca-miR-1249 -10.55 8.10E-24 -10.55 3.50E-22 -0.43 1.00E+00 0.10 1.53E-01 
Exclusive to EqPalF and 
linked to TGF-b signalling 
(Vizoso et al., 2015) 
* match= 100% identity, 100% coverage 
**BBL= below background level    
 #
NA= not applicable 
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The results of the qRT-PCR analysis of the six miRNAs selected, comparing the 
expression in EqSO4b and S62 to EqPalF (internal control) using ΔΔCt method (for 
more details please see Chapter 2), and with RNU6 as normalizer, are displayed 
in Figure 5.13.  
Figure 5.13. Histogram of expression of 6 miRNAs in EqSO4b and S6-2 
selected for validation of HTS data using qRT-PCR. Results from HTS (dotted 
outline), qRT-PCR and microarray (only available for S6-2 cells) are displayed using 
EqPalF as control cell line and for qRT-PCR data is reported after normalisation to 
RNU6. Significance was adjusted to p-adj<0.05 
 
qRT-PCR data for four miRNAs (eca-miR-127, eca-miR-196b, eca-miR-409-3p and 
eca-miR-410) successfully validated the HTS results. Of those, eca-miR-127, eca-
miR-409-3p and eca-miR-410 were also downregulated in S6-2 cells compared to 
EqPalF from the previous microarray results (see Chapter 3). These three miRNAs 
have been reported to be downregulated in HPV-induced cancer: miR-127 
downregulation has been found by microarray in tumours containing HPV-16 (Li 
et al., 2011); miR-127, miR-409-3p and miR-410 have been found to be 
downregulated in tumours containing HPV-16/18 (Lajer et al., 2011). 
Interestingly, miR-196b, a miRNA expressed in the same cluster as miR-196a, was 
not detected in EqPalF cells or S6-2 cells by any method and was highly 
expressed in EqSO4b cells as measured by both HTS and qRT-PCR. Discrepancies 
 
 
158 
in the levels of expression of miRNAs between HTS and qRT-PCR were found for 
eca-miR-23a and eca-miR-1249.  
5.3.6. Differential expression of miRNAs commonly dysregulated 
in BPV-1 positive equine fibroblasts (S6-2 and EqSO4b) when 
compared to equine primary fibroblasts (EqPalF cells) 
DESeq results 
A total number of 201 miRNA candidates were commonly dysregulated in the 
cells containing BPV-1 genomes (EqSO4b and S6-2) when compared to EqPalF 
cells. In BPV-1 containing cells, 102 mature miRNAs candidates (51%) were found 
to be upregulated and 96 (48%) were found to be downregulated (p<0.05). 
Interestingly, out of the 201 commonly dysregulated miRNAs in BPV-1 positive 
cells, only three miRNAs (<1%) show disparity between the direction of the 
expression (either upregulated or downregulated) in EqSO4b and S6-2 cells. The 
rest (198 miRNAs, 99%) when they were upregulated in EqSO4b they were also 
upregulated in S6-2 cells. Level of expression of the 201 miRNAs had a positive 
and high correlation between the two cell lines containing BPV-1 genomes 
(Pearson’s coefficient 0.91). Linear correlation of the level of expression (log10 
transformed) of each of the 201 miRNAs is displayed in Figure 5.14. The top 25 
most upregulated and top 25 most downregulated miRNAs in BPV-1 positive cells 
when compared to EqPalF is displayed in the heat map in Figure 5.15. The list of 
the top ten most up and ten most downregulated miRNAs is presented in Table 
5.6. 
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Figure 5.14. Correlation of expression of 201 miRNAs found 
dysregulated in BPV + cell lines when compared to control cell 
line. Each point in the graph corresponds to a miRNA with two 
coordinates: x-axis is the expression of this miRNA registered in S6-2 
cells and y-axis is the expression of this miRNA registered in EqSO4b 
cells 
 
 
 
Figure 5.15. Heat map and hierarchical clustering of the top 50 
most differentially expressed miRNAs in BPV-1 positive cells (S6-2 
and EqSO4b) vs. EqPalF (p adjusted <0.05) ranked by log2FC (25 
most upregulated and 25 most downregulated). When no match for 
a miRNA was found in the database (miRBase 20.0) the internal identifier 
generated after harmonising the data, was used instead (Uxx-3p or 5p). 
Hierarchical clustering was performed using correlation as clustering 
distance between rows and columns, using the average as the linkage 
criteria and the tree was ordered by the tightest cluster first. Each column 
represents one replicate of each cell line. Note that through hierarchical 
clustering the replicates from each cell line are closer to each other than 
to the different cell line, and that the S6-2 replicates are closer EqSO4b 
than to EqPalF (see purple arrow)
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Table 5.6. List of the top 10 most upregulated and most downregulated miRNA candidates in BPV positive cells (p<0.05). miRNAs 
have been ranked by Log2FC in EqSO4b vs. EqPalF cells. miRNAs with annotation U”number”_”5p”/”3p” were miRNAs with no match on the 
database. ECA signifies equine chromosome 
 
 
 
 
ID Mature sequence Annotation ECA Log2FC EqSO4b vs. EqPalF Log2FC S6-2 vs. EqPalF 
  U7_5p UACCCUGUAGAUCCGAAUUUGU eca-miR-10a 11 11.09 2.39 
U174_3p CUAGAAUGAAGCUCCUAGAGG U174_3p 5 10.82 9.95 
U201_3p UUGCCUGGGCCUCUGGAACCAU U201_3p 1 9.79 9.76 
U207_3p UCAAGGAGAUCACAGUCUAGU U207_3p 5 9.61 9.11 
U143_3p AUCAACAAACAUUUAUUGUGUGC eca-miR-545 X 7.33 5.81 
U316_3p ACAAAAGUCUGCACAUUGGA U316_3p 10 6.85 6.49 
U322_5p UUAAGACUUGCAGUGAUGUUU eca-miR-499-5p 22 6.66 6.33 
U359_3p ACUGGACUUGGAGUCUGAAA hsa-miR-378d 24 6.28 5.6 
U301_5p AGCCAGCUUGAGCCCACCUACAU U301_5p 8 6.21 6.51 
U370_5p UCCGCGGAUUGAACCAGCCACG U370_5p 18 6.04 5.31 
U245_5p CUGCUUUGCUCCCACUUUGUCCU U245_5p 19 -7.67 -1.99 
U184_5p GUGGUUAUCCCUGCUGUGUUCG hsa-miR-487a-5p 24 -7.8 -3.49 
U240_3p UGAGUAUUACAUGGCCAAUCUC eca-miR-496 24 -7.8 -2.14 
U233_3p CACAAUACACGGUCGACCUCU U233_3p 24 -8.14 -3.07 
U130_3p CACAUUACACGGUCGACCUCU eca-miR-323-3p 24 -8.42 -2.87 
U108_5p AGAGGCUGGCCGUGAUGAAUUC eca-miR-485-5p 24 -8.53 -2.43 
U9_3p UCGGAUCCGUCUGAGCUUGGCU eca-miR-127 24 -8.62 -4.44 
U214_3p AACACACCUAGUUAACCUCUUU eca-miR-329a 24 -8.72 -2.65 
U175_3p AUCAUGAUGGGCUCCUCGGUGU eca-miR-433 24 -9.98 -3.03 
U140_3p ACGCCCUUCCCCCCCUUCUUCA eca-miR-1249 28 -10.55 -10.55 
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The differences were explored in more detail between the two BPV+ cell lines. 
Out of 102 commonly upregulated miRNA candidates in BPV-1 positive cells, two 
thirds (66%, 67 miRNAs) showed no significant difference in expression when 
comparing EqSO4b and S6-2, whereas 20% (20 miRNAs) were significantly higher 
in EqSO4b cells. Amongst the upregulated miRNAs with significantly higher 
expression in EqSO4b there were several members of the miR-17~92 cluster 
(miR-17, 19a, 19b, 92a). 
Out of the 96 commonly downregulated miRNA candidates in BPV-1 positive 
cells, half (50%, 48 miRNAs) were not found to be significantly different between 
the two cell lines. The remaining 48 miRNAs were most often downregulated in 
EqSO4b (43 miRNAs downregulated, 5 miRNAs upregulated). In the group of 
downregulated with significantly lower expression in EqSO4b there were multiple 
miRNAs that were encoded within the same cluster (genomic region of 3Kbp).  
In total, 21 miRNAs were found to be encoded in seven clusters, interestingly in 
chromosome 24 (ECA24). ECA24 was found to be the chromosome with higher 
density of miRNAs and higher number of miRNAs in equine primary fibroblasts 
(please see Chapter 4). Details of clustered miRNAs are displayed in Table 5.7.  
Table 5.7. List of 21 miRNAs found downregulated in BPV-1 positive cells that 
were significantly lower in tumoural cells and encoded in 7 clusters 
Internal ID Mature sequence ECA Annotation Cluster 
U9_3p UCGGAUCCGUCUGAGCUUGGCU 24 eca-miR-127 
1 U96_5p UCUUGGAGUAGGUCAUUGGGUGG 24 eca-miR-432 
U175_3p AUCAUGAUGGGCUCCUCGGUGU 24 eca-miR-433 
U105_5p UGGUUUACCGUCCCACAUACAU 24 hsa-miR-299-5p 
2 
U133_3p UAUGUAACAUGGUCCACUAAC 24 mml-miR-379-3p 
U122_3p UAUGUAAUAUGGUCCACGUCU 24 eca-miR-380 
U40_3p UAUGUAACACGGUCCACUAAC 24 mml-miR-411-3p 
U130_3p CACAUUACACGGUCGACCUCU 24 eca-miR-323-3p 
3 U233_3p CACAAUACACGGUCGACCUCU 24 U233_3p 
U176_3p AACGAACCUGGUUAACCUCU 24 ggo-miR-329b 
U146_3p AAACAAACAUGGUGCACUUCUU 24 eca-miR-495 
4 
U180_3p AAACAUUCGCGGUGCACUUCUU 24 eca-miR-543 
U148_5p GAAGUUGUUCGUGGUGGAUUCG 24 eca-miR-382 
5 U108_3p GUCAUACACGGCUCUCCUCUCU 24 eca-miR-485-3p 
U108_5p AGAGGCUGGCCGUGAUGAAUUC 24 eca-miR-485-5p 
U165_5p AGAGGUCUUCCAUGAUGCAUUCG 24 oar-miR-154b-5p 
6 U196_5p AGAGGUUGCCCUUGGUGAAUUC 24 hsa-miR-377-5p 
U240_3p UGAGUAUUACAUGGCCAAUCUC 24 eca-miR-496 
U34_3p GAAUGUUGCUCGGUGAACCCCU 24 eca-miR-409-3p 
7 U194_5p UGGUCGACCAGUUGGAAAGUAAU 24 eca-miR-412 
U203_5p AAAGGAUUCUGCUGUCGGUCCCACU 24 hsa-miR-541-5p 
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Other miRNAs of interest in the list of downregulated miRNAs in BPV-1 positive 
cells were miR-181a, miR-181b and miR-204b. As previously mentioned, miR-
181a (U4_5p) and miR-181b (U44_5p) have been reported to be downregulated in 
HPV-16/-18 positive cell cultures with the use of microarray and qRT-PCR (Lajer 
et al., 2011; Wald et al., 2011) and they are encoded in a region of ECA25 
recently reported to be associated with the development of ES (Jandova et al., 
2012). miR-204b (U_72_5p) has been reported to be downregulated in cervical 
cancer using HTS (Witten et al., 2010) and it is encoded in equine fibroblasts 
very close to one of the regions recently identified as deleted and linked to ES 
(Bugno-Poniewierska et al., 2016). 
Comparison of HTS data with microarray and miRNAs previously reported to be 
dysregulated in HPV 
When the 201 miRNA candidates found dysregulated in BPV-1 positive cells 
compared to EqPalF cells using HTS were compared to previous data from the 
microarray (comparing S6-2 cells to EqPalF cells, see Chapter 3), a total of 52 
miRNAs had information from both technologies. The remaining 149 were either 
not interrogated by microarray or showed levels below background detection. 
Just over one third of the miRNAs where data was available from both methods 
(34%, 17 miRNAs) had results that agreed in HTS and microarray. Three of those 
were also assessed using SYBR green - qRT-PCR as part of the validation of 
microarray data (miR-181a and miR-15b; see Chapter 3, section 3.3.3.) or 
Taqman® – qRT-PCR as part of the validation of HTS data (miR-127, see previous 
section 5.3.5). miR-181a and miR-127 were shown to be downregulated in BPV-1 
positive cells, in agreement with both HTS and microarray, whereas miR-15b was 
found to be upregulated using qRT-PCR and downregulated in HTS and 
microarray.  
When the 17 miRNAs (where information was available for both HTS and 
microarray), were compared to a database generated for the current study from 
13 experimental papers on HPV related cancer and/or high-risk HPV cell cultures 
both from in vitro and ex vivo studies and four review papers (Wang et al., 2008; 
Pereira et al., 2010; Witten et al., 2010; Greco et al., 2011; Li et al., 2011; 
McBee et al., 2011; Wald et al., 2011; Yeung et al., 2011; Zheng & Wang, 2011; 
Lajer et al., 2012; Gocze et al., 2013; Gómez-Gómez et al., 2013; Sharma et 
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al., 2014; Wang et al., 2014b; Ben et al., 2015; Honegger et al., 2015; Wang et 
al., 2016), nine of those were also found dysregulated in HPV studies, of which 
six were dysregulated in HPV and BPV (U11_5p, U30_5p, U4_5p, U44_5p, U72_5p 
and U9_3p).Three out of the six dysregulated in HPV were found to be encoded 
in genomic regions previously linked to equine sarcoids (U4_5p, U44_5p and 
U72_5p) (Jandova et al., 2012; Bugno-Poniewierska et al., 2016). Details on the 
17 miRNAs are displayed in Table 5.8.
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Table 5.8. List of 17 miRNAs found dysregulated in BPV-1 + cells in the current study using HTS and microarray. Out of the 17, 9 
were reported to be dysregulated in the literature in HPV related disease/cancer and six were dysregulated in the same way as reported in HPV. It 
is worth noting that some studies on microRNA in HPV show disparity of results. miRNAs highlighted in grey are encoded in regions of the equine 
genome reported to be linked to equine sarcoids 
ID Mature sequence ECA Annotation 
Result in HTS and 
microarray Results database (16 studies) 
U105_5p UGGUUUACCGUCCCACAUACAU 24 hsa-miR-299-5p downregulated in BPV-1 + Not on HPV database 
U108_3p GUCAUACACGGCUCUCCUCUCU 24 eca-miR-485-3p downregulated in BPV-1 + Not on HPV database 
U11_5p CAACGGAAUCCCAAAAGCAGCUG 16 eca-miR-191a downregulated in BPV-1 + 
Low in CC and HPV+ cell line using microarray (Wang et al., 
2008) 
U148_5p GAAGUUGUUCGUGGUGGAUUCG 24 eca-miR-382 downregulated in BPV-1 + Not on HPV database 
U30_5p UGAGGGGCAGAGAGCGAGACUUU 11 eca-miR-423-5p downregulated in BPV-1 + 
Low in HPV-16/18 cell line using microarray and qRT-PCR 
(Lajer et al., 2012) 
U34_3p GAAUGUUGCUCGGUGAACCCCU 24 eca-miR-409-3p downregulated in BPV-1 + Not on HPV database 
U4_5p AACAUUCAACGCUGUCGGUGAGU 25 eca-miR-181a downregulated in BPV-1 + 
High in HPV + monolayer culture but low in HPV + raft tissues 
using microarray (Wang et al., 2008), low in HPV-16 cell line 
using microarray and qRT-PCR (Wald et al., 2011), low in HPV-
16/18 cell line using microarray and qRT-PCR (Lajer et al., 
2011). Encoded in ECA25, region associated with equine 
sarcoids (Jandova et al., 2012) 
U44_5p AACAUUCAUUGCUGUCGGUGGGU 25 eca-miR-181b downregulated in BPV-1 + 
High in HPV + monolayer culture but low in HPV + raft tissues 
using microarray (Wang et al., 2008); low in HPV-16 cell line 
using microarray and qRT-PCR (Wald et al., 2011), low in HPV-
16/18 cell line using microarray and qRT-PCR (Lajer et al., 
2012). Encoded in ECA25, region associated with equine 
sarcoids (Jandova et al., 2012) 
U58_5p UAGCAGCACAUCAUGGUUUACA 5 eca-miR-15b downregulated in BPV-1 + 
High in CC using microarray (Wang et al., 2008); high in HPV-
16 SCC using microarray and qRT-PCR (Li et al., 2011) and 
high in HPV-16/18 cell line (Lajer et al., 2012) 
U64_3p UAACAGUCUACAGCCAUGGUCG 11 eca-miR-132 downregulated in BPV-1 + High in CC HPV-16/18 using microarray (Pereira et al., 2010) 
U72_5p UUCCCUUUGUCAUCCUAUGCCU 23 eca-miR-204b downregulated in BPV-1 + 
Low in cancer tissue RNA seq (Witten et al., 2010). Encoded 
in ECA 23 very close to the region recently identified as 
deleted and linked to ES (Bugno-Poniewierska et al., 2016) 
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(Continuation Table 5.8) 
U73_5p UGGGUCUUUGCGGGCGAGAUGA 11 eca-miR-193a-5p downregulated in BPV-1 + Not on HPV database 
U9_3p UCGGAUCCGUCUGAGCUUGGCU 24 eca-miR-127 downregulated in BPV-1 + 
Low in CC lesions using microarray (Wang et al., 2008) and microarray 
and qRT-PCR (Li et al., 2011) 
U96_5p UCUUGGAGUAGGUCAUUGGGUGG 24 eca-miR-432 downregulated in BPV-1 + Not on HPV database 
U100_3p UAGCACCAUUUGAAAUCAGUGUU 4 eca-miR-29b upregulated in BPV-1 + Not on HPV database 
U158_3p UGUGACAGAUUGAUAACUGAAA X eca-miR-542-3p upregulated in BPV-1 + Not on HPV database 
U76_5p AACCCGUAGAUCCGAUCUUGUG 26 eca-miR-99a upregulated in BPV-1 + 
Low in CC using microarray (Wang et al., 2008; Pereira et al., 2010), 
using microarray and qRT-PCR (Li et al., 2011), low in HPV-16/18 cell line 
using microarray and qRT-PCR (Lajer et al., 2012) 
 
 
 
 
 
1
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5.3.7. miRNAs dysregulated in tumoural equine fibroblasts but 
not in BPV-1 transformed cells 
When compared with control cells (EqPalF), a total number of 329 miRNAs 
were found to be dysregulated (either up or down) in EqSO4b cells (see section 
5.3.4). Of those, 201 were dysregulated in both EqSO4b and S6-2 cells when 
compared to EqPalF. The rest, 128 miRNA candidates were dysregulated in 
EqSO4b but not in S6-2 when compared to EqPalF. Out of 128 miRNA 
candidates, 63 (49%) miRNAs were downregulated and 65 miRNAs were 
upregulated (51%) in EqSO4b cells when compared to EqPalF cells.  
In the list of downregulated miRNAs, U22_5p (eca-miR-145) and U24_3p (eca-
miR-23b) were of particular interest. These miRNAs have been reported to be 
linked to HR-HPV cancer: miR-145 has been reported to be downregulated in 
vitro (Wang et al., 2008) and ex vivo (Pereira et al., 2010; Li et al., 2011) due 
to HR-HPV E6 mediated downregulation of p53; and miR-23b has been reported 
to be downregulated via HPV-16 E5 and E6 oncoproteins (Greco et al., 2011; 
Yeung et al., 2011; Honegger et al., 2015). Amongst the 65 upregulated 
miRNAs, several have been reported to be upregulated in HR-HPV-induced 
cancer in in vitro and ex vivo studies. Of particular interest are U16_5p (miR-
16) and U120_5p (miR-196a), which were upregulated in HR-HPV cancer via E7 
oncoprotein (Wang et al., 2008; Pereira et al., 2010; Li et al., 2011; Lajer et 
al., 2012; Gocze et al., 2013). A list of the miRNAs dysregulated in EqSO4b in 
the same direction as in studies on HR-HPV related cancer and the references 
for these studies, are displayed in Table 5.9. 
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Table 5.9. List of miRNAs that were found dysregulated in tumoural equine 
fibroblasts and HPV-induced cancer 
Internal 
ID Annotation 
Expression in 
EqSo4b (vs.EqPalF) 
Studies showing same direction of 
expression change of this miRNA in HPV-
16/-18 induced cancer 
U14_5p eca-miR-125a-5p Downregulated  Wang et al. (2008) 
U121_3p eca-miR-133a Downregulated  Wang et al. (2008) 
U22_5p eca-miR-145 Downregulated 
 Wang et al. (2008); Pereira et al. (2010); 
Li et al. (2011) 
U24_3p eca-miR-23b Downregulated 
 Greco et al. (2011); Yeung et al. (2011); 
Honegger et al. (2015) 
U5_5p hsa-miR-27b-5p Downregulated  Wang et al. (2008) 
U225_5p eca-miR-539 Downregulated  Greco et al. (2011) 
U18_5p eca-let-7a Upregulated  Wang et al. (2008) 
U92_5p eca-miR-106a Upregulated 
 Wang et al. (2008); Pereira et al. (2010); 
Li et al. (2011); Lajer et al. (2012) 
U7_3p oan-miR-10a-3p Upregulated  Wang et al. (2008); Pereira et al. (2010) 
U126_3p eca-miR-130b Upregulated  Lajer et al. (2012) 
U227_3p bta-miR-142-3p Upregulated  Witten et al. (2010) 
U227_5p eca-miR-142-5p Upregulated  Pereira et al. (2010) 
U78_5p eca-miR-146b-5p Upregulated  Wang et al. (2008); Lajer et al. (2012) 
U28_3p eca-miR-148a Upregulated  Wang et al. (2008); Pereira et al. (2010) 
U16_3p gga-miR-16-1-3p Upregulated 
 Wang et al. (2008); Pereira et al. (2010); 
Li et al. (2011); McBee et al. (2011); Lajer 
et al. (2012) 
U173_5p eca-miR-192 Upregulated  McBee et al. (2011) 
U120_5p eca-miR-196a Upregulated  Pereira et al. (2010); Gocze et al. (2013) 
U115_3p mml-miR-20a-3p Upregulated  Wang et al. (2008); Li et al. (2011) 
U17_5p mmu-miR-221-5p Upregulated 
 Wang et al. (2008); Li et al. (2011); Gocze 
et al. (2013) 
U229_5p eca-miR-7 Upregulated  Li et al. (2011) 
U55_5p eca-miR-93 Upregulated 
 Wang et al. (2008); Li et al. (2011); Lajer 
et al. (2012) 
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5.3.8. Functional analysis of miRNAs dysregulated in the in vitro 
equine sarcoid model 
Functional analysis on the miRNAs associated with the presence of BPV + and 
up or downregulated in S6-2 and EqSO4b cells was carried out using Ingenuity 
Pathway Analysis (IPA). For this purpose the sequences of the miRNAs found to 
be dysregulated were matched with any human or mouse miRNAs in miRBase 
20.0 to obtain a numerical annotation (MIMAxxxxx) of the homologous miRNA in 
those species with a tolerance of two mismatches.  
Out of 329 miRNAs dysregulated in EqSO4b cells and 251 in S6-2 cells compared 
to EqPalF, the software recognised 173 and 103 miRNAs respectively. The 
number of miRNAs mapped to the IPA database did not retrieve any 
information on canonical pathways or upstream analysis. However, when using 
core analysis, the top networks associated with the dysregulated miRNAs in 
tumoural cells were: reproductive system disease (Cancer), reproductive 
system disease (cellular development) and connective tissue disorders and 
cellular development-growth and proliferation (cancer). The top molecular and 
cellular functions were cellular development (36 molecules), cellular growth 
and proliferation (33 molecules), cell cycle (16 molecules), cellular movement 
(20 molecules) and DNA repair (eight molecules). Similarly, the top networks 
associated with the dysregulated miRNAs in BPV-1 transformed cells were: 
reproductive system disease (cancer), reproductive and connective tissue 
disorders (organismal injury and abnormalities) and connective tissue disorders 
(cancer). The top molecular and cellular functions were cellular development 
(32 molecules), cellular growth and proliferation (34 molecules), cell cycle (14 
molecules), cellular movement (17 molecules) and cell death and survival (23 
molecules). The list of diseases, functions and networks from both comparisons 
(EqSO4b vs. EqPalF and S6-2 vs. EqPalF) are displayed in Tables 5.10 and 5.11.  
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Table 5.10. Diseases, functions and networks obtained from pathway 
analysis from the miRNAs dysregulated in EqSO4b vs EqPalF (using Ingenuity 
Pathway Analysis software) 
Top diseases and biofunctions 
Diseases and disorders p-value range  Number of molecules 
Organismal injury and abnormalities 4.70E-02 6.92E-44 94 
Reproductive system disease 3.41E-02 6.92E-44 62 
Cancer 4.70E-02 7.61E-32 70 
Gastrointestinal disease 3.26E-02 2.70E-27 48 
 Molecular and cellular functions p-value range  Number of molecules 
Cellular development 4.72E-02 1.92E-06 36 
Cellular growth and proliferation 4.72E-02 1.92E-06 33 
Cell cycle 4.70E-02 2.45E-05 16 
Cellular movement 3.67E-02 8.69E-05 20 
DNA replication, recombination and repair 4.33E-02 6.19E-04 8 
 Physiological system development and function p-value range  Number of molecules 
Organismal development 6.48E-03 1.23E-07 7 
Connective tissue development and function 1.59E-02 2.45E-05 6 
    Top networks Score 
Organismal injury and abnormalities, reproductive system disease, cancer 60 
Organismal injury and abnormalities, reproductive system disease, cellular development 35 
Developmental disorder, hereditary disorder, organismal functions 28 
Cancer, connective tissue disorders, organismal injury and abnormalities 24 
Cellular development, cellular growth and proliferation, cancer 24 
 
Table 5.11. Diseases, functions and networks obtained from pathway 
analysis from the miRNAs dysregulated in S6-2 vs EqPalF (using Ingenuity 
Pathway Analysis software) 
Top diseases and biofunctions 
Diseases and disorders p-value range  Number of molecules 
Organismal injury and abnormalities 4.85E-02 7.29E-41 84 
Reproductive system disease 1.71E-02 7.29E-02 56 
Cancer 4.85E-02 4.38E-30 66 
Gastrointestinal disease 4.78E-02 2.61E-29 55 
 Molecular and cellular functions p-value range  Number of molecules 
Cellular development 4.75E-02 5.18E-08 32 
Cellular growth and proliferation 4.75E-02 5.18E-08 34 
Cell cycle 3.82E-02 1.06E-05 14 
Cellular movement 2.98E-02 3.15E-05 17 
Cell death and survival 4.65E-02 1.10E-04 23 
 Physiological system development and function p-value range  Number of molecules 
Organismal development 3.77E-02 4.22E-08 6 
Connective tissue development and function 2.56E-02 1.06E-05 5 
    Top networks Score 
Organismal injury and abnormalities, reproductive system disease, cancer  64 
 25 
2564 
Organismal injury and abnormalities, reproductive system disease, connective tissue 
disorders 
 25 
  
25 
Organismal injury and abnormalities, reproductive system disease, developmental disorders  25 
  
25 
Cancer, connective tissue dissorders, organismal injury and abnormalities  24 
  
24 
Cancer, organismal injury and abnormalities, gastrointestinal disease  24 
  
24 
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As only the miRNAs with homologous human or mice could be used for 
functional analysis, and only miRNAs previously added to the database of the 
software are recognised, the list of top ten miRNAs most up and downregulated 
identified by the IPA software was dissimilar to the lists displayed in Tables 
5.3. and Table 5.4.  The top ten miRNAs most up and downregulated from the 
list uploaded in IPA are listed in Table 5.12 and Table 5.13. Of those, it is 
worth noting that miR-151-3p/5p, miR-499-5p and miR-92a-3p were found in 
the top most upregulated in both comparisons and that miR-127-3p, miR-487a-
5p and miR-485-3p were found in the top 10 most downregulated in both 
comparisons. Other miRNAs of interest are miR-196a-5p, mir-23 precursor and 
miR-485 as they were found to be involved in multiple networks: organismal 
injury abnormalities-reproductive system disease-cancer and organismal injury 
and abnormalities-reproductive system disease-cellular development and 
cancer, connective tissue disorders, organismal injury and abnormalities (mir-
23 and mature forms); and organismal injury abnormalities-reproductive 
system disease-cancer and organismal injury and abnormalities-reproductive 
system disease-cellular development (miR-196a-5p and miR-485).  
Other miRNAs not in the top most up or downregulated of the software IPA but 
found of interest were miR-181, miR-29b, miR-10b and miR-127 as they are in 
the list of molecules that are dysregulated in the networks associated with 
developmental disorder-hereditary disorder-organismal functions and cancer-
connective tissue disorders-organismal injury and abnormalities.  
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Table 5.12. List of top ten up and downregulated miRNAs 
identified during pathway analysis of miRNAs found 
dysregulated between EqSO4b cells and EqPalF cells. The 
software recognised 173 out of the 329 miRNAs found differentially 
expressed (adj p<0.05) 
 
Table 5.13. List of top ten up and downregulated miRNAs 
identified during pathway analysis of miRNAs found 
dysregulated between S6-2 cells and EqPalF cells. The software 
recognised 103 out of the 251 miRNAs found differentially expressed 
(p<0.05)
     
 
 
 
Upregulated 
miR-196a-5p (and other miRNAs w/seed AGGUAGU) 
miR-151-3p (and other miRNAs w/seed UAGACUG)  
miR-151-5p (and other miRNAs w/seed CGAGGAG) 
miR-196a-3p (miRNAs w/seed GGCAACA)  
miR-499-5p (and other miRNAs w/seed UAAGACU)  
miR-378a-3p (and other miRNAs w/seed CUGGACU)  
miR-497-3p (and other miRNAs w/seed AAACCAC)  
miR-92a-3p (and other miRNAs w/seed AUUGCAC) 
miR-16-5p (and other miRNAs w/seed AGCAGCA) 
miR-3613-5p (miRNAs w/seed GUUGUAC)  
Downregulated 
miR-23a-3p (and other miRNAs w/seed UCACAUU)  
miR-1249-3p (and other miRNAs w/seed CGCCCUU)  
miR-433-3p (miRNAs w/seed UCAUGAU) 
miR-3118 (and other miRNAs w/seed GUGACUG)  
miR-127-3p (miRNAs w/seed CGGAUCC) 
miR-485-5p (and other miRNAs w/seed GAGGCUG)  
miR-323-3p (and other miRNAs w/seed ACAUUAC) 
miR-503-3p (and other miRNAs w/seed GAGUAUU)  
miR-487a-5p (and other miRNAs w/seed UGGUUAU) 
miR-485-3p (and other miRNAs w/seed UCAUACA) 
Upregulated 
miR-151-3p (and other miRNAs w/seed UAGACUG)  
miR-151-5p (and other miRNAs w/seed CGAGGAG) 
miR-802-5p (miRNAs w/seed CAGUAAC)  
miR-499-5p (and other miRNAs w/seed UAAGACU)  
miR-378a-3p (and other miRNAs w/seed CUGGACU)  
let-7a-3p (and other miRNAs w/seed UAUACAA)  
miR-92a-3p (and other miRNAs w/seed AUUGCAC) 
miR-1-3p (and other miRNAs w/seed GGAAUGU)  
miR-590-3p (miRNAs w/seed AAUUUUA) 
miR-143-5p (and other miRNAs w/seed GUGCAGU) 
Downregulated 
miR-1249-3p (and other miRNAs w/seed CGCCCUU)  
miR-146a-5p (and other miRNAs w/seed GAGAACU)  
miR-184 (and other miRNAs w/seed GGACGGA)  
miR-122-5p (miRNAs w/seed GGAGUGU)  
miR-224-5p (miRNAs w/seed AAGUCAC) 
miR-127-3p (miRNAs w/seed CGGAUCC) 
miR-370-5p (and other miRNAs w/seed AGGUCAC)  
miR-708-5p (and other miRNAs w/seed AGGAGCU) 
miR-485-3p (and other miRNAs w/seed UCAUACA)  
miR-487a-5p (and other miRNAs w/seed UGGUUAU) 
1
7
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5.3.9. Biomarker study 
Using the list of differentially expressed miRNAs between S6-2 cells vs. EqPalF 
and EqSO4b vs. EqPalF, the linear discriminant analysis (LDA) effect size tool 
(LEfSe, Galaxy, https://huttenhower.sph.harvard.edu/galaxy), identified 59 
potential biomarkers for BPV-1 (Table 5.14) and 47 potential biomarkers for 
tumoural cells (tumoural vs. primary, Table 5.15). Examples of the relative 
expression levels of some miRNAs as biomarkers for BPV-1 and miRNAs as 
biomarkers for tumoural phenotype in the three cell lines of the ES in vitro 
model are presented in Figure 5.16. and 5.17. respectively. The mature 
sequence or the annotation name/number from miRBase is not relevant for this 
type of analysis and therefore the biomarker study conducted on LEfSe 
highlighted multiple novel miRNAs as suitable biomarker candidates that could 
not have been included in the functional analysis.  
Table 5.14. List of miRNAs selected as biomarkers for BPV-1 presence 
Internal 
ID Annotation 
Log2FC 
EqSO4b 
vs EqPalF 
Log2FC 
S6-2 vs 
EqPalF 
Direction 
HTS EqSO4b 
vs EqPalF 
Direction 
HTS S6-2 vs 
EqPalF  
Direction 
HTS S6-2 
vs EqSO4b 
U1_3p mmu-miR-21-3p 4.35 2.70 Up Up not DE 
U1_5p eca-miR-21 2.05 2.07 Up Up not DE 
U10_3p eca-miR-92a -1.52 -1.73 Down Down Down 
U105_5p hsa-miR-299-5p -7.59 -2.88 Down Down Up 
U107_5p U107_5p 3.06 3.27 Up Up Up 
U108_3p eca-miR-485-3p -7.62 -3.50 Down Down Up 
U11_5p eca-miR-191a -1.39 -1.30 Down Down Up 
U111_3p eca-miR-454 2.07 2.42 Up Up not DE 
U114_3p eca-miR-483 -3.99 -1.46 Down Down Up 
U117_3p eca-miR-671-3p -1.95 -2.20 Down Down not DE 
U118_5p U118_5p -1.74 -1.57 Down Down not DE 
U122_3p eca-miR-380 -4.83 -1.43 Down Down Up 
U125_5p eca-miR-149 -1.76 -2.60 Down Down not DE 
U129_3p eca-miR-7177b -1.34 -2.56 Down Down Down 
U13_3p eca-miR-222 -0.86 -1.74 Down Down Down 
U130_3p eca-miR-323-3p -8.42 -2.87 Down Down Up 
U16_5p eca-miR-16 1.48 1.19 Up Up not DE 
U20_5p bta-miR-6119-5p 2.27 1.97 Up Up not DE 
U23_5p eca-let-7f 1.73 1.95 Up Up Up 
U27_3p eca-miR-27a 1.98 1.83 Up Up Down 
U3_5p eca-miR-10b 2.45 -1.21 Up Down Down 
U30_5p eca-miR-423-5p -1.87 -1.41 Down Down Up 
U34_3p eca-miR-409-3p -6.84 -2.77 Down Down Up 
U36_3p hsa-let-7d-3p -1.88 -1.29 Down Down not DE 
U37_5p eca-miR-30e 2.72 2.77 Up Up Up 
U4_3p efu-miR-181f -3.03 -2.25 Down Down not DE 
U4_5p eca-miR-181a -2.57 -1.36 Down Down Up 
U40_3p mml-miR-411-3p -5.70 -1.87 Down Down Up 
U41_3p eca-miR-101 3.19 1.90 Up Up Down 
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U43_3p eca-miR-193b -1.11 -1.01 Down Down not DE 
U44_5p eca-miR-181b -2.00 -1.27 Down Down Up 
U47_5p eca-miR-340-5p 3.26 2.28 Up Up not DE 
U51_5p eca-let-7g 1.59 1.79 Up Up Up 
U53_5p bta-miR-6529a -2.38 -1.07 Down Down Up 
U54_3p eca-miR-301a 3.29 3.03 Up Up Down 
U56_3p eca-miR-532-3p -1.27 -1.28 Down Down not DE 
U58_5p eca-miR-15b -1.85 -1.99 Down Down not DE 
U59_5p eca-miR-1388 2.59 2.35 Up Up not DE 
U6_3p eca-miR-199a-3p 1.50 1.48 Up Up not DE 
U6_5p eca-miR-199b-5p 1.96 1.86 Up Up not DE 
U60_5p eca-miR-15a 2.70 1.96 Up Up not DE 
U61_3p eca-miR-197 -1.85 -1.54 Down Down not DE 
U64_3p eca-miR-132 -4.21 -1.79 Down Down not DE 
U66_3p eca-miR-342-3p -1.17 -1.11 Down Down not DE 
U67_5p eca-miR-98 2.50 2.33 Up Up not DE 
U68_5p bta-miR-1260b -3.48 -1.62 Down Down Up 
U72_5p eca-miR-204b -2.38 -1.81 Down Down Up 
U73_3p eca-miR-193a-3p 3.20 2.46 Up Up not DE 
U73_5p eca-miR-193a-5p -2.32 -1.17 Down Down Up 
U74_5p hsa-miR-128-1-5p -1.76 -2.14 Down Down not DE 
U77_3p eca-miR-410 -6.01 -2.37 Down Down Up 
U79_5p eca-miR-486-5p -3.75 -2.88 Down Down Up 
U80_3p ssc-miR-374a-3p 2.83 2.34 Up Up Down 
U80_5p eca-miR-374a 1.94 1.92 Up Up not DE 
U82_5p eca-miR-450b-5p 3.71 2.52 Up Up not DE 
U86_3p mml-miR-106b-3p -1.36 -1.60 Down Down Down 
U89_3p eca-miR-3200 -1.64 -1.73 Down Down not DE 
U9_3p eca-miR-127 -8.62 -4.44 Down Down Up 
U96_5p eca-miR-432 -7.19 -2.49 Down Down Up 
 
 
 
 
Table 5.15. List of miRNAs selected as biomarkers for tumoural 
transformation (tumour vs primary cells) 
Internal 
ID Annotation 
Log2FC 
EqSO4b 
vs EqPalF 
Log2FC 
S6-2 vs 
EqPalF 
Direction 
HTS EqSO4b 
vs EqPalF 
Direction 
HTS S6-2 vs 
EqPalF  
Direction 
HTS S6-2 
vs EqSO4b 
U100_3p eca-miR-29b 4.07 2.67 Up Up Down 
U102_3p eca-miR-381 -3.32 0.16 Down not DE Up 
U103_5p eca-miR-450c 3.22 2.14 Up Up not DE 
U109_3p hsa-miR-136-3p -2.47 1.06 Down not DE Up 
U113_3p eca-miR-889 -4.90 -0.51 Down not DE Up 
U119_3p eca-miR-487b -4.72 -0.34 Down not DE Up 
U120_5p eca-miR-196a 12.37 0.00 Up not DE Down 
U121_3p eca-miR-133a -0.93 0.57 Down not DE not DE 
U14_5p eca-miR-125a-5p -0.77 -0.52 Down not DE Up 
U201_3p U201_3p 9.79 9.76 Up Up not DE 
U22_5p eca-miR-145 -2.62 -0.74 Down not DE Up 
U223_5p eca-miR-490-5p -5.14 -1.79 Down not DE not DE 
U24_3p eca-miR-23b -1.69 -0.33 Down not DE not DE 
U26_5p eca-miR-186 1.18 1.25 Up Up Up 
U275_3p U275_3p -7.15 -6.95 Down Down not DE 
U28_3p eca-miR-148a 3.23 1.08 Up not DE Down 
U316_3p U316_3p 6.85 6.49 Up Up not DE 
U32_3p eca-miR-29a 1.16 1.52 Up Up not DE 
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U359_3p hsa-miR-378d 6.28 5.60 Up Up not DE 
U370_5p U370_5p 6.04 5.31 Up Up not DE 
U371_5p eca-miR-9126 5.63 5.08 Up Up not DE 
U40_5p eca-miR-411 -3.77 0.23 Down not DE Up 
U429_5p U429_5p 5.51 3.71 Up not DE not DE 
U435_3p mmu-miR-92a-3p 5.38 4.82 Up Up not DE 
U439_3p U439_3p 5.36 0.00 Up not DE Down 
U45_5p hsa-miR-181c-5p 2.50 1.00 Up Up not DE 
U46_5p eca-miR-30c -0.95 0.28 Down not DE Up 
U49_3p eca-miR-92b -1.78 -0.93 Down not DE not DE 
U491_3p U491_3p 4.58 3.61 Up not DE not DE 
U5_5p hsa-miR-27b-5p -1.01 -0.12 Down not DE Up 
U62_3p eca-miR-365 -1.39 -0.57 Down not DE not DE 
U63_3p eca-miR-130a 1.18 1.47 Up Up not DE 
U65_5p eca-let-7c 1.36 1.63 Up Up Up 
U7_5p eca-miR-10a 11.09 2.39 Up Up Down 
U75_3p eca-miR-19b 2.91 1.93 Up Up Down 
U76_5p eca-miR-99a 1.45 1.86 Up Up Up 
U78_5p eca-miR-146b-5p 2.26 -0.17 Up not DE Down 
U83_3p eca-miR-3958 -5.22 -0.57 Down not DE Up 
U83_5p oar-miR-3958-5p -5.29 -1.44 Down not DE not DE 
U86_5p eca-miR-106b 2.69 1.94 Up Up not DE 
U88_3p eca-miR-615-3p 13.34 3.39 Up not DE Down 
U88_5p eca-miR-615-5p 4.75 0.00 Up not DE not DE 
U91_5p eca-miR-195 5.75 0.82 Up not DE Down 
U93_3p eca-miR-505 -1.10 -0.62 Down not DE not DE 
U97_3p rno-miR-196b-3p 4.76 0.00 Up not DE Down 
U97_5p eca-miR-196b 13.19 0.00 Up not DE Down 
U98_5p eca-miR-497 5.23 0.23 Up not DE Down 
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Figure 5.16. Examples of biomarkers of BPV-1 in equine fibroblasts. 
Histograms 1-4 are examples of miRNAs that equine fibroblasts, in the presence of BPV-
1 genomes, expressed at a low level or undetectable level. Histograms 5-8 are examples 
of miRNAs where presence of BPV-1 genomes was linked to increased expression. Data is 
based on normalised read number from HTS. Average expression from three libraries per 
cell lines is represented as continuous horizontal line and standard deviation is 
represented as dashed line 
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Figure 5.17. Examples of biomarkers of tumoural phenotype in equine 
fibroblasts. Histograms 1-3 are examples of miRNAs that equine fibroblasts, in the 
tumoural phenotype, expressed at a low level or undetectable level. Histograms 4-6 are 
examples of miRNAs of tumoural phenotype linked to increased expression. Data is 
based on normalised read number from HTS. Average expression from three libraries per 
cell line is represented as continuous horizontal line and standard deviation is 
represented as dashed line 
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5.4. Discussion 
In the current chapter, the differences in microRNA profiles associated with ES 
were explored using HTS in three cell lines that represent an in vitro model of 
equine sarcoids, namely EqPalF cells (equine primary fibroblasts), S6-2 cells 
(equine primary fibroblasts in vitro transformed with BPV-1 genomes and 
expressing BPV-1 oncoprotein E5) and EqSO4b cells (equine fibroblasts from a 
naturally occurring sarcoid that have episomal BPV-1 genomes and express BPV-1 
oncoprotein E5) (Yuan et al., 2008a). Bioinformatic tools identified a group of 
putative novel miRNAs in equine fibroblasts (285), miRNAs linked to BPV-1 
presence (201), miRNAs linked to tumoural transformation (128) and miRNAs 
with potential use as biomarkers for the presence of BPV-1 and/or tumoural 
development (106). Novel miRNAs will be submitted to miRBase 
(http://mirbase.org/) to confirm their identity and they will represent an 
important contribution to the scientific community as a resource for further 
studies on equine miRNAs.  
Data obtained from the nine libraries representing the three cell lines was 
considered robust as RNA was of good quality and linear correlation of read 
counts between replicates was strong. Additionally, results for four out of the six 
miRNAs (miR-127, miR-196b, miR-409-3p and miR-410) quantified using Taqman® 
qRT-PCR were in agreement with the results obtained by HTS, quantifying 
differential expression among the three cell lines. MA and PCA plots indicated 
that there is a clear biological differences between the three cell lines, grouping 
EqSO4b and S6-2 together suggesting that the BPV-1 positive cells are more 
similar to each other than to EqPalF (Figures 5.7-5.8). In the pair-wise 
comparisons, the pattern of expression of miRNAs is clearly different between 
EqPalF and the two cell lines that contain BPV-1 genomes, with some miRNAs 
showing substantial differences in levels of expression. In some cases this 
marked upregulation or downregulation was due to the lack of expression or very 
low expression of some miRNAs in one or more of the cell lines. This was the 
case for U120-5p (eca-miR-196a) and U97_5p (eca-miR-196b) that were not 
expressed in S6-2 cells nor EqPalF cells but had over 4,000 reads in EqSO4b 
(average of three libraries). miRNA U154-3p (eca-miR-296) was marginally 
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expressed in EqSO4b and absent in S6-2 cells but had an intermediate level of 
955 reads in EqPalF.  
A higher number of miRNAs were found dysregulated between tumoural cells and 
equine primary fibroblasts (329) than between equine primary fibroblasts in 
vitro transformed with BPV-1 genomes and equine primary fibroblasts (251). This 
is unsurprising as, although the miRNA profile in S6-2 cells and EqSO4b is more 
similar to each other than to EqPalF, S6-2 cells were derived from EqPalF (Yuan 
et al., 2008a). Interestingly, there was strong correlation between the levels of 
expression of dysregulated miRNAs between the two cells lines containing BPV-1 
genomes (please refer to Figure 5.14). In fact, only three miRNAs showed 
differences between the two cell lines. The rest, 198 (99%) were commonly 
regulated in S6-2 and EqSO4b cells. This high degree of correlation indicates that 
BPV-1 is likely to play an important role in miRNA dysregulation in the in vitro 
model of ES utilised in the current study.  
In recent years, multiple HTS studies performed in in vitro and ex vivo HPV-16/-
18 positive specimens highlighted differences associated with HPV infection and 
tumour development (Witten et al., 2010; Greco et al., 2011; Wang et al., 
2014b; Honegger et al., 2015) and many dysregulated miRNAs are known to be 
linked to the expression of HR-HPV oncoproteins (see Table 5.1). Of the miRNAs 
dysregulated in BPV-1 positive cells (201), when compared to primary 
fibroblasts, a similar number were found to be upregulated (102) and 
downregulated (96). The 201 miRNAs commonly dysregulated in BPV-1 positive 
cells compared to equine primary fibroblasts may be attributed to the presence 
of episomal BPV-1 genomes and BPV-1 oncoprotein expression. Of the 201, the 
20 miRNAs that were significantly higher in the tumoural cell line (EqSO4b) and 
the 43 that were significantly lower in the tumoural cell line when compared to 
BPV-1 transformed cells (S6-2), may play an important role in neoplastic 
transformation and cellular pathology associated with tumorigenesis.  
In the group of miRNAs upregulated in BPV-1 positive cells, several members of 
the miR-17~92 cluster were found (miR-17, miR-18a, miR-19a, miR-19b, miR-20 
and miR-92a). Members of this cluster have been reported to be upregulated as 
a consequence of HPV c-Myc and p21 activation and some of them such as miR-
19a, miR-19b and miR-20a, have validated targets that infer tumorigenic activity 
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in HPV-induced cancer (Sharma et al., 2014; Diaz-Gonzalez et al., 2015). It has 
been suggested that upregulation of these miRNAs in HPV-16/-18 induced cancer 
may be related with increased expression of c-Myc due to HR-HPV E7 
oncoprotein activation (Gómez-Gómez et al., 2013). BPV-1 E7 does not have a 
domain to activate pRB directly, which is how HPV-16/-18 E7 activates c-Myc, 
but it can activate p600, a member of the retinoblastoma family (DeMasi et al., 
2005; Corteggio et al., 2011). It is possible that BPV-1 E7 may trigger similar but 
not identical mechanisms to HPV to upregulate these miRNAs. Upregulation of 
another miRNA from this cluster, eca-miR-92a in both BPV-1 positive cell lines, 
may be linked to the expression of BPV-1 oncoproteins since the human 
homologue of eca-miR-92a, hsa-miR-92a is thought to contribute to tumour 
development and is upregulated by HPV-16 E6 (via PTEN protein) (Yu et al., 
2013). Further experiments will be necessary to corroborate how BPV-1 
upregulates some of the members of the miR-17~92 cluster.  
Other miRNAs of interest in the upregulated group were miR-106b, miR-15a, 
miR-16 and miR-21. These four miRNAs have been found to be upregulated in 
HR-HPV induced cancer and have been linked to the expression of HPV 
oncoproteins E6 and E7 (Wang et al., 2008; Pereira et al., 2010; Li et al., 2011; 
Lajer et al., 2012; Wang et al., 2014b). It is unclear whether upregulation of 
miR-106b in HPV occurs via E6 or E7 but it leads to an increase in cell migration 
(Gómez-Gómez et al., 2013). miRNAs from the 15/16 cluster (miR-15a and miR-
16) on the other hand, have been reported to be upregulated via c-Myc, again by 
HPV E7 activation. They are thought to promote angiogenesis and metastasis 
(Myklebust et al., 2011). miR-21 is a well-known oncomiR that has been reported 
to be upregulated in numerous types of neoplasias and in HPV-related cervical 
cancer through the expression of E6 oncoprotein (Ben et al., 2015; Xu et al., 
2015). Excess miR-21 promotes proliferation, cell migration and invasion in 
cervical cancer cells by increasing phosphorylation of Akt and degradation of 
tumour suppressor PTEN (Ben et al., 2015). Further studies are needed to 
ascertain the roles and target genes of miR-106b, miR-15-16 cluster and miR-21 
in BPV-1 tumorigenesis.  
Amongst the 43 most downregulated miRNAs in BPV-1 positive cells when 
compared to equine primary fibroblasts, miR-181a, miR-181b and miR-204b were 
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of particular interest. miR-181a and miR-181b were found to be downregulated 
by both methods (HTS and microarray) in BPV-1 positive cells and miR-181a 
showed the same pattern by qRT-PCR (see section 3.3.3. Chapter 3). 
Importantly, low levels of miR-181a were flagged up by the algorithm in LEfSe as 
a suitable biomarker for BPV-1 presence. Interestingly, the human homologue 
hsa-miR-181a has been reported to be downregulated in HR-HPV in vitro studies 
by microarray and qRT-PCR (Wang et al., 2008; Lajer et al., 2011; Wald et al., 
2011) and there is evidence that HPV-16 inhibits the expression of this miRNA by 
directly preventing its transcription (Lee et al., 2015). What effect reduced 
levels of miR-181a have on fibroblast cells will require further examination, for 
example with the use of miRNA inhibitors. Both miR-181a and b were found to 
be encoded in a region of the equine genome that has been associated with 
increased risk of ES (Jandova et al., 2012).  
miR-204b was also observed to be downregulated in BPV-1 positive cells using 
two techniques (HTS and microarray). The homologue hsa-miR-204b-5p was 
previously reported from HTS data to be downregulated in HR-HPV-induced 
cancer (Witten et al., 2010) although the mechanisms by which this occurs 
remain unknown. A recent genetic study has reported deletions, amplifications 
and polymorphisms associated with predisposition to equine sarcoids (Staiger et 
al., 2016) and some of these mechanisms may explain aberrant expression 
associated with HPV-induced cervical cancer (Sharma et al., 2014). Notably, 
miR-204b is encoded in a region of the equine genome recently identified as 
being deleted in horses with ES (Bugno-Poniewierska et al., 2016). miR-181a/b 
and miR-204 may be examples of deletions triggered by BPV-1 during 
tumorigenesis and may be useful to determine tumorigenic status in ES as they 
appear to be depleted in both BPV-1 transformed and tumoural cells. Further 
studies using clinical samples would help determine the usefulness of these 
miRNAs as biomarkers for ES and to ascertain the mechanisms by which BPV-1 
triggers their downregulation. In addition, biomarkers may help identify whether 
a change in expression of any single miRNA can lead to ES or if dysregulation of 
multiple miRNAs is involved.  
In total, 128 miRNAs were dysregulated in the tumoural cells and not in the BPV-
1 transformed cells (S6-2). Amongst the upregulated miRNAs miR-16-3p, miR-
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106a, miR-20a-3p, miR-196a-3p/5p and miR-196b-3p/5p were of interest. miR-
16-3p is part of cluster miR-15/-16 and miR-20a and miR-106a are part of cluster 
17~92. Other members of these two clusters were found upregulated in both 
BPV-1 positive cells of the ES in vitro model (EqSO4b and S6-2 cells), and both 
clusters have been linked to expression of HPV E6 and E7 oncoproteins in the 
literature as discussed above. Currently it is unclear what the mechanisms are 
behind the upregulation of these clusters in ES but it is likely that they are 
linked to BPV-1 oncoproteins. miR-196a and miR-196b on the other hand are two 
miRNAs that have been linked to tumorigenesis and invasion and reported to be 
upregulated in HPV-induced cancer and suggested as a biomarker for prognosis 
(Pereira et al., 2010; Gocze et al., 2013; Lu et al., 2014; Vojtechova et al., 
2016). Higher expression of miR-196a in HPV-induced cervical cancer has been 
associated with expression of oncoprotein E7 via the PI3K pathway (Pereira et 
al., 2010). Both miR-196a and b have been associated with increased levels of 
MMPs through activation of the NME4-JNK-TIMP1-MMPs pathway in oral cancer, 
and in colon cancer miR-196b has been reported to regulate apoptosis by 
targeting Fas receptor (CD95) (Lu et al., 2014; Mo et al., 2015). In the in vitro 
model used for the current project, EqPalF and S6-2 cells were depleted of miR-
196a and miR-196b. In contrast, levels of miR-196b were shown to be 
significantly upregulated in EqSO4b cells by HTS and qRT-PCR and both miR-196a 
and miR-196b were identified as potential biomarkers for tumoural phenotype by 
the LEfSe algorithm. In ES, the PI3K pathway has been reported to be 
upregulated via activation of PDGFβ-R by BPV-1 E5 and upregulation of MMPs is 
linked to expression of BPV-1 E6 and E7 (Borzacchiello et al., 2009; Yuan et al., 
2010b; Yuan et al., 2011a). It is possible that BPV-1 regulates miR-196a and b in 
a similar way to HPV and it is likely that the upregulation of these miRNAs 
contributes to the upregulation of MMPs registered in ES (Yuan et al., 2010b).  
Amongst the miRNAs downregulated in EqSO4b cells and not in S6-2 cells, miR-
23a, miR-23b and miR-27b-5p were of interest as they form part of a cluster that 
has also been found to be downregulated in HPV-16/-18 induced cancer (Wang et 
al., 2008; Greco et al., 2011; Yeung et al., 2011; Honegger et al., 2015). HPV-16 
E6 decreases the amount of tumour suppressor p53 by degrading it and, as a 
consequence of p53 deactivation and degradation, multiple miRNAs are 
downregulated such as miR-145, miR-23b, miR-218 and miR-34a (McBee et al., 
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2011; Yeung et al., 2011; Shi et al., 2012; Diaz-Gonzalez et al., 2015). A 
decrease in levels of miRNAs such as miR-23b has an effect on cell migration and 
metastasis (Sharma et al., 2014). Although BPV-1 downregulates p53 in a 
different way to HPV, it is likely that mislocation of p53 by BPV-1 E6 will have an 
effect on miRNAs that are regulated by p53 such as miR-23b and therefore 
contribute to the tumoral phenotype seen in EqSO4b cells.  
Functional analysis of the differentially expressed miRNAs in the two BPV-1 
positive cell lines identified almost identical networks, diseases and biofunctions 
for both cell lines. Interestingly these were related to cancer, reproductive 
system (HPV), connective tissue and cellular mechanisms that participate in 
tumorigenesis (such as cell proliferation and cell cycle). The findings of the 
analysis fit with the disease model of ES, although it needs to be said that 
multiple miRNAs were excluded as no homologous annotation was available in 
miRBase 20.0 or they were novel miRNAs. Some of the miRNAs included for IPA 
were ‘transformed’ to their related miRNA in human or mice and the cut-off 
point for mismatches was set at 2 nucleotides (either in length or composition). 
Although some miRNAs could not be included in the analysis and there were 
dissimilarities between the miRNAs found in equine fibroblasts and the miRNAs 
used as the input for IPA analysis, interesting miRNAs were highlighted by the 
software due to their involvement in multiple networks and/or because multiple 
dysregulated miRNAs were members of the same network. Several miRNAs were 
identified by the algorithm of LEfSe as suitable biomarkers for the presence of 
BPV-1 and biomarkers for tumoural phenotype and are presented in section 
5.3.9. LEfSe is a free online tool with the advantage over other tools that it does 
not require the mature sequence of a miRNA or the annotation from miRBAse as 
the calculations are based purely on the levels of expression of the miRNAs. The 
software is not specific for miRNAs and it has been used to suggest potential 
biomarkers in periodontitis, inflammatory bowel disease and cervical cancer 
(Davenport et al., 2014; Szafranski et al., 2015; Dareng et al., 2016). Although 
the list produced by the software identified 59 miRNAs for BPV-1 presence and 
47 miRNAs for tumoural phenotype, several miRNAs showed the same pattern of 
expression (displayed in Figure 5.16 and Figure 5.17). Tumorigenesis is 
associated with changes in expression of multiple miRNAs rather than one unique 
miRNA (Jansson & Lund, 2012; Liu, 2013). Further analysis using clinical tumour 
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samples will be required to assess the utility of the suggested biomarkers in ES 
and perhaps to refine the list based on in vivo expression levels. 
Comparisons to microarray results and to data from previous studies of miRNAs 
in HPV-induce cancer were challenging. Firstly, numerous miRNAs found in BPV-1 
positive equine fibroblasts had no annotation in miRBase (novel miRNA 
candidates). Secondly, differences were present between the nucleotide 
composition and/or length of miRNAs obtained with HTS and the probes used in 
the microarray. Lastly, there is no centralised database for miRNAs dysregulated 
in papillomavirus related diseases. The closest found was HPVbase although this 
database did not include many miRNAs. Four review studies together with the 
results from 13 publications on HR-HPV related cancer dysregulated miRNAs from 
in vitro and ex vivo samples were utilised to construct a database to compare 
the data from HTS obtained from the ES in vitro model from the current study 
(Wang et al., 2008; Pereira et al., 2010; Witten et al., 2010; Greco et al., 2011; 
Li et al., 2011; McBee et al., 2011; Wald et al., 2011; Yeung et al., 2011; Zheng 
& Wang, 2011; Lajer et al., 2012; Gocze et al., 2013; Gómez-Gómez et al., 
2013; Sharma et al., 2014; Wang et al., 2014b; Ben et al., 2015; Honegger et 
al., 2015; Wang et al., 2016). 
Discrepancies between the results obtained by microarray from S6-2 vs. EqPalF 
cells and HTS may be attributable to the differences in sensitivity between 
microarray and HTS as HTS can detect very low levels of expression. The probes 
utilised for microarray were from an external company using equine predicted 
sequences and human sequences and therefore mismatches between these and 
the miRNAs in equine fibroblasts may have reduced the hybridisation signal 
detectable. This type of discrepancy has been recognised in previous studies 
where HPV+ cells/tissues also showed disparity between techniques used to 
assess miRNA expression (reviewed by Sharma et al. (2014)). Additionally, 
although the EqPalF RNA sample for both microarray and HTS was obtained from 
the same culture and RNA extraction (technical replicates), the RNA obtained 
from S6-2 cells for the microarray and for the HTS was from four different cell 
cultures (biological replicates). It is well known that in papillomavirus infection, 
miRNA profile changes with time and miRNAs that may be expressed in low 
amounts in early stages may increase with time or vice versa (Greco et al., 2011; 
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Li et al., 2011). Examples of this effect are miR-106a, miR-92a and miR-375 (Li 
et al., 2011). Despite this, correlation between libraries of each cell line was 
excellent which accounts the robustness of the data present in this chapter.  
Despite difficulties in the comparison between miRNAs found in BPV-1 positive 
cells and HR-HPV studies, and the inherent differences in the tumoural 
transformation induced by each virus (Moody & Laimins, 2010; Corteggio et al., 
2011; Venuti et al., 2011; Gil da Costa & Medeiros, 2014; Munday, 2014), 
multiple miRNAs were found dysregulated in BPV-1 positive cells in the current 
study that were also dysregulated in the database elaborated with information 
from HR-HPV induced cancer studies. This was the case for miR-23b, miR-181a, 
miR-191a, miR-145, miR-204b and miR-409-3p; miR-10a, miR-15a, miR-16 and 
miR-21 that were found downregulated and upregulated respectively in both 
BPV-1 positive equine fibroblasts and HPV-16/-18 in vitro and ex vivo studies 
(Wang et al., 2008; Pereira et al., 2010; Witten et al., 2010; Lajer et al., 2011; 
Li et al., 2011; McBee et al., 2011; Yeung et al., 2011; Lajer et al., 2012; Wang 
et al., 2014b). In other cases such as miR-15b, miR-92a, miR-99a and miR-132, 
opposite direction of dysregulation was noticed between BPV-1 positive cells and 
HPV-16/-18 cancer cell lines and cervical cancer samples (Wang et al., 2008; 
Pereira et al., 2010; Witten et al., 2010; Li et al., 2011; Lajer et al., 2012). 
Regardless of differences in the direction of expression, the comparison to HR-
HPV was useful and suggests that there may be miRNAs regulated in a similar 
manner between BPV-1 in ES and HR-HPV. 
Regarding data analysis, no unique model or pipeline for miRNA description and 
miRNA discovery was found in the literature. Therefore several assumptions 
were made during data mining. In the first place, during pre-processing any 
sequence found five or more times in the equine genome was excluded from the 
analysis. In removing ubiquitous sequences, potential paralogous may have been 
lost. Additionally, for the annotation methods (BLAST and Edit distance, 
described in section 2.5.2, Chapter 2), taking two as a cut-off point to define 
different miRNAs may have introduced errors in annotation. This cut-off point 
was applied after consulting with external companies and assessing the data 
with different cut-off points. It was observed that the majority of the miRNAs 
when compared to miRBase 20.0 were either identical or had up to two or three 
 
 
185 
differences. Where four or more differences in nucleotides (in length or in 
composition) sequences were considered to be unrelated miRNAs to the 
sequence being interrogated. Based on these conclusions, two differences in 
length or composition were set as the limit. This was deemed important since 
functional analysis can only be performed using annotated miRNAs once 
sequence data have been accepted for publication. Following acceptance of the 
752 sequences of miRNAs candidates found in equine fibroblasts by miRBase, 
additional functional analysis will be possible as the tools for functional analysis 
rely on miRNA annotations from the miRBase, either in the form of eca-miR-xx-
5p/3p or MIMA-XXXXX. 
Another limitation found during post-processing was selecting the criteria of 
‘presence of miRNAs in at least two of the replicates of each cell line’ to be 
considered a ‘real’ miRNA, irrespectively of the read count. Some publications 
have used a minimum number of reads but since this study was the first to 
characterise miRNAs expressed in equine fibroblasts, utilising a minimum 
number of reads would have excluded miRNAs expressed at low levels. Presence 
in multiple replicates from the three cell lines rather than a minimum number of 
reads was thought more appropriate in this case, although it would have left out 
miRNAs that were only present in one replicate of each cell line. When the 
distribution of the reads across replicates and cell lines was initially studied, all 
but one of the miRNAs left out by the ‘at least present in two replicates’ filter 
had a read count lower than 1,000, thus supporting the appropriateness 
methodology. 
In summary, this chapter describes the differential expression of miRNAs in an ES 
in vitro sarcoid model with the use of HTS. Results were validated with qRT-PCR 
and compared to previous microarray data and previous studies on miRNAs in HR-
HPV-induced cancer. In total, 285 novel miRNAs were identified and 201 and 128 
miRNAs were found to be linked to BPV-1 presence and tumoural development 
respectively. Further studies assessing potential cellular targets and the role of 
BPV-1 oncoproteins in the dysregulation of these miRNAs will be warranted to 
understand the roles of these miRNAs in the tumorigenesis process. 
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6.1.  Introduction 
In this final discussion, I will review how the aims of this PhD project were met, 
followed by a summary of the major discoveries described in each chapter. I will 
compare the results generated using different techniques and the limitations of 
each approach. Lastly, reflection on how findings from this project have 
contributed to our knowledge of equine miRNAs and equine sarcoids and what 
objectives future work should address, are presented.  
6.2.  How the aims were met, comparative analysis of the 
results and limitations of the approaches used 
This project aimed to improve knowledge of equine miRNAs and provide a better 
understanding of the miRNAs dysregulated in equine sarcoids using an in vitro 
model with BPV-1 transformed equine fibroblasts.  
The miRNA profile in normal equine fibroblasts (EqPalF cells) was assessed using 
two different techniques: microarray and high throughput sequencing (HTS). The 
microarray included probes that would potentially hybridise to predicted equine 
mature miRNAs, human mature miRNAs, and a small number of non-
papillomavirus miRNAs, synthetic miRNAs and small nucleolar RNA sequences. 
This technique was fast and required a very small amount of RNA from the cells 
therefore proved to be useful for an initial identification of miRNAs in equine 
fibroblasts. The drawbacks of the microarray technique were that multiple 
miRNAs with low levels of expression were not detected and the hybridisation 
may have not been as efficient as expected due to sequence differences 
between the expressed and predicted miRNAs on the array. Nevertheless, a total 
of 492 probes out of 2164 on the array showed hybridization. One quarter of the 
probes (124) corresponded to predicted equine miRNA sequences deposited in 
miRBase 21, and detection of these by microarray provided experimental 
evidence that these predicted sequences are indeed expressed in horse 
fibroblast cells.  
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Extension of this initial analysis using HTS provided a more detailed description 
of all miRNAs expressed in these cells. As expected, HTS had a higher dynamic 
range than microarray which allowed detection of miRNAs expressed at low 
levels. In addition, as HTS does not require previous knowledge of the sequence 
of the mature miRNAs, discovery of novel miRNAs was possible. The drawbacks 
of the HTS technique were that it required a higher amount of much higher 
quality RNA and involved intensive data analysis. Nevertheless, this approach 
identified 593 miRNAs expressed in equine fibroblasts, of which 335 were never 
described in the horse before. However, although bioinformatic analysis of the 
HTS results was carried out in detail, from this analysis alone it cannot be 
concluded that these are true, novel miRNAs; further clarification of this and 
naming of new miRNAs will be provided by the miRBase curators who will test if 
the read pattern provides evidence for processing by Drosha and Dicer with 
criteria such as mismatches on the sequence between mature forms and hairpin 
precursor, abundance of mature forms from both arms of the hairpin, folding 
energy and mismatches with the predicted sequences (Kozomara & Griffiths-
Jones, 2014). However, HTS did provide data on a number of interesting aspects. 
Firstly, equine miRNA length and GC content were found to be highly similar to 
what was previously predicted in the horse and suggested in previous studies on 
equine miRNAs (Zhou et al., 2009; Desjardin et al., 2014; Kim et al., 2014). 
Secondly, all equine chromosomes (ECA), with the exception of one (ECA 31), 
encoded miRNAs and interestingly ECA 24 encoded a high number and high 
density of miRNAs. miRNAs from equine fibroblast cells were commonly 
expressed in clusters of between 2 and 13 miRNAs and 6.75% of the miRNAs 
expressed  mapped to multiple regions in the genome, indicating gene 
duplication. The range of expression of those miRNAs was variable and the top 
50 most abundant miRNAs found in clusters had reads above 1000 (average reads 
for three replicates of EqPalF). Finally, 258 predicted miRNAs and 335 novel 
miRNAs were verified in equine primary fibroblasts. Of these novel miRNAs, 162 
sequences were potentially new equine miRNAs and 173 sequences were 
potentially novel miRNAs, not previously described in any species. 
To address the second aim of the project, the study of differential expression of 
miRNAs in a well-established in vitro model of ES, three state-of-the-art 
technologies were utilised: microarray, HTS and real-time quantitative reverse-
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transcription polymerase chain reaction (qRT-PCR). The in vitro model, 
developed at the University of Glasgow, included an in vitro transformed cell 
line with BPV-1 episomal genomes (S6-2; equine primary fibroblast containing 
BPV-1 genomes and expressing BPV-1 oncoproteins), a tumoural cell line 
(EqS04b; equine fibroblasts obtained from naturally occurring sarcoids, 
containing BPV-1 genomes and expressing BPV-1 oncoproteins) (Yuan et al., 
2008a) and a control cell line (EqPalF; equine primary fibroblasts). Results from 
the microarray showed that 206 miRNAs were differentially expressed between 
the control and in vitro transformed cell lines (statistical significance at p<0.05). 
Interestingly, more than two thirds of the miRNAs interrogated on the 
microarray (70%) were downregulated as a consequence of the presence of BPV-
1 genome. There are two possible explanations for this result. Firstly, a true 
biological reason may be responsible for this general downregulation of miRNAs, 
such as the presence of BPV-1 episomal genomes. Secondly, possible bias may 
have been introduced by the set of probes that are included on the microarray, 
the list of which is dictated by the external company. When the results from the 
three cell lines of the model were examined using HTS a different profile of 
miRNAs was seen. The distribution of the dysregulated miRNAs was relatively 
even: approximately 50% of the miRNAs were downregulated when comparing 
BPV-1 positive cells (either in vitro transformed or tumoural cells) to control 
cells. Therefore, the finding from the microarray data that the presence of BPV-
1 genomes led to general downregulation in the expression of miRNAs in equine 
fibroblasts was not supported by the HTS data. In the light of the HTS results it 
is hypothesised that this trend was due to technical reasons such as the bias in 
the set probes. The highly similar miRNA expression profiles in both BPV-1 
positive cell lines (S6-2 and EqSO4b) strengthens this hypothesis because similar 
results were found when comparing these to the control cell line. Furthermore, 
analysis of the HTS data showed a number of interesting discoveries. Firstly, 
different biological replicates (different group of cultured cells and different 
RNA preparations) showed excellent correlation in the miRNAs expressed and in 
level of expression. This was an expected finding as there should be no major 
differences in the culture procedure and RNA extraction. However it added 
robustness to the data set. Secondly, by comparing the miRNA profiles, higher 
similarities were found between the in vitro transformed cells and the tumoural 
cells than between the in vitro transformed cells and the control cells. This was 
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perhaps an unexpected finding since transformed cells are descendants of the 
control cells. Clearly, the presence of BPV-1 genomes seems to be sufficient to 
alter the miRNA expression profile of in vitro transformed cells and make these 
more similar to tumoural cells, as shown in Figure 5.8. (Chapter 5). Additionally, 
as there was a strong correlation between the expression and types of miRNAs 
dysregulated in both BPV-1 positive cells relative to control cells, the 
dysregulation of those miRNAs could be directly attributed to the presence of 
BPV-1 virus and to the expression of BPV-1 oncoproteins. Thirdly, a subset of 201 
miRNAs was found to be dysregulated due to the presence of the BPV-1 genome 
and amongst these, several miRNAs had been previously linked to the tumoural 
transformation driven by high-risk human papillomaviruses (HR-HPVs) 
oncoproteins. Three miRNAs within this group, U4_5p (miR-181a), U44_5p (miR-
181b) and U72_5p (miR-204b) were also encoded in areas of the equine genome 
previously reported to be linked to ES (Jandova et al., 2012; Bugno-Poniewierska 
et al., 2016). miR-181a and miR-181b were found to be downregulated by both 
HTS and microarray in BPV-1 positive cells and miR-181a showed the same 
pattern by qRT-PCR. Importantly, low levels of miR-181a were flagged up by the 
algorithm in LEfSe as a suitable biomarker for BPV-1 presence. Interestingly, the 
human homologue hsa-miR-181a has been reported to be downregulated in HR-
HPV in vitro studies by microarray and qRT-PCR (Wang et al., 2008; Lajer et al., 
2011; Wald et al., 2011) and there is evidence that HPV-16 inhibits the 
expression of this miRNA by directly preventing its transcription (Lee et al., 
2015). Nevertheless, the roles of these three miRNAs in ES warrants further 
investigation. Studies assessing tumoural transformation parameters in miR-
181a/b and miR-204b knocked-down cell lines and quantification of those 
miRNAs in BPV-1 E5, E6 and E7 transformed cells would help to clarify the roles 
of those miRNAs in the in vivo BPV-1 tumoural transformation. Quantification of 
those miRNAs in the six different clinical types of equine sarcoids using qRT-PCR 
may help to understand their role in the disease. 
Another interesting finding was a subset of 128 miRNAs that were found to be 
linked to the tumoural phenotype. These were not dysregulated in BPV-1 
transformed cells but were significantly dysregulated in tumoural cells when 
compared to control cells. Amongst these miRNAs, several were reported to be 
linked to HR-HPV oncogenic transformation. In particular, miR-196a and b were 
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reported to be associated with increased levels of MMPs through activation of 
NME4-JNK-TIMP1-MMPs pathway in oral cancer, and in colon cancer miR-196b has 
been reported to regulate apoptosis by targeting Fas receptor (CD95) (Lu et al., 
2014; Mo et al., 2015). Higher expression of miR-196a in HPV-induced cervical 
cancer has been associated with expression of oncoprotein E7 via PI3K pathway 
(Pereira et al., 2010) and it has been suggested as a biomarker for prognosis in 
this disease (Pereira et al., 2010; Gocze et al., 2013; Lu et al., 2014; Vojtechova 
et al., 2016). Finally, the use of bioinformatic tools for pathway/network 
analysis and biomarker prediction proved to be informative in the in vitro ES 
model, as the major networks identified fit the disease model for ES (cancer, 
reproductive tract disease linked to HPV and tumorigenesis) and several miRNAs 
considered relevant, due to their association with HR-HPV cancer or other types 
of cancer, were predicted as suitable biomarkers. Predicted biomarkers for BPV-
1 presence were miR-92a (member of the miR-17~92 cluster), miRNAs from the 
15/16 cluster and miR-21. miR-92a in HR-HPV is thought to contribute to tumour 
development and is upregulated by HPV-16 E6 (via PTEN protein) (Yu et al., 
2013), miRNAs from the 15/16 cluster have been reported to be upregulated via 
c-Myc, again by HPV E7 activation and miR-21 is a well-known oncomiR that has 
been reported to be upregulated in numerous types of neoplasias and in HPV-
related cervical cancer through the expression of E6 oncoprotein (Ben et al., 
2015; Xu et al., 2015). Following submission of the subset of miRNAs identified 
in equine fibroblasts to the official miRNA database, a more comprehensive 
functional analysis will be warranted; currently the tools for functional analysis 
list only a small number of miRNAs found in equine fibroblasts in the current 
study. Results from these predictive tools will need to be validated with ex vivo 
specimens to assess the clinical usefulness of these miRNAs as potential 
biomarkers.  
6.3. Contribution of these findings to the current 
knowledge of ES and equine miRNAs.  
Bioinformatic analysis of the data obtained by HTS and validation using qRT-PCR 
showed that 280 of the predicted miRNAs listed in miRBase for the horse are 
indeed expressed in equine fibroblasts (including BPV-1 positive equine 
fibroblasts). Of these, 42 miRNAs were exclusively expressed in the two cell lines 
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with BPV-1 genomes and expressing BPV-1 oncoproteins. Furthermore, 187 
miRNAs (162 from EqPalF cells, and 25 from BPV-1 positive cells) that have not 
been reported in the horse but have orthologous in other species (novel in the 
horse); and 285 miRNAs (173 found in EqPalF and 112 found in BPV-1 positive 
cells) that have not been described in any other species (novel miRNAs) were 
found in equine fibroblasts. These results represent the first experimental 
verification that the 280 predicted miRNAs are indeed expressed in the horse 
and demonstrate expression of 285 additional novel miRNAs in horse fibroblast 
cells, which are also conserved in other species. These findings, when deposited 
in miRBase, will be a substantial contribution to the scientific community and 
will constitute a starting point for further studies in equine miRNAs. 
With the use of three different techniques (microarray, HTS and qRT-PCR) 201 
miRNAs were found to be significantly dysregulated in BPV-1 positive cells, 
attributable to the presence of BPV-1 genomes and BPV-1 oncoprotein 
expression. A subset of 59 miRNAs were predicted by linear discrimination 
analysis algorithm as suitable candidates for biomarkers of presence of BPV-1. 
Furthermore, 128 miRNAs were linked to tumoural transformation and of those 
the aforementioned algorithm predicted 47 to be suitable candidates for 
biomarkers of tumoural transformation. Interestingly, within both groups there 
were miRNAs linked to BPV-1 presence and miRNAs linked to tumoural 
transformation which are also reported to be linked to HR-HPV oncogenesis. 
These two subsets of miRNAs represent the proof that there is dysregulation of 
miRNAs in ES. Ex vivo analysis of miRNAs expressed in clinical ES samples, 
together with histopathological characterization, is ongoing and the data will be 
important in testing the hypothesis that these miRNAs may be useful as 
diagnostic and prognostic tools. Further studies corroborating the in vivo results 
in ex vivo specimens with the use of HTS and qRT-PCR validation would help to 
understand the miRNA changes attributed to BPV-1 in the live disease. Future in 
vitro studies adding miRNA mimics or inhibitors of the miRNAs summarised above 
to test their effects on gene expression and phenotype will be required to fully 
understand the consequences of miRNA dysregulation in ES oncogenesis and will 
be an initial step to therapeutic options. Further studies assessing the miRNA 
expression patterns in different clinical types would be required to potentially 
developing accurate tools to aid with diagnosis and prognosis of ES. 
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6.4. Conclusions 
Understanding of the oncogenic mechanisms of BPV-1/-2 in equine sarcoids 
remains an important goal to create future diagnostic, prognostic and 
therapeutic tools. The combination of several molecular biology and 
bioinformatic technologies has proven to be an efficient way to verify 280 
previously predicted miRNAs, to discover 285 novel miRNAs in the horse and to 
identify 201 dysregulated miRNAs as a consequence of BPV-1 presence and 128 
dysregulated miRNAs associated to tumoural transformation in ES. These results 
will be an addition to the scientific community when deposited in miRBase and 
have contributed to a better understanding of miRNAs in the horse and BPV-1 
oncogenesis in ES.  
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